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SUMMARY
In this thesis, the genotoxic potential of andrographolide, which is a primary phytochemical 
of an annual herb Andrographis paniculata, was assessed and the possible mechanisms of 
action were elucidated.
In silico predictions showed that andrographolide may be capable of inducing skin 
sensitisation and chromosome damage in mammals in vitro and the identification of possible 
metabolites.
Andrographolide was demonstrated to induce micronuclei formation in vitro in three cell 
lines tested namely AHH-1, MCL-5 and V-79. In AHH-1 and V-79 cell lines, the highest 
frequency of micronuclei was recorded at 30 pM whereas in MCL-5 cell line, 50 pM of the 
compound was necessary to elicit similar damage, which may be due differences in cellular 
metabolism capacity. The phytochemical was shown to cause dose-dependent cellular 
cytotoxicity in all the cell lines tested with cells dying primarily via necrosis compared to 
apoptosis and effectively reduced cell number.
Kinetochore labelling on MCL-5 cells challenged with increasing doses of andrographolide 
revealed that the phytochemical acts in aneugenic manner evident from the increment in 
kinetochore-positive micronuclei.
The compound of interest was also found to disrupt segregation fidelity via centrosome 
amplification resulting in chromosomal aberration. The presence of extra microtubule 
organising centres may play a role in the promotion of aberrant mitoses. Disruption to normal 
cell division was observed even after the removal of the compound in vitro.
Mammalian HPRT point mutation assay using AHH-1 cell line revealed that andrographolide 
induced mutation evident from HPRT~ mutant colonies formation between 5pM and 30pM. 
The phytochemical was also found to exert cytotoxicity in a concentration-dependent manner 
between 1 pM and 50pM.
Thus, andrographolide is capable of disrupting normal mammalian cell division and causing 
dose-dependent cytotoxicity in vitro.
VI
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DMAPP. Dimethylallyl pyrophosphate.
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Mitochondrial membrane potential.
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CHAPTER 1
PART 1: INTRODUCTION TO THE IMPORTANCE OF 
PHYTOCHEMICALS AND THE NEEDS TO ASSURE THEIR SAFETY
“It does not matter that rhubarb is a purgative. The question is, what purges? 
Names do not have virtues. Substances do.”
Paracelsus; in Archidoxa of the Arcanum, circa 1524.
1.1 Phytochemicals and Herbal Applications in Traditional Medicines
Traditional medicines captivate a wide spectrum of reactions in general, ranging from 
uninformed scepticism to abiding enthusiasm from the general public as well as the 
scientific community. Traditional medicines are still widely used in developing countries 
and are increasingly popular in developed countries. In certain parts of the world, it is the 
only geographically accessible and economically feasible mode of healthcare. Globally the 
public, health professionals and policy-makers are wrestling with the questions about the 
quality, efficacy, safety, preservation and further development of this type of health care. 
This thesis is focusing on herbal applications in traditional medicine and highlighting the 
need to ensure safe application of medicines derived from plants.
Modem pharmaceutical dmgs are based on chemicals with active properties and many 
drugs used today have been discovered through research into the physiological effects of 
phytochemicals, which are chemicals derived from plant sources. The primacy of plants as 
the source of new drug discoveries throughout human civilisation remained unrivalled until 
the recent competition from combinatorial chemistry (Schreiber, 2000) and computational 
drug design (Clark and Pickett, 2000), which effectively reduced its influence in dmg
thdiscovery process. During the 20 century especially since the Industrial Revolution, 
efforts gradually shifted from producing medicinal plant extracts to synthetically producing 
these phytochemicals or their active analogues. Figure 1.1 highlights the factors that 
contribute to the decline of natural products in drug discovery and development. Although 
many can now be synthesised, such as aspirin, which is a safer analogue of salicylic acid 
derived from Salix alba, some of these dmgs are still derived directly from plants (e.g.
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digitalin from foxglove, Digitalis sp.). Chemicals in some plants are extracted and 
transformed, providing the building blocks of drugs (e.g. progesterone, synthesised from 
chemicals found in some species of wild yam, Dioscorea sp.). Generally, phytochemicals 
are referred to as new chemical entities (NCEs) especially in the industry circle and viewed 
as templates for structure optimisation in making perfect new drugs. Other compounds are 
potentially useful to humans or are of toxicological relevance.
Although synthetic chemistry is currently more appealing as an approach to produce new 
drugs, flora’s contribution in preventing and treating diseases cannot be ignored. At the 
beginning of the 21st century, it was reported that 11% of the 252 drugs regarded as vital by 
the World Health Organisation (WHO) and about 25% of drugs prescribed worldwide were 
solely derived from plants (Rates, 2001). Furthermore, 49% of 877 new chemical entities 
introduced between 1981 and 2002 were natural products, semi-synthetic natural products 
or mimics based on natural-products (Newman et al., 2003). As shown in Figure 1.2, there 
was an increasing trend in natural product patents worldwide whereas Table 1.1 lists the 
percentage of identified medicinal plant species in selected countries and the world in 
general.
400-1
Cl*
£ 20: -
1 0 0 -
□  Total woHdwide natural-product patents 
[H  Original natural-product patents
T384 1985 1986 1997 1 998 1939 1993 1991 1992 1933 1994 1 935 1 936 1997 1993 1999 2*000 2C01 2002 20C6
Fig 1.2. Worldwide pharmaceutical natural product patents. Original natural product patents refer to all first­
time grants o f  patents for novel composition o f  small molecule natural products as pharmaceuticals. Whereas 
those for total worldwide natural products are global grants for patents asserting composition-of-matter or 
small natural products applications as therapeutics. One single natural product can generate several patents 
based on multiple filings in different countries or for different indications. (Adopted from Koehn & Carter,
2005.)
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Table 1.1. The percentage o f  identified medicinal plant species in selected countries and the world in general.
India 15,000 3000 20.0
China 26,092 4941 18.9
United States 21,641 2564 11.8
Malaysia 15,500 1200 7.7
World 422,000 52,885 12.5
Data obtained from Schippmann et a/, 2002.
The idea that evolution has been selecting and improving phytochemicals longer than any 
pharmaceutical companies and in greater diversity than any chemical library made by 
humans should be recognised. This is especially true in areas where there are insufficient 
synthetic leads. Furthermore, plants have utilised a more holistic tactic in their biochemical 
defence against pathogens by producing arrays of structurally and functionally diverse anti- 
pathogenic compounds that act in concert, not only to neutralise the threat but also in 
averting the development o f resistance in the future. For example, Berheris fremontii 
(Fremont barberry) produces both anti-microbial berberine alkaloid and inhibitors of a 
bacterial pump that strongly potentiate the activity of berberines (Hsiang & Lewis, 2000). It 
is for the same reason that made herbal medicines appealing not only to the scientific 
community but also to the public, where multi-factorial nature of many complex diseases 
such as psychiatric disorders and cancers cannot be ideally solve with a ‘single golden 
molecular bullet’. Most of these diseases are not a result o f one single factor but from a 
combination of genetic, behavioural and environmental influences. Furthermore, many 
proteins and molecular targets are involved in complex biochemical and cellular processes. 
Thus, carelessly tampering with one reaction might affect the others.
Pharmacognosy (derived from Greek words pharmakon, ‘remedy’, and gignosco, 
‘knowledge’) is the science of biogenic or nature-derived pharmaceuticals and poisons. It 
concerns all medicinal plants including those yielding complex mixtures, those used in the 
crude forms or extracts (phytotherapy), pure compounds such as morphine, and foods 
having additional health benefits (nutraceuticals). Phytomedicines generally refer to herbal 
medicinal products used in phytotherapy. Phytotherapy should not be confused with other 
“special therapeutic disciplines” that also utilise plant materials such as anthroposophy and 
homeopathy. Homeopathy, whose efficacy is still being critically assessed, was proposed 
by Samuel Hahnemann and works on the principle o f ‘similia similibus curentur’- similar
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symptoms are healed by similar medicines. Furthermore, homeopathy mainly involves 
really low doses where ‘efficacy’ is believed to increase with dilutions, in stark contrast to 
current scientific comprehension.
There are various ways in which plants can be used as therapeutics as listed in Table 1.2.
Herbal teas and other homemade remedies are very popular. Crude or standardised extracts 
can be prepared in pills or capsules and can also be use as tinctures. Ultimately, as 
mentioned briefly before, successive extraction and purification procedures to isolate 
phytochemicals from plants of interests, that is bioactive and can be used straight away as 
drugs (e.g. ergotamine and digoxin) or use as leads in hemisynthetic processes.
Table 1.2. A variety o f  ways in which phytochemicals can be used.
Drugs Primarily single active 
pharmaceutical 
compounds originating 
from plants.
Via prescription or
over-the-counter
purchases.
Aspirin, vinblastine 
and taxol.
Botanical drugs Standardised 
phytochemical mixtures 
that are clinically 
proven.
Via prescription or
over-the-counter
purchases.
Hypericum
perforatum.
Dietary
supplements
A plant component 
with health benefits.
Over-the counter 
purchases.
Garlic or Echinacea 
extract.
Phytochemicals can also be use as reference models for total synthesis with well-defined 
pharmacological activity or structure activity relationship studies determining a prototype 
drug (e.g. morphine). One good example would be artemisinin. Artemisinin, a 
sesquiterpene trioxane lactone containing a peroxide bridge that is necessary for its activity, 
was first isolated by Chinese researchers from Artemisia annua (sweet wormwood) and its 
structure was elucidated in 1979 (Klayman, 1985). Various soluble and more active forms 
o f artemisinin have been synthesised to combat malaria. The phytochemical and its 
derivatives kills Plasmodium in all stages o f life cycle by interacting with heme resulting in 
carbon-centred free radicals, which alkylate protein thus damaging the membrane and 
microorganelles o f the parasites (Meshnick, 1998). Up to this day and to the best of the 
author's knowledge, there are no known cases of artemisinin-resistant malaria in humans
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(Balint, 2001). Figure 1.3 highlights the evolution of Artemisia annua application starting 
with traditional medicine to modem drug discovery and Figure 1.4 shows the similar 
passage of the senna plant. The variety of development and use of natural products is 
shown in Figure 1.5.
1.2 Increasing Public Interest in Phytomedicines and Phytotherapy
It is widely accepted that there is an increasing use of phytomedicines by the general public 
to replace or complement allopathic medicines (Newall et al., 1996). This revival of 
interest in phytomedicines is largely driven by the public’s increasing interest and 
confidence in self-medication (Blenkinsopp and Bradley, 1996). There are many reasons 
for the increasing popularity of phytotherapy and most likely to include the following:
• Increasing consumer interest in self-medication.
• Increasing consumer interest in using herbal remedies as daily supplements.
• As a complementary to allopathic medicine.
• The popular notion that phytomedicines are safe and natural.
• Growing concern about the adverse effects of synthetic dmgs.
• Disappointment with the efficacy of conventional dmgs, especially in chronic 
conditions.
• The desire for a more natural lifestyle.
• Cost factor. Herbal medications are normally available over the counter and are 
cheaper than prescribed modem dmgs.
The world market for phytomedicines is estimated to be £38 billion (UNCTAD, 2000). It is 
estimated that Europe imports about 400,000 tonnes of medicinal plants annually with 
Germany as the largest market and consumer of medicinal plants, spending about £1.4 
billion, followed by France with £116 million (Masood, 1997). The UK is third in place.
As highlighted in the House of Lords Select Committee’s report on complementary and 
alternative medicine, comprehensive information on the use of herbal medicines in the UK 
is insufficient (House of Lords, 2000). There are several estimates available but it is 
difficult to make an accurate determination as many products could be categorised as food
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supplements rather than medicines mainly for regulatory purposes, effectively the public in 
many cases are unable to differentiate phytomedicines for dietary supplements or 
therapeutic applications. A report by the Mintel market research group on retail sales of 
licensed homeopathic, herbal remedies and essential oils showed that phytomedicines make 
up more than 50% of the total complementary market in the United Kingdom with 
estimated value of £38 million in 1996 compared to £27.2 million in 1991 (Mintel, 1997). 
However, the total market value is likely to be higher since the study excluded ginkgo and 
unlicensed herbal products from its analysis.
Another report estimated the phytomedicines market to be over £60 million (Mintel, 2000).
More recent reports estimated the market value of herbal remedies (excluding traditional 
Chinese and Ayurvedic medicines) had grown to £75 million in 2002, dominating the UK 
natural health market and accounting for almost 60% of the sector value (Mintel, 2003).
Another Mintel report in 2005 noted that herbal medicines have shown greatest growth 
over the last two years with value sales hitting £87 million in 2004, accounting for half of 
overall category sales. All these estimates should be considered as broad brush since some 
companies might not always have an accurate view as to which of their products would be 
classified as medicines.
The analysis of the market structure for unlicensed phytomedicines is complicated by 
several factors such as:
• Most phytomedicines possess borderline status as to whether they should be 
categorised as medicines or fall within other regulatory classification such as 
supplements, cosmetics or general consumer products.
• A number of companies supply herbal ingredients (e.g. for herbalists’ use or by 
manufacturers) rather than manufacture the product themselves.
• Under existing regulations, companies are not required to submit products to the 
Medicines and Healthcare products Regulatory Agency (MHRA) for determining 
their status.
One must recognised the fact that future growth in the industry remains vulnerable to 
adverse publicity arising from issues over the safety and quality of phytomedicines.
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1.3 The Regulation of Phytomedicines in the United Kingdom and 
the European Union
The House of Lord’s Select Committee on Science and Technology 6th report (2000) 
stressed for a need of a more effective guidance to the public regarding the safety and 
efficacy of alternative medicines. The absence of central information provision for 
healthcare practitioners and the general public, effectively gave the media and other 
unregulated information sources unchecked influence in shaping opinions in the field. Over 
25% of consumers believed that pharmacists should provide more information on herbal 
medicines highlighting increasing consumer concern, with about 20% of consumers 
worried about the possible side-effects from alternative medications (Mintel, 2003).
Whilst the government and the industry need to address this consumer concern, Mintel’s 
report also found that around 1 in 5 UK consumers worry about the possible side effects 
from standard medication too. And 18% admitted they have tried conventional medicine 
which did not work, suggesting a significant opening for the phytomedicine industry 
(Mintel, 2003).
Phytomedicines intended for general retail sale reach the UK market by two different 
routes. First, an authorisation can be obtained from the licensing authority for marketing 
purposes under the Medicines for Human Use (Marketing Authorisation Use) Regulations 
1994 (SI3144/1994) that fundamentally transposed European Directive 2001/83/EC into 
UK law. Under these Regulations, authorisation is requisite for most industrially produced 
medicines that are to be marketed. Such authorisation is obtained by providing standards of 
quality, efficacy and safety.
Alternatively, exemption from product licence requirement (compulsory under the 
Medicines Act) can be obtained under Section 12(2) of the Medicines Act 1968 [and 
regulation 1(3) of the 1994 Regulations] for phytomedicines that do not need marketing 
authorisation, providing that the remedy meets various conditions. There are restrictions or 
prohibitions on certain ingredients, but generally there are no specific requirements for 
quality, safety and efficacy. Written medical claims are not permitted for these herbal 
remedies and specific requirement to provide the consumers with systematic information 
about the safe application of the product is absent.
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Even though several hundred phytomedicines posses marketing permission in the UK, most 
herbal medicines were marketed on general sale by utilising the exemption provided in 
Section 12(2) of the Medicines Act as explained above.
The primary piece of European legislation is Directive 2001 /83/EC of the European 
Parliament and of the Council of 6 November 2001 on the Community code regarding 
medicinal products intended for human use. Thus, there was no distinction in the European 
legislation for medicines made from non-herbal ingredients and phytomedicine. Medicinal 
products are also subjected to some non-specific legislation, such as Directive 85/374/EEC 
on product viability, which was transposed into the UK law as Consumer Protection Act 
1987 and applies in part to medicinal products for consumer protection.
On 30th October 2005, the MHRA introduced a new scheme, the Traditional Herbal 
Medicines Registration Scheme implemented through the Medicines (Traditional Herbal 
Medicinal Products for Human Use) Regulations 2005 (SI 2005 No. 2750), which is 
required by the European Directive on Traditional Herbal Medicinal Products 2004/24/EC. 
This scheme will assist in protecting public health, consumer confidence and the industry 
itself by requiring specific standards to be met relating to the product namely quality, 
safety, manufacturing standards, patient information, wholesale and import. However, the 
key feature of this scheme is the requirement for evidence of traditional application in the 
EU for 30 years. Evidence for up to 15 years of traditional applications outside the Union is 
admissible. This new EU Directive effectively amends Directive 2001/83/EC, to introduce 
the scheme and applies many existing requirements of the later to traditional herbal 
medicinal products. Another separate new EU Directive 2004/27/EC is simultaneously 
amending Directive 2001/83/EC. All manufactured traditional herbal medicines that 
marketed with exemption under Section 12(2) of the Medicines Act, will be required to be 
registered under this new scheme.
However, for unlicensed herbal medicines that were legally on the market by 30 April 
2004, Her Majesty’s Government has opted for a seven-year transitional period that ends 
on 30 April 2011, a flexibility accorded to EU member States under Directive 2004/24/EC 
intended to allow companies to adjust to the new regulations.
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Herbal products that are not classified as medicines are still subject to other regulations. 
The fact that a product is not medicinal in nature thus not necessarily means that it is safe 
or acceptable from a legal standpoint. Food and supplements are regulated by the Food 
Standards Agency (FSA) while cosmetics or other consumer products fall under the 
jurisdiction of the Department of Trade and Industry. The MHRA accepts no 
responsibilities on these points. The Food Safety Act (1990) states that food sold in the 
United Kingdom cannot be injurious to health and according to the FSA, herbal ingredients 
that do not possess a history of significant consumption within the European Union prior to 
May 1997 may be subject to Novel Food Regulation (EC) 258/97.
1.4 The Importance of Natural Products and Phytomedicines
Natural products have enjoyed an undisputedly important role as new chemical entities 
(NCEs). Between the years 1981 and 2002, approximately 28% of NCEs were natural 
products or derived from natural products, with another 20% were considered as synthetics 
based on natural product pharmacophores (Newman et al., 2003).
Natural products (phytochemicals) have many common structural features such as chiral 
centres, degree of molecule saturation, complex ring systems and aromatic rings that have 
been demonstrated to be highly applicable in drug discovery process (Koehn & Carter, 
2005). Furthermore, the realisation that combinatorial chemistry may not always provide 
high degree of compound diversity led to the exploration of combining the natural product 
and natural product-like libraries with the potential of combinatorial chemistry in drug 
discovery and Table 1.3 shows some of the well-known phytochemicals in use today.
The existence and application of new technologies such as combinatorial synthesis, 
genomics and screening technology allow new research and development strategies to be 
adopted and contributed to revival of interest in phytochemicals. Table 1.4 listed some 
phytochemicals with their known molecular targets which might pave the way for better 
comprehension on their mode of action(s) and possible development into clinically 
applicable drugs.
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Table 1.3. Shows some medicinally and chemically important phytochemicals known, their source(s), 
chemical type and application._______________________________________________________________ ___
Artemisinin Artemisia annua Sesquiterpene
lactone
Antimalarial
Camptothecin Camptotheca
acuminata
Indol alkaloid Antineoplastic
Cocaine Erythroxylum coca Cocaine alkaloid Local anasthetic
Codeine,
morphine
Papaver somniferum Opium alkaloid Analgesic, antitussive
Digitoxin,
digoxin
Digitalis spp. Steroidal glycosides Cardiotonic
Quinine Cinchona spp. Quinoline alkaloid Antimalarial
Reserpine Rauwolfia serpentina Indole alkaloid Antihypertensive
Sennosides A& B Cassia angustifolia Hydroxy-anthracene
glycosides
Laxative
Taxol Taxus hrevifolia, T. 
hacata
Diterpenes Antineoplastic
Vinblastine,
vincristine
Catharanthus roseus Bis-indole alkaloid Antineoplastic
Table 1.4. A short list o f  phytochemical compounds and their reported molecular targets.
Betulinic acid Selective melanoma cytotoxicity via p38 
activation
Pisha et al., 1995; Tan et al 
2003;
Cichewicz & Kouzi, 2004.
Cucurbitacin 1 Highly selective in inhibiting the 
JAK/STAT3 pathway in tumours with 
activated STAT3
Blaskovich et al., 2003.
Indirubin Selectively inhibits cyclin-dependent 
kinases
Hoessel et al., 1999; 
Eisenbrand et al., 2004.
Kamebakaurin Inhibition of NFkB Lee et al., 2002.
B-lacaphone Kills cancer cells selectively via direct 
checkpoint activation during cell cycle
Li et al., 2003.
Recently, a well-known pharmaceutical company, Novartis has set up the so-called 
Novartis Institutes for Biomedical Research in Shanghai’s Zhanjiang Park and 
collaborating with the Chinese Academy of Sciences to harness purified natural compounds 
from plants and fungi normally used in traditional Chinese medicine. In May 2007, another 
pharmaceutical heavyweight, GlaxoSmithKline (GSK) announced the establishment of its 
own drug research and development facility in Shanghai, China (Corporate Press Releases,
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Novartis and GSK respectively, 2007). Embracing phytochemicals again and re-designing 
strategies for discovering new molecules from plants including studying those described in 
traditional medicine texts such as in China, is understandable since the new chemical 
entities pipeline of pharmaceutical companies were reported to be at historically low levels 
(Bolten & DeGregorio, 2002).
1.5 The Efficacy of Phytomedicines
The extraordinary level of phytomedicines popularity in recent years made it ethically 
imperative to elucidate its efficacy. There were opinions that the criteria for efficacy as 
well as safety of herbal medicines should be on par as those for conventional medicines and 
the author concur with these views. Many phytomedicines possess a long history of 
traditional use but most are of unproven efficacy by acceptable scientific standards, and 
traditional use does not necessarily confer safety usage mark. Insufficient evidence does 
not mean that phyomedicines are unsafe and ineffective, but that rigorous scientific 
investigation has not been carried out. Base on the same line of argument, the lack of 
evidence cannot be use to justify that all phytomedicines are safe.
The accepted ‘gold standard’ for testing the efficacy of medicines, whether it is synthetic or 
herbal, is the randomised clinical trials. Depending on the research objectives, these trials 
can be conducted against reference medications should one exists, or against placebo or no 
treatment at all. There is good evidence of efficacy for some phytomedicines but usually 
such an evaluation is scientifically inadequate. Figure 1.6 shows the percentage of 
randomised clinical trials highlighting the benefit of phytomedicines based on 50 trials with 
10 herbal medicines for 18 therapeutic indications, where only 34% exhibited benefit when 
compared against placebo and 18% showed the same activity as placebo. Almost half 
(48%) of the results from the trials has an unlikely benefit due to discrepancies in 
experimental design or data analysis.
Copy 7 15
Y. Sharifuddin
Chapter 1
Percentage of randomised trials showing benefit of 
phytomedicines
□ Same as compared to placebo 
■ Benefit as compared to placebo
□ Benefit reported unlikely - due to design or analytic flaw
Fig. 1.6. Percentage o f  randomised trials showing benefit o f  phytomedicines. 
Based on data in Herbal Medicines: an evidence-based look. 
(Therapeutics Letter, Issue 25, June-July 1998.)
However, in order to provide a fair estimate of overall efficacy of a particular herbal 
medication, relying on the data generated from randomised trials alone is not sufficient. 
Only the totality of the available data that can be achieved by performing systematic 
reviews and meta-analyses can provide the most reliable evidence while minimising bias 
and random error. Determining the efficacy of an herbal product against its safety is 
important.
1.6 Safety of Phytomedicines: Clear and Hidden Risks
The advances in organic chemistry, biological and medical sciences in the 20th century had 
paved the way for the introduction and consumption of powerful synthetic drugs, resulting 
in the decline of phytomedicines usage in modern medicine. However, the current revival 
of interest in phytotherapy had caused the pharmaceutical industry to start marketing an 
increasing amount o f new phytomedicines to accommodate the needs o f consumers. This 
makes the need to ensure the quality, efficacy and safety of phytomedicines even more 
pressing since these products are generally self-prescribed, used to treat minor and often
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chronic conditions. The assumption that they only possess beneficial effects has proven to 
be inaccurate.
Furthermore, traditional medicines have developed in many different regions, having been 
very much influenced by historical conditions and local cultures within which they first 
evolved. Thus, there has been no parallel development of methods and standards, both at 
national or international level that are suitable for evaluation purposes.
Safety evaluation of phytomedicines is difficult. Identifying plants accurately is essential as 
well as isolation of active ingredients, which is far more complex since the properties of 
phytochemicals are influenced by several factors such as environmental conditions. A 
single medicinal plant can also contain hundreds of phytochemicals and elucidating the 
individual effect of each can therefore be prohibitively expensive. Unsurprisingly, research 
effort has been inadequate, resulting in inadequate methodology development and paucity 
of reliable data. Although many phytomedicines showed promising potential and are 
increasingly used, many of them are untested and their use by the public not properly 
monitored leading to limited knowledge of their side-effects. Benefit-risk assessment can 
also be difficult due to insufficient information in several areas relevant to safety. 
Consequently, proper development of legislation and regulation of herbal medicines has 
been impaired at the public expense.
Generally, data are currently lacking on:
• The active constituents and/or metabolites
• Pharmacology
• Pharmacokinetics
• Toxicology
• Possibilities of drug-herb interactions, as well as interactions with food and alcohol
• Frequency of possible adverse effects, and effects of long term use
• Possible effects in specific patient groups e.g. children, the elderly
• Possible effects for use during pregnancy and lactation
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Insufficient data on the factors stated above also makes it hard to compare and contrast the 
risk-benefit profile of several phytomedicines with that of conventional drugs, where 
effectiveness has been reported.
Toxicity related to the use of phytomedicines may have multiple causes but generally can 
be divided into two distinguishable categories as highlighted in Tables 1.5 and 1.6 
respectively. The first category can be designated as extrinsic or non-plant associated, 
where toxic effects or adverse reactions occurred due to accidental or deliberate 
substitution or contamination of the plant material described on the label. On the other 
hand, the second category is more intrinsic or plant-associated in nature. In this category, 
the plant material itself or the phytochemicals present, thus an active agent in the herbal 
medicinal products, which causes the health risks.
Table 1.5. Extrinsic or non-plant-associated causative factors involved in adverse drug 
reactions.
Adulteration
• Accidental or deliberate substitution of the original plant material by other 
plant species
Contamination
• Micro-organisms (bacteria including Salmonella, E.coli, yeasts, moulds)
• Microbial toxins (aflatoxins, lipopolysaccharides)
• Heavy metals (mercury, lead, etc.)
• Pesticides and/or herbicides
• Fumigants
• Radioactive particles
Substitution
• Synthetic drugs (anti-inflammatory agents, corticosteroids etc.)
• Animal substances (enzymes, hormones etc.)
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Table 1.6. Intrinsic or plant-associated causative factors; health risks related to the 
medicinal herb itself as active ingredient in the phytomedicine.
• Use of plants containing constituents that are known to affect bioavailability 
and/or pharmacokinetics of other compounds or drugs
• Ignored toxicity of plant constituent(s) present in the product
• Use of plants, either as raw material or in processed form, of which at present 
no or insufficient data regarding safety are available
• Use of highly concentrated or specifically processed extracts
Although the number of side effects attributed to the use of phytomedicines represents only 
a small proportion of the total amount of adverse drug reactions in the WHO database 
(Barnes, 1998), reports on toxic effects of or adverse reactions to herbal preparations have 
regularly been published over the past years (Barnes, 1998). Proponents of phytotherapy 
usually present long-standing experience in traditional medicine as evidence of their safety, 
unfortunately this type of evidence has considerable deficiencies. Determining botanicals 
that contain phytochemicals, which manifest their toxicities and acute adverse effects in a 
large fraction of users is relatively easy. A 5-year toxicological study by the UK National 
Poisons Unit from 1991 to 1995 on potentially serious adverse reactions attributed to 
exposure to herbal remedies, showed there were 785 cases of possible or definitive positive 
poisoning out of 1297 inquiries (Shaw et al., 1997). Although the study concluded that the 
overall risk to public health was low, there were clusters of cases that deserve serious 
attention where there were 21 incidents of hepatotoxicity including two deaths due to the 
use of traditional medicines although no causative agent was identified.
The harder task is recognising subtle adverse effects that develop over time and occur 
infrequently, for example hypokalemia from the use of anthranoid laxatives (Blumenthal, 
1998), or that are readily ascribed to an underlying disease such as hepatitis from 
celandine, a bile duct remedy derived from Chelidonium majus (Benninger et al., 1999). 
Hypothetically, for a herb that caused an adverse reaction in 1 for every 1000 users, a 
traditional practitioner would have to prescribed the herb to 4800 patients, that is 1 new 
user per day for more than 18 years, in order to obtain a 95% probability of observing such 
reaction in more than 1 user (De Smet, 1995).
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Thus, the more chronic but subtle form of toxicity such as mutagenicity and 
carcinogenicity effects of phytochemicals will remain unrecognised if their applications in 
traditional settings were left unexamined, as these may have been undetermined by 
previous generations. For example, although Aristolochia fangchi have been used for 
centuries in Chinese traditional medicine, its nephrotoxicity and potential to induce 
urothelial carcinoma by DNA-adduct formation has only recently been elucidated (Nortier
|
| et al., 2000; Lord et al., 2001) and it was the same case with the hepatotoxicity potential of
| Piper methysticum (Escher et al., 2001).
!I
f
Furthermore, there is always a belief among the general public that herbal medicines or
j  supplements are safe primarily because they are derived from nature, compared to synthetic
j
| compounds. Therefore, it was often considered harmless by the public that the consumption 
of these herbal products would not cause profound injury directly or vice-versa. Herb-drugs 
interactions for example, can occur at the pharmaceutical, pharmacodynamic and/or 
pharmacokinetic levels (Beijnen & Schellens, 2004). The application of herbal medicines 
in combination with conventional therapeutics may increase the risk for undesired 
interactions primarily due to the narrow therapeutic window of many oncolytic drugs.
| Alarmingly, more than 72% of cancer patients in the US for example, failed to inform their
i
j  doctors about herbal products consumption when undergoing conventional therapy at the
| same time (Sparreboom et al., 2004). One of the well-known examples of a clinically
significant effect displayed by herbs on the pharmacokinetic of chemotherapeutic drugs is 
Hypericum perforatum (St. John’s wort), which is popular among cancer patients due to its 
suggested activity on mild to moderate levels of depression (Mathijssen et al., 2002). The 
plasma levels of SN-38, the active metabolite of irinotecan was 42% lower in cancer 
patients who took Hypericum at the same time. Co-administration of cyclosporin with 
Hypericum leads to decrease cyclosporin plasma concentration (Barone et al., 2000) and 
disrupts hormonal contraception with irregular bleeding when taken together with 
ethynylestradiol (Schwarz et al., 2003). Even the innocently looking grapefruit (iCitrus 
paradisi) juice, has been shown to caused 26.2% reduction in etoposide bioavailability 
(Reif et al., 2002) and the culprit is bergamottin, a major furanocoumarin that reversibly 
inhibited the activities of CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4 in human liver 
microsomes (He et al., 1998), which may last up to 24 hours. It also alters the 
concentration of many drug substrates for CYP3A4 when taken simultaneously (Quo et al.,
2000). These examples highlight the need for more research not only into direct detrimental
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effects pose by phytochemicals but also indirect effects or impacts that are not clearly 
manifested including mutations and metabolic enzymes manipulation. The public may not 
| be aware of these hidden risks due to the ‘naturally safe’ paradigm long held about herbal
i
products.
Although phytomedicines are not devoid of risk, they could still be safer than synthetic 
drugs. Currently, the relative safety of phytomedicines is undefinable, many existing data 
indicate that adverse reactions, especially serious ones, occur less frequently than with 
prescribed synthetic drugs. Kava {Piper methysticum), an herbal anxiolytic (Pittler & Ernst,
2003) that raised serious concern due to its hepatotoxicity effect, could be safer than 
benzodiazepines, according to preliminary data (Schulze et al., 2003) and herbal 
I antidepressant St. John’s wort {Hypericum perforatum), has only about half the rate of
I possible adverse reactions compared to conventional antidepressants (Linde et al, 1996;
Stevinson & Ernst, 1999). However, its use is only recommended for weak and mild 
| depression and was found not to be effective for major depression cases compared to
| placebo (Linde et al., 1996; Shelton et al., 2001; Hypericum Depression Trial Study Group,
i
1 2002) The World Health Organization’s monitoring centre collected 8985 reports of
j  adverse reaction events associated with phytomedicines from 55 countries between 1968
! and 1997 (Farah & Edwards, 2000). Even though this figure may seem impressively high,
j
it amounts to only a small fraction of adverse events associated with synthetic drugs held in 
I the same database (Farah & Edwards, 2000). However, one must recognise the fact that
relative paucity could also be due to a relatively higher level of underreporting due to the 
perceived safety of natural herbs among the general population and more conclusive 
evidence on the relative safety risks of phytomedicines against conventional drugs is 
scarce.
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1.7 Plants and Secondary Metabolites
As briefly stated before, plants have evolved various defence mechanisms including 
chemical, mechanical or even mimicry to improve their survival and reproduction by 
reducing the impact of herbivory and infection. Over billions of years of evolution, plants 
continually produce the necessary metabolites to out-manoeuvre pathogens in their local 
environment or to repel herbivores. If the metabolites were useful to the plant, the 
biosynthetic genes were retained, with subsequent genetic modifications and improving the 
I process yielding exotic structures rich in functional groups and stereochemistry. Chemical
i
defence involved the production of organic compounds that are not essential to metabolic, 
photosynthetic or other physiologically crucial activities and are known as secondary 
metabolites. They are usually synthesised as by-products during the production of primary 
metabolic process and play a major role in deterring herbivores.
Plants have developed various secondary metabolites and can generally be classified into 
three sub-groups namely nitrogen compounds (including alkaloids and glucosinolates), 
terpenes and phenolics.
1.8 Brief Introduction to Andrographis paniculate
Andrographis paniculata is a shrub that is found throughout tropical and sub-tropical Asia 
| and is locally known in Malaysia as ‘Hempedu bumi’ and ‘Akar cerita bidara’. This 
herbaceous, annual herb is from the family Acanthaceae with a slightly, characteristic odour 
and an intensely bitter taste, hence commonly known as ‘king of bitter’. Pictures of various 
parts of the plant is shown in Figure 1.7 and Table 1.7 shows the systematic position of 
Andrographis paniculata.
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Fig. 1.7. Pictures o f various parts o f  Andrographis paniculata. (a) The whole plant can grow up to 1 m in height.
(b) The flowering part o f  the plant, (c) Seeds.
Table 1.7. Systematic position of A. paniculata
Angiosperms
Dicotyledonae
Gamopetalae
Bicarpellatae
Personales
Justicieae
Acanthaceae
Andrographis
paniculata
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The aerial part of the herb contains several diterpenoids and diterpene glycosides especially 
andrographolide, a major constituent which is not less than 6% of the total diterpene lactones 
present and is mainly responsible for its bitter taste. Other diterpene lactones present free and 
in glycosidic forms include 14-deoxyandrographolide, 14-deoxy-l 1,12- 
didehydroandrographolide, neoandrographolide, andrographiside, deoxyandrographiside and 
andropanoside (Kleipool, 1952). Table 1.8 listed the reported medical properties of 
andrographolide or extracts obtained from the herb.
Table 1.8. Reported medical properties of A. paniculata.
Anti-cancer Siripong et al., 1992; Rajagopal et al., 2003; Kumar et al., 
2004.
Anti-inflammatory Shen et al., 2002.
Immuno-stimulatory Puri et al., 1993; Rajagopal et al., 2003; Kumar et al., 
2004.
Anti-bacterial Singha et al., 2003.
Anti-viral Chang et al., 1991; Calabrese et al., 2000.
Anti-pyretic Deng et al., 1982; Vedavathy & Rao, 1991; Madav et al., 
1995.
Anti-diarrheal Gupta et al., 1990; Gupta et al., 1993; Chiou et al., 1998.
Anti-venom Misra et al., 1992; Nik A. Rahman et al., 1999.
Coon and Ernst (2004) conducted a systematic review on the safety and efficacy of 
Andrographis paniculata in the treatment of upper respiratory tract infections. It was found 
that the data collectively showed that A. paniculata is superior to placebo in alleviating the 
subjective symptoms of uncomplicated upper respiratory tract infection. The authors also 
found a few spontaneous reports of adverse events and A. paniculata may be a safe and 
efficacious treatment for the relief of symptoms of uncomplicated upper tract infection but 
more research is warranted. However, there were several shortcomings of the review that 
need to be addressed (Coon & Ernst, 2004).
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Fig. 1.8. The chemical structure of andrographolide 
with numbered carbon positions.
1.9 The Compound of Interest: Andrographolide
[ Andrographolide (CAS no: 5508-58-7) with IUPAC designation 3-{2-[decahydro-6-
|
I hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-l-napthalenyl]-ethylidene}dihydro-
4-hydroxy-2(3H)-furanone is the major bioactive constituent found in various parts of 
Andrographis paniculata particularly in the leaves. It is a labdane diterpene harbouring a y- 
lactone ring attached to a decahydronapthalene ring system via an unsaturated C-2 moiety. 
As shown above in Figure 1.8, it contains an a-alkylidene y-butyrolactone moiety as well as 
three hydroxyl groups located at C-3, C-14 and C-19 with these being secondary, allylic and 
primary respectively. These hydroxyls are responsible for the bioactivities of 
andrographolide (Nanduri et al., 2004). The stereochemistry of this phytochemical has been 
previously elucidated with the furan ring adopting an envelope conformation whereas the two
j  bicyclic rings adopt a chair conformation (Smith et al., 1982; Fujita et al., 1984; Spek et al.,
I 1987). Andrographolide was considered to be the most active constituent present in A.
; paniculata extract (Kumar et al., 2004; Nanduri et al., 2004)
Terpenes are ubiquitous in nature and occur in most species including humans and are 
sometimes referred to as isoprenes due to a common repetitive structural motif, the branched
5-carbon (C5) unit or isopentane skeleton that is comparable to isoprene. They are a good 
example of a class of natural compound where many members are chiral, structurally diverse 
and have many functional group chemistry. Terpenes contribute to many of the aromas 
associated with plants and range in complexity from C5 units to polyisoprenes that includes 
leaf waxes, latex and rubber. This class of compounds are derived from a number of 
extensive reactions between two C5 units namely dimethylallyl pyrophosphate (DMAPP) and 
isopentenyl pyrophosphate (IPP) whose chemical structures are depicted in Figure 1.9. Thus,
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the products of these reactions shall possess multiples of five carbons (C5). DMAPP and IPP
1 are biosynthesised from two sources, either deoxyxylulose phosphate or mevalonic acid.
I
| (a) (b) (c)
; Fig. 1.9. Chemical structure of (a) isoprene, (b) dimethylalyll pyrophosphate and (c) isopentenyl pyrophosphate.
The simplest of terpenes are hemiterpenes (C5) produced by modification reactions to either 
; IPP or DMAPP and include simple acids such as angelic acid and tiglic acid, which are 
i structural isomers and form esters with many natural products. The complexity of structure 
| then progresses to monoterpenes with 10-carbon skeleton (C10), sesquiterpenes (C15),
j
j diterpenes (C20), triterpenes and steroids (C3o-derived) and tetraterpenes (C40, also known as 
1 carotenoids).
j
| Diterpenes are widely distributed in plant resins and latex, some can be quite toxic. The|
i presence of diterpenes in Rhododendron sp. leaves rendered them poisoinous. Diterpenes are|
formed by the reaction of a 15-carbon chain, famesyl pyrophosphate (FPP) with IPP, which 
is the common basic unit of all terpenes with the first step of this reaction yields famesyl 
j allylic cation. This cation then reacts with IPP causing stereospecific loss of a proton forming 
I geranyl geranyl pyrophosphate (GGPP). Depending on how GGPP cyclise and folds in 
subsequent reactions, an extraordinarily wide range of diterpenes groups can result as shown 
in Figure 1.10 which include taxol and ginkgolide B, one of many ginkgolides obtainable 
from Ginkgo hiloba.
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Biologically Active Polycyclic Natural Products
Simple precursors lead to diverse poly cy lie products
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Fig. 1.10. Depending on subsequent reactions, a simple precursor geranyl geranyl 
pyrophosphate can produce diverse biologically active polycyclic compound. Taxol is a 
well known anticancer compound, ginkgolide B is an active component from Ginkgo biloba  
and abietic acid is the primary irritant in pine wood and resin o f  coniferous trees. (Diagram 
obtained from the Sloan-Kettering Institute official website accessible via www.mskcc.org).
High purity andrographolide which is easily obtained commercially was chosen for this study 
rather than extract from the plant itself. Furthermore, of all phytochemical components 
identified from A. paniculata, andrographolide was shown to be the most active (Kumar et 
al., 2004; Nanduri et al., 2004)
It is estimated that 40% of plants extracts lack reproducibility of activity (Cordell, 2000) and 
this is one of the primary obstacles in incorporating flora in pharmaceutical discovery 
process, despite the diversity o f phytochemicals available. The data generated often do not 
replicate when sampling and extraction procedures were repeated. Different locations, 
climates, micro-environments, chemical stimuli and physical stresses, known as elicitors, will 
affect the content of phytochemicals in quantitative and qualitative manner since the 
biochemical pathways involved in the biosynthesis o f these bioactive compounds are highly 
inducible. This is especially true for terpenoids, where levels usually increase up to three 
orders of magnitude following elicitation (Turlings & Tumlinson, 1992; Trapp & Croteau, 
2001). Recently, Bhan et al. (2006) showed the production of andrographolide, neo- 
andrographolide and 14-deoxy andrographolide from 10 different accessions was susceptible
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| to intrinsic factors such as genotype and ontogeny as well as external factors (elicitors),
I which supported previous finding by Pholphana et al. (2004). Other compounds that often 
! exhibit the same propensity are phenylpropanoids and alkaloids. Furthermore, the presence 
I of polyphenols and pigments in complex plant extracts can interfere with the activity of 
j  bioactive compounds.
Another important factor is the lack of rapid and efficient methods in isolating and 
characterising phytochemicals, particularly if they are only present in trace amounts. It 
usually requires almost 6 months isolating and characterising compounds from a plant 
extract. This does not include the production of standardised extracts. Cultivation and 
harvesting times will also affect total yield of andrographolide (Polphana et al., 2004; Bhan
i
I et al., 2006) and the fact that A. paniculata is an annual herb must also be taken into account.
| Furthermore, only a standardised extract is ideal for experiments. Thus, employing extracts 
| for experiments within the time limit for this PhD was not feasible.
Other argument that can be put forward is that by studying one potentially beneficial 
phytochemical at a time, in this case andrographolide, more understanding can be gained on 
| many aspects of that particular bioactive compound, in contrast to working with standardised 
| extract where the level of qualitative understanding can be limited. Taxol (paclitaxel), an
S important diterpene isolated from Taxus (T. bacata and T. brevifolia) which exhibited anti-
!
| tumour activity, is a good example. The main impediment to its wide clinical use is the 
! sourcing of the compound. To obtain 2.5kg of taxol, approximately 12,000 of T. brevifolia 
; must be cut down (Wall & Wani, 1996). Thus, an alternative source must be sought, either 
from hemi-synthetic production or an analogue from other Taxus species. This task would be 
both scientifically inappropriate and economically unfeasible if the whole extract is 
examined rather than potentially beneficial individual compounds.
On the other side of the coin, isolating an active compound may exclude other 
pharmacologically relevant phytochemicals. This is particularly true when pharmacological 
activity is a result of pharmacokinetic influences and/or pharmacodynamic synergism of 
more than one bioactive compound. Ginkgolides A, B, C, and M from Ginkgo biloba is a 
good example.
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| 1.10 Genotoxicity Information on A. paniculata extracts and Andrographolide
I
i
| Realising the medical potential of A. paniculata, particularly androrapholide which is the 
I major active compound, genotoxicity testing is crucial. There are no existing genotoxicity 
| studies published, to the best of the author’s knowledge at the time of study, especially 
| recommended tests for genotoxic potential such as in vitro cytokinesis block micronucleus 
assay (CBMA). Furthermore, the toxic effects of this plant are not well known.
| However, Liu et al. (1990) suggested that the extract of the aerial parts are not mutagenic in 
vitro. This suggestion is questionable since water extract was used instead of alcohol-based 
j extract. Most of the experimental pharmacological studies mentioned previously utilised 
| either alcohol-based or dried extract of the aerial parts or purified andrographolide. Gupta et
j
| al. (1990,1993) demonstrated that the aqueous extract of the aerial parts was not active ini
exerting anti-diarrhoeal activity. Yin et al. (1991) tested the aqueous extract of A. paniculata 
with the Ames test utilising Salmonella typhimurium strains TA98 and TA100 as well as 
chromosomal aberration assays in mice did not find a positive result on genotoxicity. 
However, it must be pointed out that even with plant extracts that yielded positive results, 
there was noticeable discrepancy in results obtained from the mammalian chromosomal 
aberration and micronucleus assay with those from the Ames test. Usually, the results 
obtained from mammalian in vivo tests will outweigh those derived from bacterial test 
system in vitro. In the study conducted, the coherence between the two was low (Yin et al.,
2001). Furthermore, Yin et al. (1991) justified the extraction method employed in the study 
as to simulate the traditional practice conducted in preparing extract for oral medication. As 
| has been pointed earlier, aqueous extract of A. paniculata are not ideal for experiment 
; because the diterpene lactones such as andrographolide, are sparingly soluble in water 
compared to methanol or chloroform (O’Neil et al., 2001) therefore reducing the 
bioavailability of the compound to the target in this case DNA. Thus, aqueous extract of 
j andrographolide is unable to provide an accurate picture of genotoxicity. Another important 
| aspect that needs to be considered is the suitability of using bacterial test system such as the 
Ames test, since the extract of A. paniculata appeared to have antibacterial activity (Singha et 
j  a/., 2003).
A standardised dried extract of A. paniculata did not produce reproductive toxicity in male 
| Sprague-Dawley rats. There was no sign of testicular toxicity with the treatment of 20, 200
I
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and lOOOmg/kg body weight for 60 days as evaluated by testicular histology, testosterone 
levels, reproductive organ weight and ultrastructural analysis of Leydig cells (Burgos et al.,
1997). However, the paper mainly concentrated on histological evaluation and no 
observation was made on the possibilities of genotoxicological effects of the compound 
examined. Furthermore, it is known that testicular histology is subjective and not quantitative 
in testicular toxicity evaluation. Akbarsha and Murugaian (2000) demonstrated that the 
treatment of andrographolide to male Wistar albino rats at 25mg and 50mg/kg body weight 
for 48 days resulted in decreased sperm counts, immotile spermatozoa with several of them 
possessing abnormalities, limited number of fully differentiated spermatozoa, the disruption 
of the seminiferous tubules and seminiferous epithelium as well as vacuolated Sertoli cells.
The Leydig cells did not show any pathological change and supported the finding made by 
Burgos et al. (1997) but there were spermatotoxic effects observed and possible disruption(s) 
to spermatogenesis.
Andrographolide extract did not cause significant reduction in progesterone concentration in 
pregnant rats and at therapeutic dose, is incapable of inducing progesterone-mediated 
termination of pregnancy (Panossian et al., 1999). However, the extract of A. paniculata 
should not be used during pregnancy or lactation due to potential antagonism with 
endogenous progesterone (Panossian et al., 1999). To the best of the author’s knowledge, the 
teratogenicity effect of the herb has not been evaluated to this date.
As a brief summary, Figure 1.11 overleaf illustrated the factors that are involved in the 
revival of interest in phytomedicines and the imperative needs for more information on their 
safety and efficacy.
Copy I 30
Y. Sharifuddin
Chapter 1
Factors that contribute  to its increasing  
popularity  a m on g  co nsum ers
•  Increasing interest in self-medication
• Increasing interest for its use as daily 
supplements
•  As complementary to allopathic medicine
• Popular notion that it is naturally safe
• Growing concern o f  adverse effects o f  
synthetic drugs
• Disappointment with the efficacy o f  
conventional drugs
• Desire for more natural lifestyle
•  Lower cost than modern drugs
Scientific factors that contribute  to its revival
•  The potential to provide novel treatment for 
known diseases
• The possibilities for treatment that carries 
less side effects
• Availability o f  new technologies allow s 
better understanding o f  phytochemicals
• Advances in medical sciences increased the 
number o f molecular targets
Phytomedicines
Increasing popularity among consumers lead to increasing 
market value, which in turn provide economic opportunities
1
Increasing use by the public warrants monitoring and 
regulat ion o f the industry
I
A more accurate picture o f the industry needed for regulation 
purposes, requires better blueprint o f safety, quality and 
efficacy assessment.
Dev elopment o f  assessment techniques is also essential
Fig. 1.11 Shows the factors involved in phytomedicines’ revival and the need for more information on safety.
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CHAPTER 1
PART 2: INTRODUCTION TO THE GENETIC TOXICOLOGY IN 
MAMMALIAN CELLS AND ITS IMPORTANCE
1.11 Brief Introduction to Genetic Toxicology
Paracelsus first described the ‘wasting disease of miners’ in 1567 based on his observations 
in Austrian and other several European mines in the Middle Ages. He later suggested that the 
exposure to realgar (arsenic sulphide) and other natural ores might have been the culprit in 
causing this condition, which is today known as cancer. Although this type of cancer was 
eventually attributed to radioactivity emitted from decay products of radon gas rather than 
arsenic, Paracelsus was among the first to consider chemical compounds as potential 
carcinogens.
The study of chemical mutagenesis began in the early 1940s when Charlotte Auerbach and 
colleagues discovered that mustard gas, a chemical warfare agent used against soldiers in 
trenches during the First World War was capable of causing genetic mutation in fruit fly, 
Drosophila (reviewed by Beale, 1993). Since then and for the next three decades, most 
experiments were performed on mice or flies to study chemically-induced mutation. 
Eventually, better test systems based on yeast and bacteria were developed where data can be 
obtained cheaper and quicker than using flies or mice. Furthermore, the inclusion of liver 
extracts and cofactors allowed the detection of more mutagenic agents and highlight the 
importance of biotransformation in mutagenesis studies. Then, in 1973 Bruce Ames 
successfully showed that various chemical carcinogens induced mutation in the genetically- 
engineered Salmonella typhimurium bacteria (Ames et al., 1973), known today as the Ames 
test which has been widely used to screen potential cancer-causing agents.
Genotoxic agents are rather ubiquitous in the environment whether they are man-made 
products or found naturally. Many synthetic chemicals employed in manufacturing industry,
X-rays developed for medical diagnosis and carcinogenic hydrocarbons in coal tar or 
smelters are examples of genotoxic compounds of man-made in origin. Even the way of how
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food is being prepared such as grilling red meat at high temperatures are known to yield 
potent mutagens. Naturally occurring agents include aflatoxin produced by Aspergillus flavus 
| that grows on nuts and isothiocyanates, the mutagenic phytochemicals found in cruciferous
i
vegetables. Reactive oxygen species and free radicals that are endogenously produced as a 
result of cellular metabolism are also known to be genotoxic. Figure 1.12 shows the 
mechanisms of actions of DNA and non-DNA reactive genotoxicants.
Genetic toxicology is a broader term than chemical mutagenesis, dedicated to the study of 
genetic damage, the physical and chemical agents that are responsible, the mechanism 
involved for it as well as the cellular and organisms’ responses to this injury. Since the 
potential consequences of genetic damage include birth defects and cancer, the elucidation of 
novel substances’ potential to elicit DNA damage and genome instability is an important step 
in the development of new medicines and other products intended for human use. Various 
endpoints can be employed in assessing genotoxic damage and they are shown in Figure 
1.13.
1.12 Biotransformation of Xenobiotics
All organisms are constantly exposed to foreign chemicals and these can be man-made 
(drugs, industrial chemicals) or naturally occurring compounds from the environment.
Uptake is usually via ingestion, however inhalation and transdermal routes are also possible.
Due to the lipophilicity of many chemicals that facilitate their uptake via these routes, 
organisms have evolved mechanisms to increase their hydrophilicity for rapid excretion via 
bile and urine. Otherwise, the accumulation of these xenobiotics will overwhelm defense 
mechanisms and disrupt systemic homeostasis. This process is known as biotransformation 
and is catalysed by various enzymes primarily in the liver of higher organisms but are also 
present in other organs such as the gut, kidneys and lungs.
Plants have been known to be one of the reasons for the evolution of biotransformation in 
animals. Most animals are plant-eaters and customarily being bombarded by various 
secondary metabolites which play a role in plants’ defence mechanisms. However, many 
chemicals can also be transformed into more reactive metabolites. In pharmacology for 
example, the metabolites of some parent drugs impose the desired therapeutic effect but in
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|
the case of polycyclic aromatic hydrocarbons (PAHs), that can be subjected to epoxidation 
| resulting in the production of eletrophile that is damaging to DNA and proteins.
Xenobiotic metabolism occurs in two stages namely Phase I and Phase II. Different 
compounds will possess varying effects due to the length of time they remain in the 
organism. A compound that is toxicologically very active but is extremely hydrophilic will 
be easily excreted from the body without the possibility of inducing severe damage in 
contrast to relatively low activity compound that is hydrophobic but lingers longer in the 
body and could potentially be more harmful. Biotransformation will be discussed in greater 
length in Part 2 of the second Chapter in this thesis.
I
| Various pro-mutagenic and pro-carcinogenic compounds require metabolic activation before
| they can exert their effect and typical cell culture techniques do not often maintain the
[ metabolic capacity of the liver. Accordingly, the addition of S9-fraction of liver homogenate
into cell cultures in vitro was intended to provide an external metabolic capability. The 
creation of cell lines for genotoxicology applications, which have been genetically 
engineered to be metabolically competent such as AHH-1 and MCL-5 serve as an alternative 
! to the addition of S9-fraction, thus permitting the assessment of xenobiotics that need
j
bioactivation.
1.13 The Cycle of Cell Division
Cells proliferate in response to extracellular growth factors, passing through a repeated 
sequence of events known as the cell cycle. This has four major phases: Gi, then S, G2 and 
lastly the mitotic or M-phase. This is followed by division of the cytoplasm and plasma 
membrane to produce two daughter cells. Gi, S and G2 together constitute interphase, which 
is the majority of the cell cycle. During interphase, the cytoplasm increase in volume, the 
DNA is uncoiled then diffuse within the nucleus and is a stage of general growth where 
ribosomes, mitochondria and other cellular proteins are synthesise. The chromosomes are 
replicated during the DNA synthetic or S-phase. Most somatic cells in the body are not 
actively dividing and are arrested at Go within Gi. Figure 1.14 shows the assorted phases of 
the cell cycle.
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Mammalian cells will proliferate only if stimulated by extracellular growth factors secreted 
by other cells. These operate within the cell through the proto-oncogene signal transduction 
cascade. If deprived of such signals during Gi, the cell diverts from the cell cycle and enters 
the so-called Go state. Cells can remain in Go for years before recommencing division.
The Go block is imposed by mitosis-suppressor proteins such as the retinoblastoma (Rb) 
protein encoded by the normal allele of the retinoblastoma gene. These bind to specific 
regulatory proteins preventing them from stimulating the transcription of genes required for 
cell proliferation. Extracellular growth factors destroy this by activating Gi-specific cyclin- 
CDK complexes, which phosphorylate the Rb protein, altering its conformation and causing 
it to release its bound regulatory proteins. The latter are then free to activate transcription of 
their target genes and cell proliferation ensues (reviewed by Lodish et al., 1995).
The cell cycle is driven by alternating activation and de-activation of key enzymes known as 
cyclin-dependent protein kinases (CDKs), and their cofactors called cyclins. This is 
performed by phosphorylation and de-phosphorylation by other phosphokinases and 
phosphatases, specific cyclin-CDK complexes triggering specific phases of the cycle. At 
appropriate stages, the same classes of proteins cause the chromosomes to condense, the 
nuclear envelope to break down and the microtubules of the cytoskeleton to re-organise to 
form the mitotic spindle.
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Growth * 
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normal 
metabolic 
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x: preparation 
5 for mitosis
DNA
replication
Growth
Fig. 1.14. Shows the main stages o f  the cell cycle divided into two main parts, the interphase and 
the mitotic phase. Interphase consists o f  G), S and G2 phases whereas the mitotic (M) phase can be 
further sub-divided into prophase, metaphase, anaphase and telophase. Cytokinesis marks the end 
o f the cell cycle and produced two genetically identical daughter cells. (Diagram obtained from 
http://bhs.smuhsd.org).
1.14 Cell Cycle Checkpoints and the Integrity of the Genome
Directly after mitosis, in Gi phase the cell increases in size and initiates necessary RNA 
synthesis (transcription) and proteins (translation). In subsequent S phase, nuclear DNA is 
replicated to produce an exact copy o f the genome for the ensuing daughter cells. During G2 , 
the cells will grow and produce extra proteins to ensure that two viable daughter cells can be 
formed. The process of RNA and protein syntheses that began in the Gi phase are extended 
during the S and G2 phases. Finally, during M phase, the chromosomes are organised so that 
two genetically identical progeny cells can be configured, after which the entire cycle can 
begin again. Cells can also stop dividing to remain in Go and may stay in this state for a 
considerable amount of time before starting to divide again or remain in Go permanently until 
the organism dies (reviewed by Lodish et al., 1995; Purves et al., 1998).
In a normal cell cycle, the passage from one phase to another is strictly governed. Although 
still being debated, genetic evidence that proteins involved in the orderly progression through 
the cell cycle are also involved in the checkpoint response to DNA damage is accumulating.
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This connotes that in all cells, these cell cycle checkpoint pathways are active in basal state 
but they are up-regulated in response to DNA damage. The term checkpoint is defined more 
upon the transition between phases that is being inhibited by DNA damage at the Gi/S, intra- 
S and G2/M checkpoints. Although these checkpoints are temporally distinct, they all 
j  response to DNA damage and share many proteins (reviewed by Klug and Cummings, 2005).
|
The DNA damage responses during any phase of the cell cycle possess the same pattern.
After the detection of DNA damage by sensor proteins, signal transducer proteins transmit 
the signal to effector proteins, which in turn launch a cascade of events that cause cell cycle 
arrest, DNA repairs, apoptosis and/or activation of damage-induced transcription programs.
1.14.1 The Gi/S checkpoint
The Gi/S transition is promoted by non-phosphorylated CDC25A protein. The type of DNA 
damage encountered determines the response pathway of cell cycle arrest. DNA double 
strand breaks lead to phosphorylation of ATM which in turn phosphorylates Chk2. Single­
strand gaps cause the activation of the ATR, Radl7-RFC and the 9-1-1 complex, resulting in 
the phosphorylation of Chkl. Thus the phosphorylation of CDC25A by Chkl or Chk2 causes 
inactivation of this protein by nuclear exclusion and ubiquitin-mediated proteolytic 
degradation, leading to Gi arrest. ATM and ATR also phosphorylates p53, which leads to 
stabilisation and accumulation of p53 protein as well as the promotion of p53 transcription 
factor activity. The target of the transcription factor p53 is p21 , whose role is to inhibit 
CDK2 activity causing the maintenance of cell cycle arrest. For this reason, p53 is known 
affectionately as ‘the guardian of the genome’.
1
1.14.2 The Intra-S-phase checkpoint
There are two pathways mediating this checkpoint. The first pathway, the ATM/ATR- 
Chk2/Chkl-CDC25A-CDK2 is almost similar to Gi/S checkpoint and is responsible for 
postponing DNA replication by inhibiting the loading of CDC45 onto chromatin. As a 
consequent, DNA polymerase-a attach to the pre-replication complexes and prolonging the 
DNA replication period thus permitting DNA repair to occur.
The second pathway involves NBS1 (NBS stands for Nijmegen breakage syndrome, referring 
to a human disorder characterised by cancer predisposition, chromosomal instability, 
immunodeficiency, hypersensitivity to ionising radiation and growth impediment) that is 
phosphorylated by ATM together with Chk2. This activation leads to a cascade involving
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Rad50- and Mrel 1-like initial DSB recognition that is not only required in cell cycle arrest 
but also in repair processes activation.
1.14.3 The G2/M checkpoint
| When cells confront DNA damage in G2, the G2/M checkpoint halts the cell cycle in order to
! restrain the cell from entering mitosis. As in the Gi/S checkpoint, the type of DNA damage
dictates the cellular response route; the ATR-Chkl-CDC25 for DNA lesions such as those|
I caused by UV light and ATM-Chk2-CDC25 for double-strand breaks. Apart from down-i
| regulating CDC25A, both Chkl and Chk2 up-regulate WEE1 via phosphorylation, which
i
together manage CDC2/CyclinB activity. This latter complex augments G2/M transition 
under normal circumstances and inactivation blocks the cell cycle when damage occurs in 
G2. The maintenance of this arrest seems to be partly independent of p53/p21, unlike in the 
Gi/S checkpoint, whereas tumour cells lacking functional p53 still tend to accumulate in G2 
after the induction of DNA damage (reviewed by Klug and Cummings, 2005).
As the cell cycle checkpoint pathways are predominantly evolved to prevent transferring 
DNA damage to daughter cells, it is obvious that defects in checkpoint responses can result 
in genomic instability leading to transformation of normal cells into cancer cells. Indeed, the 
absence of p53 or ATM causes syndromes featuring cancer susceptibility. In addition, other 
genes involved in cell cycle checkpoints are related to cancer, most of them also having 
function in DNA repair. This combination probably makes mutations or deletions more 
severe where there is less repair and less control.
After the successful completion of interphase, mitosis which is the second major stage of the 
cell cycle will commence. The replicated chromosomes must become condensed to be able to 
migrate to the opposite poles, which ultimately will become two separate daughter cells. The 
sequence of events in mitosis is described below with the aid of Figure 1.15 that shows the 
delicate dance of chromosomes during mitosis.
Prophase.
Prophase begins immediately after interphase. The chromosomes each consisting of two 
identical sister chromatids, begin to contract and become visibly condensed within the 
nucleus. The nucleoli gradually disperse. The centrosomes begin to duplicate, split and 
subsequently migrate to the opposite sides of the cell and forming the spindle poles
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(microtubule organising centres, MTOCs). The spindle apparatus of tubulin fibres begins to 
assemble around the two centrosomes at opposite poles of the cell.
Pro-metaphase (late prophase).
The nuclear membrane dematerialises and kinetochores develop around the centromeres of 
| the chromosomes. Tubulin fibres enter the nucleus and assemble, radiating out from the
| kinetochores and linking up with those radiating from the centrosomes.
I Metaphase.
| Tension in the spindle fibres causes the chromosomes to align midway between the spindle 
poles thus creating the metaphase plate. This alignment facilitates the separation of 
chromatids.
Anaphase.
When the chromatids of each chromosome begin to separate, the cells enter anaphase and 
this is the shortest part of mitosis. The centromeric DNA shared by sister chromatids is
duplicated, they separate and are drawn towards the spindle poles. All of the chromosomes
begin to separate at the same time.
Telophase.
This is the final stage of mitosis and is essentially the reverse of prophase. The separated 
sister chromatids (now considered to be chromosomes) reach the spindle poles and a nuclear 
membrane reforms around each group. New nuclear membranes are produced by the 
endoplasmic reticulum. The spindle fibers depolymerise, condensed chromatin uncoil then 
diffuses and nucleoli re-appear. Telophase ends when the nuclei of the two resultant daughter 
cells appear to be in interphase.
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Fig. 1.15. The delicate dance o f  chromosomes during mitosis can be sub-divided into four main 
stages. Centrioles are crucial element in centrosome which act as spindle poles pulling sister 
chromatids in opposite direction. (Diagram obtained from www.britannica.com).
Cytokinesis.
After a successful completion of karyokinesis, cytokinesis or the physical separation of one 
cell into two daughter cells marks the end of the cell cycle. This process requires a 
synchronious operation of the membrane systems, the cytoskeleton and the cell cycle 
mechanism, which are spatially and temporally controlled in a precise manner. One must 
point out that cytokinesis actually begins in late anaphase where microtubules have elongated 
and contact the cortex. The rearrangement also created a region of bundled microtubules 
between the chromosomes termed the midzone. In early telophase, the cleavage furrow 
ingresses and as cytokinesis progresses, the cleavage furrow has fully ingressed constricting 
the midzone effectively forming an intercellular bridge containing a microtubule midbody. 
When the intercellular bridge is resolved and eventually separates the two daughter cells, 
cytokinesis and ultimately the cell cycle is completed. Figure 1.16 highlights the progressive 
part of the cytokinesis process.
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M i d z o n e
Fig. 1.16. Different stages o f  cytokinesis shown in a progressive manner by schematic and 
immunoflurescence illustrations, (a) Cell is in a metaphase stage where chromosomes are aligned at the 
equator (metaphase plate) by the microtubules o f  the mitotic spindle, (b) Microtubules have extended and 
contract the cortex, a region o f  bundled microtubules between chromosomes known as the midzone was 
created after microtubule rearrangement. The cell is in late anaphase and the cleavage furrow components 
(red) have rallied at the equator, (c) Cell is in early telophase and cleavage furrow continues to ingress, (d) In 
late telophase, the cleavage furrow has completely ingressed and compacted the midzone producing an 
intercellular bridge consisting o f  microtubule midbody. Cytokinesis is completed when the intercellular 
bridge is resolved giving rise to two genetically identical daughter cells. (Eggert et a l., 2006)
1.15 The Centrosome Cycle
At Gi the pair of centrioles associated with each centrosome separate. During S-phase and G2 
a new daughter centriole grows at right angles to each old one. The centrosome then splits 
the beginning of M-phase and the two daughter centrosomes move to opposite spindle poles. 
This cycle will be discussed in further details in Chapter 4 of this thesis.
1.16 DNA Damage Repair Mechanisms
There are two processes that enable a cell to cope with the severity of DNA damage it 
sustains. If the damage is extensive, the cell can initiate apoptosis. However, if the damage is 
less serious, cells have developed a range of repair processes that restore the DNA to its 
undamaged state (error-free repair) or to an improved but still altered state (error-prone 
repair).
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DNA damage checkpoints can only prevent the transfer of mutations to daughter cells in the 
[ presence of an efficient DNA damage repair machinery. Different types of DNA repair
pathways have evolved to counter various categories of lesions possible. Important pathways 
in mammalian cells include base excision repair (BER), nucleotide excision repair (NER), 
mismatch repair (MMR) and double-strand break (DSB) repair.
1.17 Genotoxicants and Mutations
When xenobiotics are internalised by cells, most of them are metabolised and the resultant 
metabolites are either retained or excreted. Inside the cell, genotoxicants or their metabolites 
are capable of directly or indirectly affect the regulation and expression of genes that are 
j  crucial in DNA repair, cell cycle oversight, cell differentiation and/or apoptosis. Some
genotoxicants act directly by forming DNA adducts or inducing chromosomal abnormalities 
such as chromosome fusion, breakage, deletion, non-disjunction and missegregation. For 
example, arsenic and nickel are known to cause numerical and structural chromosome
l
| abnormalities (Hughes, 2002; Kasprzak et a!., 2003). Other genotoxicants may act via non-
| genotoxic routes such as causing inflammation, formation of reactive oxygen species,
immunosuppression, epigenetic silencing as well as receptor activation such as oestrogen 
receptor or arylhydrocarbon receptor. Cumulatively, these genotoxic and non-genotoxic 
mechanisms can change signal-transduction pathways resulting in hypermutability, genomic 
| instability, failure in cell proliferation control and resistance to apoptosis, which are some of
the hallmark of cancer cells (reviewed by Hanahan & Weinberg, 2000). Figure 1.17 overleaf 
provides an overview of genotoxic and non-genotoxic action routes of genotoxicants.
A mutation is an alteration that occurs to the structure or quality of the genetic material that 
could lead to a change in phenotype. Mutations can involve modifications of the nucleotide 
sequence of a single gene, block of genes or whole chromosomes. Changes in: (1) single 
genes are the consequence of a point mutation, (2) blocks of genes are generally due to strand 
breaks; and (3) whole chromosomes are due to aneuploidy.
Mutations are permanent changes to nuclear DNA and can be inheritable if germ cells are 
involved. During cell division, replication errors may arise from damaged bases (e.g. Alkyl- 
Guanine) resulting in mutation which potentially capable of altering the gene product. The
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occurrence of such errors during replication are usually due to exposure to viruses, 
chemicals, radiation or even internally during normal biological processes such as meiosis
!
and hypermutation (reviewed by Griffiths et al., 2004). Although mutations can have 
| undesirable effects, they are valuable currency in evolution. Deleterious and unfavourable
| mutations will be removed from the gene pool via natural selection and those that confer
! advantageous adaptation to a species will accumulate in the population. There are also
| neutral mutations that accumulate with time but are not deleterious in nature (reviewed by
Griffiths et al., 2004).
!
i
I
Mutations can be categorised into somatic mutations that result in neoplasia (cancer) or cell 
death and germline mutations, which are inheritable and in some cases such as familial 
adenomatous polyposis (FAP) involving colorectal cancer is attributed to the APC gene 
mutation, capable of causing somatic mutations in the progeny (reviewed by Klug and 
Cummings, 2005)
Mutations may be genetically sub-divided into different order and those that occur at 
nucleotide level are micro-mutations whereas those that cause changes at chromosomal level 
are macro-mutations.
1.17.1 Micro-mutations
a) Point mutations:
Transitions are exchanges of a purine with another purine (i.e. A<-»G) or a pyrimidine for a 
pyrimidine (i.e. C«-*T). Transversions in comparison are less common where a pyrimidine 
has been exchanged with a purine and vice-versa (e.g. A/G«-»C/T). There are essentially three 
kinds of point mutations depending on what the erroneous codon codes for:
1) Silent mutations: Changes to the amino sequence but code for the same amino 
acid, thus no changes in biological homeostasis.
2) Mis-sense mutations: Changes to the DNA are manifested by changes in amino 
acid resulting in protein sequence alteration that have no impact, can be lethal or 
in some rare occasion lead to gain of function.
3) Non-sense mutations: Code for a stop codon that shorten the protein, which may 
have no effect, leading to a loss or gain of function.
Copy 1 46
Y. Sharifuddin
Chapter 1
b) Insertions:
One or more nucleotides added into the DNA that normally formed by transposable elements 
or errors during replication of repeating components (e.g. tandem repeats). Insertions are well 
known to cause frameshift mutations and modified mRNA splicing, which can both alter the 
gene product.
ij
| c) Deletions:
I As the name implies, are removal of a single or multiple nucleotides from DNA that can
| result in ffameshifts. Unlike point mutations and insertions, deletions are irreversible damage
to the DNA (Brown, 2002).
1.17.2 Macro-mutations
As stated before, these types of mutations occur at the physically observable chromosomal 
level and can be categorised as below.
a) Duplications:
Duplication is the presence of two adjoining copies of a chromosomal segment and can be 
either ‘direct’ or ‘inverted’. Duplications may originate by unequal crossing-over in a 
previous meiosis or as a result of translocation, inversion or presence of an iso-chromosome 
in a parent. Generally, duplications are more common and cause higher levels of gene dosage 
but are less detrimental than deletions.
b) Deletions:
Deletion can arise from two breaks, followed by faulty repair, from unequal crossing-over in 
a previous meiosis or as a consequence of a translocation in a parent. Deletions of 
chromosomal regions can be interstitial or terminal. Cri-du-chat syndrome is caused by 
terminal deletion of the short arm of chromosome 5 and is so-called because the malformed 
larynxes in the affected babies made them to cry like cats. Sufferers have profound learning 
disability, low birth weight, low-set ears, epicanthal folds and hypertelorism (widely spaced 
eyes).
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c) Inversions:
Arise from two chromosomal breaks with end-to-end switching of the intervening segment.
If this includes the centromere it is pericentric; if not the inversion is paracentric. The 
medical significance of inversions lies in their ability to cause chromosomally imbalanced 
i gametes following crossing-over.
I
| d) Translocations:
A translocation involves exchange of chromosomal material between chromosomes and three 
types are recognised namely centric fusion (Robertsonian translocation), insertional and 
reciprocal. Approximately 4% of Down syndrome cases are due to Robertsonian 
translocation between the long arms of chromosome 21 and any other acrocentric, normally 
chromosome 14. Sometimes, one parent has a balanced version of the same translocation.
e) Isochromosomes:
An isochromosome has a deletion of one arm but duplication of the other. In live births, the 
most prevalent involves the long arm of chromosome X, causing Turner syndrome due to 
short arm monosomy and long arm trisomy. Most incidents of isochromosomes lead to 
spontaneous abortion.
f) Loss of heterozygosity:
A locus (or even loci) where a deletion or other process has converted the locus from 
heterozygosity to homozygosity. This event can lead to cancers due to loss of tumour 
suppressor genes (Griffiths et ah, 2004).
1.18 Aneuploidy
Aneuploid cells have chromosome numbers that differ from the normal number for the 
species. In aneuploidy, the deviation is due to one or a small number of chromosomes. For 
example, in humans where the diploid (2n) number of chromosomes is 46, cells with 45 or 47 
would be referred to as aneuploid. Cells can give rise to aneuploidy by: (1) the failure of 
homologous chromosomes to separate properly (non-disjunction) in meiosis I or mitosis or 
sister chromatids in meiosis II (Dellarco et al., 1985); or (2) the chromosome(s) do not bind 
to the spindle during division so that the chromosome(s) is lost to either nucleus. The result
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of non-disjunction is that one pole receives both homologous chromosomes or chromatids. 
Assuming only one chromosome or one pair of chromosomes is involved, the daughter nuclei 
will have one chromosome too many or one too few (2n ±1).  Unlike direct mutagenesis, 
there are many potential targets for aneuploidy.
I
|
Aneuploidy may arise either on a spontaneous basis or chemically-induced during cell 
division in somatic and germ cells. Aneugens are chemicals that are capable of inducing
i
aneuploidy or polyploidy. There are many possible targets for aneugens including molecules:
• that are crucial part of DNA-containing structures such as centromeres and telomeres.
• essential in chromatid attachment and separation including chromatin glue proteins
i
and kinetochores.
• that are part of the spindle apparatus for example centrioles and tubulins.
• that are part of the anaphase promoting complex (APC) or involved in cell cycle 
control such as cyclins and p53.
• indirectly involved in the cell cycle such as calmodulin.
Any abnormal putsch to the cellular division by disrupting one or more of its crucial 
components can be detrimental to chromosome segregation fidelity. There are two classical 
processes that lead to aneuploidy namely chromosome non-disjunction and chromosome 
loss. Chromosome non-disjunction occurs when a metaphase chromosome unable to 
disassociate and both sister chromatids migrate to one of the daughter nuclei (Kirsch-Volders 
et al., 2002) resulting in one daughter cell gaining a chromosome (e.g. trisomic 2N+1) and 
the other loses a chromosome (e.g. monosomic 2N-1). Chromosome loss arise due to 
| chromosome lagging during anaphase for example involving the failure of spindle fibres to 
attach to a chromosome. Lagging chromosomes are displaced chromosome that usually 
forms a micronucleus and thus are not part of the daughter nuclei at the end of mitosis. 
Consequently, one or both of these daughter nuclei are hypoploid, where the chromosome 
number is less than the normal euploid configuration. Micronuclei formed can be detected 
cytogenetically.
Centrosome amplification may also contribute to aneuploidy where the presence of 
multipolar microtubule organising centres (MTOCs) pulled chromosomes in different 
directions resulting in aneuploid progeny with either single, multiple nuclei or even
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micronuclei (Pihan & Doxsey 1999; Brinkley, 2001) as shown in Figure 1.18 below. 
Alternatively, aberrant MTOCs may form pseudo-bipolar spindle poles to mute the 
supernumerary effect but still incapable of maintaining normal chromosome segregation 
resulting in unequal chromosome numbers and lagging chromosomes, which would later 
form a micronucleus (Pihan & Doxsey 1999; Brinkley, 2001). The amplified centrosomes 
will also be transferred to daughter cells and may be involved in further rounds of abnormal 
mitoses.
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Fig. 1.18. Frequent factors contributing to chromosomal segregation infidelity that leads to aneuploidy. In (A), 
chromosomes aligned at the metaphase plate and migrate equally to opposite spindle poles producing two 
euploid daughter cells. (B) shows the outcome o f  mitosis in the presence o f  a lagging chromosome which gives 
rise to a micronucleus. In (C) and (D), anomalous centrosome number presents a segregational putsch to the 
normal chromosome distribution mechanism causing uneven configuration in daughter cells. In (E), 
chromosomal non-disjunction generates a hypoploid and hyperploid daughter cells. (Adopted from Yang et a l., 
2003).
Apart from the two classical processes stated, aneuploidy may also arise via other pathways 
such as defective centromere division, chromosome replication errors during meiosis and 
non-conjunction, which is the inability of the homologous chromosomes to achieve a paired 
state. Some compounds presence in certain concentrations may interact physico-chemically 
such as lipophilic interaction and in effect disrupt cellular components or processes such as 
cytokinesis and spindle synthesis. Furthermore, at higher concentrations, cytotoxicity can 
also induce physico-chemical interactions that may cause non-specific modifications to
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cellular division mechanism (Parry et al., 1996). Figure 1.19 also illustrates various routes 
leading to aneuploidy.
Aneuploidy induction through the inhibition of spindle function for example, does not occur 
via direct interaction between the suspected compound or its active metabolite with DNA but 
acting on its target receptor(s) such as tubulin in a characteristic dose-dependent manner that 
may include a threshold level (Aardema et al., 1998). The existence of thresholds for the 
initiation of chromosome loss and chromosome non-disjunction by spindle inhibitors such as 
carbendazim, colchicine, mebendazole and nocodazole has been reported (Kirsch-Volders, et 
a l,  2003).
a Aberrant mitosis b Cohesion d efects c  Merotelic centromere 
attachment
d Mitotic checkpoint 
defects
'6N
DNA and
Aberrant cytokinesis
vr
Multipolar spindle Premature separation Lose at cytokinesis of chromosome
yielding both sister chromatids attached to both poles 
attached to the same pole
Both sister chromatids 
delivered to one daughter cell 
after unstable attachment or 
mitotic checkpoint defect
Fig. 1.19. Shows various other routes to aneuploidy. Gains and losses o f  chromosomes can occur in several 
ways as displayed. Aberrant mitosis can be caused by abnormal centrosome number due to centrosome 
amplification resulting in polyploidisation, centrosome duplication errors and ultimately aberrant cytokinesis. 
Cohesion deficiency and merotelic attachment, where a kinetochore is attached to microtubules from both poles 
can also cause chromosome loss. Finally in (d), defects in the mitotic checkpoint where weakened mitotic 
checkpoint signalling by one or more unattached kinetochores does not produce enough signal level for the 
‘wait anaphase’, preventing anaphase advancement in the presence o f  unattached kinetochores. (Adopted from 
Kops et al., 2005).
Polyploidy on the other hand corresponds to an exact multiple of the haploid number of 
chromosomes (N), for example 3N and are caused by the absence of a functional mitotic 
spindle and the consequent failure of chromatid migration to the opposite poles. This mitotic 
slippage or the inability to migrate to spindle poles produced cells that possess 4N and 4C
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with C denoting to the haploid DNA contents (Elhajouji et al, 1998). Cytokinesis failure and 
nuclear fusion in binucleated cells can also lead to polyploidy (Kirsch-Volders et al., 1998).
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Fig. 1.20. Shows the relation between the mitotic checkpoint with different stages o f  the cell cycle 
beginning with prophase and ending with telophase and cytokinesis producing two identical daughter cells. 
To initiate mitosis, the cell needs the master mitotic kinase, the cyclin-dependent kinase-1 (CDK1) activity 
that depends on the binding o f  cyclin B to CDK1. Separase is a protease that is required to abolish sister- 
chromatid cohesion at the metaphase-anaphase transition. This enzyme is kept inactive by another protein 
known as securin (SEC) prior to anaphase. Cohesins which hold sister chromatid together are shown as 
yellow spheres in the expanded view o f  the chromosome. Unattached kinetochores trigger the formation o f  
the mitotic checkpoint complex (MCC) which prevents CDC20 to activate the anaphase promoting 
complex/cyclosome (APC/C). The attachment o f  all sister chromatid pairs to kinetochore mirotubules and 
their bi-orientation generates congression to the metaphase plate and negatively regulates the mitotic 
checkpoint signal. Concomitantly, CDC20 is released followed by APC/C activation and leads to 
polyubiquitination o f  anaphase substrates such as securin and cyclin B that is subsequently eliminated by 
the proteasome. Securin destruction activates separase, which immediately separates the sister chromatids 
by targeting the cohesion rings that are holding them together. The elimination o f  cyclin B also inactivates 
the master mitotic kinase CDK1-cyclin B, initiating cytokinesis and the mitotic-exit programme. (Adopted 
from Musacchio & Salmon, 2007).
The spindle assembly checkpoint or also known as the mitotic checkpoint prevents 
chromosome missegregation and aneuploidy by repressing anaphase commencement until all
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of the replicated chromosomes are successfully connected to spindle microtubules. Figure 
1.20 highlights the relationship between the mitotic checkpoint with cell cycle machinery. 
However, an impaired mitotic checkpoint response or the inability to sustain mitotic 
checkpoint signalling, has been observed in human tumour cell lines challenged with 
microtubule poisons as observed by a decreased percentage of cells in mitosis and/or a 
reduced length of metaphase arrest.
1.18.1 Aneuploidy and Cancer.
As mentioned previously, aneuploidy may arise spontaneously or due to chemical induction 
of chromosome gain or loss during cell division in somatic and germ cells. Aardema et al.
(1998) reported that the environment does not possess a major influence on aneuploidy 
induction based on the similarity of aneuploidy incidence levels found at birth in various 
evaluations of newborns in different geographical localities. Although various compounds 
have been examined for their potential aneugenic effects on germ cells, information on 
carcinogenicity is rather limited for aneugens compared to clastogens and gene mutation 
inducers (Aardema et al., 1998).
Aneuploidy induction may alter the distribution of oncogenes and tumour suppressor genes 
(Deusberg et al., 2004) where chromosomes containing genes involve in the mitotic process 
leads to asymmetric segregation of chromosomes, instituting an autocatalytic karyotypic 
evolution that generates pre-neoplastic and subsequently cancerous cells (Fenech 2002). 
However, this is currently not a consensus within the scientific community. Some regarded 
; aneuploidy to be immaterial to tumourigenesis (Hahn et al., 1999), whereas others have 
argued it to be a wholly benign side-effect accompanying transformation (Marx, 2002) and 
yet another school of thought considered aneuploidy to play a contributing role to tumour 
progression but not tumour inititation (Zimonjic et al., 2001).
Cancer cells are not polyploid but aneuploid, which means in addition to alterations in the 
total chromosome number they also harbour various chromosomal abnormalities such as 
amplifications and deletions. Thus, comparable to Tolstoy’s unhappy families, every 
aneuploid tumour has its own version of aneuploidy, rendering the quest to determine the 
role of aneuploidy and in identifying common features shared by aneuploid tumour cells, to
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be very challenging. This correlation between anueploidy and cancer has been known for 
decades but the answer as to whether aneuploidy is the contributing factor or just a secondary 
consequence of transformation still remains an intriguing mystery (Duesberg & Rasnick,
2000; Matzke et al., 2003).
Even though the relative influence of abnormal chromosome numbers and gene mutations in 
human cancers is still a focal point of intense debate, aneuploidy is regarded to play a role in 
tumourigenesis (Fenech 2002). The ubiquity of aneuploidy incidence in human cancer cells 
cannot be disputed and it is the prominent type of chromosome instability observed in solid 
tumours in general (Lingle et al., 1998). Aneuploidy is reported to be an early event or 
present at an early stage in human pre-cancerous neoplasias of the throat, oesophagus, lung, 
skin, gonads, pancreas and acute leukaemia (Duesberg et al., 2004). Aneuploidy has been 
used as a screening and prognosis marker for several cancers such as for patients with 
Barrett’s oesophagus (Teodori et al., 1998) and individuals with high risk of developing head 
and neck squamous cell carcinomas (HNSCC) (Barrera et al., 1998; 1999).
Centrosome amplification is almost consistently associated with aneuploidy but is absent in 
stable diploid cells (Hollander and Fomace, 2002). Numerical centrosome anomaly may be a 
common cellular response to genotoxic damage or other cellular stress incidents (Sato et al.,
2004). The origin of supernumerary centrosomes in response to genotoxic agents such as 
radiation (Sato et al., 2004) and metals (Holmes et al., 2006) is not known but various 
possible suspects include temporal disengagement between centrosome duplication and DNA 
replication cycles combined with the loss of a centrosome-intrinsic mechanism to prevent re­
duplication, centrosome fragmentation and failure of cytokinesis associated with 
polyploidisation. Cells harbouring multiple centrosomes constantly exhibited abnormal 
nuclear morphology including the presence of micronuclei.
In light of the detrimental consequences caused by aneugenic compounds such as 
reproductive failure and tumourigenesis, understanding the mechanisms of action as well as 
routine testing for regulatory purposes is considered to be paramount (Parry et al., 2002) 
where the development of suitable detection techniques has been a primary drive of research 
programmes within the European Union (Parry & Sors, 1993; Parry et al., 1996). The in vitro 
micronucleus assay in combination with kinetochore labelling and chromosome specific 
centromeric/telomeric probes is a recommended method to screen for aneugens by both the
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Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment 
(COM) and the European Union Research Group (Parry et al., 2002).
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Fig. 1.21. Comparative interactions between mutagen (M), cellular target (T) and the endpoint being measured 
(E). The identity o f  possible targets are shown in brackets and different molecules from the same mutagen or 
different targets are denoted by the numbered subscripts. Diagram adopted from Kirsch-Volders et al. (2003).
Indirect mechanisms of genotoxicity is the direct interaction of a genotoxin with non-DNA 
targets leading to genotoxic effects (Kirsch-Volders et al., 2003). Furthermore, the existence 
of biologically meaningful threshold dose-response curves for indirect-acting genotoxins 
such as aneugens is possible since more than one cellular targets need to be overwhelmed 
before any significant and observable effects are manifested (Parry et al., 1993; Kirsch- 
Volders et al., 2002). Since the elucidation of possible threshold is beyond the scope of this 
thesis, it will not be discussed in depth. However, Kirsch-Volders et al. (2000; 2003) 
suggested three important aspects in analysing the basis for the existence of threshold namely 
the number of targets involved, target identity as well as the sensitivity and type of endpoints 
measured. As depicted in Figure 1.21, a threshold dose-response curve is considered to be 
absent from a single hit-single target interaction.
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1.19.1 Hazard and Risk Assessments
Since the introduction of the Ames test, various other test systems were developed utilising 
prokaryotic and eukaryotic cells with each advocated to possess the best ability in detecting 
carcinogenic agents. Despite this cornucopia of tests, not all o f them could singly, reliably 
differentiate between carcinogenic and non-carcinogenic analogues of similar chemical 
structure. There was also no or little guidance and consistency in the experiment designs or 
acceptance criteria. Furthermore, the number and types of studies required for products 
registration differs widely between regulating agencies worldwide, which in some cases can 
be viewed as a subtle form of trade barrier rather than scientific requirements.
T oxicity
m ech an ism s
Exposure
H azard
identification
R isk
assessm ent
To detect ■  To com p reh en d  I  To p red ict & p reven t
Fig. 1.22. The elucidation o f  mechanism(s) o f  toxicity (including genotoxicity) connects hazard detection with 
risk assessment for human health and permits toxicity prediction and prevention o f  detrimental exposure.
A plethora of potentially hazardous substances has been detected in the past and the number 
of new chemicals added to this list is growing steadily. One of the most compelling reasons 
for improving our detailed comprehension of toxicity mechanisms is that a deeper 
understanding will allow better data extrapolation and improving risk assessment of 
potentially genotoxic chemicals for human safety. This does not only apply to 
pharmacophore in development stage but also chemicals in the work place and in agriculture, 
pollutants as well as naturally occurring or synthetic hazardous compounds in food or 
residues in drinking water. The step from the mere detection o f a genotoxic hazard 
(qualitative aspect) to the final assessment of risk in human populations (quantitative aspect) 
involves a number o f assessments, estimations and considerations. For a chemical, it is 
clearly insufficient to introduce a safety margin based on animal data or cell culture 
experimentations, instead realistic exposure information has to be taken into account.
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Furthermore, information on genotoxicants’ mode of actions is useful in calculating more 
accurately the risk for humans such as exposure to harmful aneugens (Parry et al., 2002;
| Kirsch-Volders et al., 2003).
1i
i
I
I As illustrated in Figure 1.22, hazard and risk assessment generally involves three main steps
namely hazard identification and characterisation, exposure assessment and risk 
I characterisation. For an agent of interest, firstly the possible hazard such as the compound’s
inherent properties that may cause adverse health effects upon human exposure are 
| identified. Subsequently, the qualitative and quantitative responses after exposure are 
determined taking into account the mode of actions as well as type, duration and route of 
exposure which are normally established through dose-response adverse effects, if there is 
any. Exposure assessment is the estimation, measurement or prediction of exposure/intake of 
the agent of interest by the general population, sub-population or individuals in terms of 
frequency, duration and severity of exposure. Finally, risk characterisation is the integration 
of information obtained in order to establish a safe level of exposure.
1.19.2 Genotoxicity Testing for Regulatory Purposes
The awareness of this fact prompted the scientific and regulatory communities to pursue the 
standardisation and harmonisation of protocols and test systems. There are various platforms 
on which the international experts used to issue guidance such as the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) and the International Workshops on Genotoxicity 
Testing (IWGT) which look into test methods resulting in OECD (Organisation for 
Economic Co-Operation and Development) guidelines and testing strategies. There are also 
! advisory panels on national level such as the Committee on Mutagenicity of Chemicals in 
Food, Consumer Products and the Environment (COM) for the UK. Furthermore, Good
i
Laboratory Practice regulations (GLPs) have always been a requirement to guarantee the 
integrity of non-clinical studies conducted to support regulatory submissions.
Changes or damage to the DNA can be manifested in various forms such as gene mutations 
or chromosomal aberrations. No single test system is capable of detecting all these changes, 
thus the concept of using a battery of different tests was conceived.
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Testing strategies for mutation detection should include all three levels of mutation with the 
aim to assess the possibility of gene mutations, aneugens and clastogens. Since the initiation 
of genotoxicity testing, there has been a steady and continuous development of a wide variety 
of test systems employing bacterial, yeast and mammalian cell cultures. Most of the test
I
j systems have specific endpoints. The Committee on Mutagenicity of Chemicals in Food, 
Consumer Products and the Environment (COM) is an expert advisory committee 
responsible in providing advice to the Department of Health and other departments and
|
j  agencies within Her Majesty’s government that possess regulatory roles. The Committee
| recommends a three-stage testing approach for mutagenic potential. Stage 1 is a battery of in
vitro screening for potential mutagen involving three test systems. Stage 2 involves in vivo 
tests in somatic cells and the third stage is activity assessment in germ cells (COM, 2000).
The COM guidelines (COM, 2000) will be discussed in this thesis unless otherwise stated.
1.19.2.1 In Vitro Assays in Somatic Cells in Stage 1
As outlined previously, Stage 1 is the initial screening based on in vitro tests and for most 
chemicals, three tests are recommended where detection for both aneugenicity and 
clatogenicity is possible at this point (COM, 2000). These three tests are bacterial test for 
gene mutation, in vitro metaphase analysis or in vitro micronucleus test and mammalian cell 
mutation assay. Negative results from these three tests or just two, where small or no human 
exposure is expected such as industrial intermediates, would provide sufficient data for the 
assessment of most chemicals. A clearly positive outcome from any of these tests or in cases 
where equivocal results that cannot be resolved by further in vitro tests, warrants in vivo 
assessment in Stage 2. Figure 1.23 shows a flow chart for stage 1 testing procedures.
1.19.2.2 In Vivo Assays in Somatic Cells in Stage 2
Stage 2 is a continuation of mutagenicity assessment to elucidate the potential of genotoxic 
activity seen in Stage 1 to be manifested in somatic cells in vivo. A malleable strategy is 
required for in vivo tests taking into consideration the nature of the chemical being 
investigated, its metabolism information and data obtained in Stage 1. The most suitable test 
is bone marrow micronucleus assay to measure aneugenicity and clastogenicity unless there 
is a contradiction to the initial considerations. If the results are negative, further tests
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involving other tissue(s) are required to provide clear assurance for the absence of in vivo 
activity for all compounds that was shown to be positive in earlier in vitro studies.
Second in vivo test(s) that may be appropriate includes the liver UDS (Unscheduled DNA 
synthesis) assay, comet assay, 32P-postlabelling assay, covalent DNA binding and assays 
using transgenic animals. The choice of assay in any circumstances should be justified and 
| considered on a case-by-case basis taking into account the available information including 
data from previous tests. Figure 1.24 shows a flow chart for stage 2 testing procedures.
1.19.2.3 Testing in Germ Cells in Stage 3.
Stage 3 is mutagen assessment in germ cells and requirements for such studies needs careful 
consideration. Generally, chemicals that have been classified as in vivo somatic cell 
mutagens will be considered to be both potential genotoxic carcinogens and germ cell 
mutagens, therefore does not warrant further genotoxic testing. However, in some cases germ 
cell studies may be undertaken to prove otherwise. A number of assays such as micronuclei 
induction in spermatocytes and the dominant lethal assay, both for clastogenicity and 
aneugenicity detection, can be used to determine whether the compound of interest is 
genotoxic in germ cells. Information on DNA lesions induction can be obtained via various 
Stage I methods discussed previously. Results on mutation types observed in earlier tests will 
be crucial when considering the most suitable assay in a particular case and none of the 
assays mentioned is capable of providing definitive data as to the possibility that the 
mutations are heritable in future generations. The only methods that allow estimates of such 
risks to be calculated are the mouse specific locus test and the mouse heritable translocation 
test. However, this route of action is not practical taking into account the very large number 
! of animals required and should only be considered in exceptional circumstances. At the 
moment there are no routine tests available for elucidating the induction of aneuploidy in 
progeny of treated animals. Figure 1.25 shows a flow chart for Stage 3 germ cell testing 
procedure.
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Fig. 1.23. Stage 1 initial screening procedure. Adapted from Guidance on Strategy for Testing o f  Chemicals for
Mutagenicity (COM, 2000).
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Figure 2. STAGE 2:
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Fig. 1.24. Flow chart for Stage 2 in vivo screening procedure. Adapted from Guidance on Strategy for Testing
o f  Chemicals for Mutagenicity (COM, 2000).
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Figure 3. STAGE 3: Strategy for geim cell testing:
For most compounds that are recognised as in-vivo somatic cell mutagens no further 
genotoxicity testing is necessary. This strategy applies only in cases where it is important 
to consider the potential o f somatic cel mutagens to  affect germ cells.
Test mutagenicity/genotoxicity to germ cel from the folowing:- 
Assay for dastogenicity and aneugenisity in mammalian spermatogonia! cells, 
or spermatocytes, dominant lethal assay or other methods for measuring 
mutagenicity or DNA damage.
The choice o f test should take into account data from earlier mutagenicity 
tests, and the properties o f the chemical and its toxicokinetics and 
metabolism
7 [ \
If POSITIVE chemkal should be f  If NEGATIVE consider al the N
c cnsidere«d as a germ cell available information with a view
mUtagen/aneugen. to  drawing the conclusion that the
chemical is not a germ cell
mutagen.
If EQUIVOCAL review a l the avaiable 
information and consider whether further 
testing is justified cr whether a conclusion 
can be reached based on weight o f  
evidence.
In cases where there is strong 
justification undertake father studies to  
evaluate risk o f heritable effects 
(see text for dscussion). )
Fig. 1.25. Flow chart for Stage 3 germ cell testing procedure. Adapted from Guidance on Strategy for Testing
o f  Chemicals for Mutagenicity (COM, 2000).
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CHAPTER 2
PART 1: IN  SILICO ASSESSMENT OF GENOTOXICITY AND 
TOXICITY POTENTIAL OF ANDROGRAPHOLIDE
2.1 General Introduction
There is a general understanding that an in-depth comprehension of all toxicities associated 
with a new chemical is important to its successful development and marketability. Thus, 
toxicology in general faces the immensely challenging tasks of conducting safety 
evaluations in supporting the development of new chemicals prior to human exposures and 
determining the potential hazard posed by agents whose safety assessments were 
insufficient.
Currently, genotoxicity is examined through the application of a battery of experimental in 
vitro and in vivo test systems that are not always uniformly concordant but applied in a 
weight-of-evidence approach. However, these tests can be overwhelmed in light of the 
accelerating pace of chemical discovery and development as well as the economic 
feasibility of such endeavours, have highlighted the need for efficient prioritisation and 
toxicity screening approaches in the ‘fail-early, fail-safe’ context. There is also a 
requirement to elucidate the genotoxic potential of metabolites, impurities, degradants and 
in the occupational health aspect, process intermediates. Since exposure to genotoxic 
chemicals bears the risk of inducing somatic mutations including those leading to cancer as 
well as germ-line mutations with the possibility of inherited disorders, evaluating genotoxic 
potential is regarded to be an essential step in the safety assessment of chemicals.
2.2 Chemical Reactivity and Possible Mechanisms of Action
There is quite a large overlap between genotoxicity and carcinogenicity since the initiating 
step of the carcinogenic process often involves one or more genotoxic insults. A unifying 
concept has been that genotoxicants and carcinogens act by attacking the DNA, based on 
their electrophilicity per se or after metabolic transformation. Thus, genotoxicity should be
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easier to anticipate than other form of toxicities, such as organ-specific toxicities that can 
be induced by various chemical or pharmacological mechanisms not directly or necessarily 
related to chemical structure analysis. However, there are indirectly-acting genotoxicants 
such as aneugens while epigenetic carcinogens do not act through genotoxic mechanisms 
and the progress in the identification of structural alerts responsible for epigenetic damage 
has been much slower (Woo, 2003). It is not surprising that chemical genotoxicity has been 
the focus of various attempts to develop predictive models and among the theoretical 
models available, the application of structure-activity relationships concepts has emerged to 
be promising. This concept and with supporting experimental data, has paved the way to 
several chemical functional groups and substructures identification, which are referred to as 
structural alerts.
These are capable of causing both mutation and cancer and includes acylating 
intermediates, aldehydes, carbonium ions (alkyl-, aryl-, benzylic-), epoxides, free radicals, 
nitrenium ions, oxonium ions, polarized double bonds (a,p-unsaturated carbonyls or 
carboxylates) and peroxides (Ashby, 1995; Woo et al, 2002). The structural alerts 
characterisation has been a very important scientific progression because it permitted the 
possibility of designing safer compounds by avoiding the known structural alerts. In 
addition, the structural alerts for genotoxicity and carcinogenicity have been incorporated 
into expert systems for predicting toxicological effects of chemicals (e.g. DEREK, 
MCASE).
2.3 Computer-assisted Structure Activity Relationships (CSAR)
Structure activity relationships (SAR) examine the correlation between the chemical 
structure of a compound and its biological or pharmacological activity. Compounds are 
often grouped together because they possess common structural characteristics including 
topology, stereochemistry, size, arrangement and distribution of functional groups. Other 
factors contributing to structure-activity relationship include electronic effects, resonance, 
chemical reactivity and inductive effects. Quantitative structure-activity relationships 
(QSAR) is a refined attempt to correlate structural or property descriptors of compounds 
with activities using mathematics and more recently, by computational methods.
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MCASE, DEREK and TOPKAT are examples of computer-assisted structure activity 
relationship (CSAR) systems that are widely used in predicting genotoxicity and 
carcinogenicity by studying quantitative structure-activity relationships (QSARs). MCASE 
(www.multicase. com) stands for Multiple Computer Automated Structure Evaluation and it 
dissociates each input molecule into 2-10  atom fragment (biophore) and statistically 
examines the strength of the fragments from its database with an associated mutagenicity 
value that is based on observed mutagenic potency. The database contains information on 
3000 compounds and includes Drosophila mutation data. Another program, named 
TOPKAT (Toxicity Prediction by Komputer Assisted Technology) was originally designed 
by Health Systems Inc. and is now marketed by Accelrys 
(www.accelrys.com/products/topkat/index.html) is based solely on bacterial mutagenicity 
data. It applies ‘electro-topological’ descriptors rather than chemical structures to predict 
mutagenic reactivity with DNA. The program cannot be customised by the user.
There are also other computer programs that is based on QSAR but built for different 
purposes. METEOR for example was designed to harness QSAR and expert knowledge in 
elucidating possible metabolic outcomes of a compound of interest in silico.
2.4 Introduction to DEREK
DEREK (Deductive Estimation of Risk from Expert Knowledge) is an expert- knowledge 
base system that was originally created by Schering Agrochemical Company and was 
subsequently donated to an independent not-for-profit organisation, Lhasa Limited, UK. 
Effectively, toxicologists from other organisations are now able to use DEREK and 
continuously contributing to toxicological data in improving the qualitative structure- 
activity relationships (QSARs) and expert knowledge rules in the program.
The main difference of an expert knowledge base system such as DEREK and a database is 
that DEREK is a software that utilises toxicological expert knowledge rules in predicting 
the toxicity of chemicals, usually in the absence of known toxicological data. Whereas a 
database is merely a large set of structured data and database management system is a 
computer software programmed to manage a database. VITIC (Lhasa Ltd.) is an example 
of a data management system.
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DEREK makes semi-quantitative predictions as to whether or not a DNA-reactive moiety 
is present on the chemical structure of interest and performs a series of key functions based 
on a substance’s chemical structure:
• Acts as a high-throughput screen for genotoxic and mutagenic activities.
I
! • Predicts whether a chemical will be carcinogenic.
| • Predicts whether a chemical will be skin sensitiser.
I • Highlights potential toxicological hazards covering a spectrum of endpoints from
irritancy to hepatotoxicity.
DEREK’s learning set was constructed based on bacterial mutagenicity (Ames test) and 
other available genotoxicity data. Query outputs define the structural alert recognised and
!
[ the type of genotoxicity attributed to the alert.
How DEREK works.
• Molecular chemical structures are entered into DEREK for Windows by either 
importing MDL Molfiles or SDF files, or via a chemical editor program such as 
ISIS/Draw. All the parameters such as species and endpoints were selected. Figures
2.1 and 2.2 shows an example of this step. MDL Molfile is a file format created by
I
Elsevier Molecular Design Limited (MDL) containing information about the atoms, 
chemical bonds, connectivity and coordinates of a molecule. SDF (structure-data 
file) file is another file format for holding chemical information especially data on 
chemical structure.
• Then DEREK will utilise QSARs information and other expert knowledge rules to 
develop reasonable prediction about the potential toxicity of the chemical in 
question. Example of this step is shown in Figure 2.3.
• The program also provides supporting evidence for its conclusion that includes 
literature references, toxicity data and comments. Toxicological data from 
structurally similar molecules can also be viewed as shown in the example in Figure 
2.4.
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2.5 METHODS
DEREK version 8.0.1 ISIS/Draw was used to draw the chemical structure of 
andrographolide. The main parameters to the query were set as listed below:
1. Testing against all alerts.
2. Species: bacteria and mammals.
3. Super-Endpoints:
• Carcinogenicity
• Genotoxicity
• Irritation
• Respiratory sensitisation
• Skin sensitisation
• Thyroid toxicity
• Miscellaneous endpoints
4. Consider tautomers as true.
5. Hydrogen options: perceive implicit and explicit hydrogens.
Full report created by DEREK can be found in the Appendix section. The probability was 
set to be ‘plausible’ and above only. Anything less than ‘plausible’ will not be registered by 
the program.
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2.6 RESULTS
The molecular weight of andrographolide calculated by DEREK is 350.455, a 100% match
to the figure supplied by Sigma-Aldrich. Figure 2.5 shows the chemical structure of
! andrographolide drew using ISIS/Draw. The program made several predictions based on
! the molecular structure of andrographolide as described below.
0
0
Fig 2.5. Chemical structure o f  andrographolide.
The ability of andrographolide to induce peroxisome proliferation and a-2-p globulin 
j nephropathy in mammals is doubted. However, it is plausible for the compound to induce 
such effect in rat, mouse and other rodents. Figure 2.6 shows all possible locations that can 
cause peroxisome proliferation and a-2-p globulin nephropathy in rodents.
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Fig. 2.6. Shows three possible locations where andrographolide may 
induce nephropathy and peroxisome proliferation in rodents.
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Skin sensitisation in mammal is predicted to be plausible. The location of a, p-unsaturated 
ester (or precursor) within the compound, as shown in Figure 2.7, may cause this effect.
The same location of a, P-unsaturated ester or thioester within the compound can also 
cause chromosome damage in mammals in vitro.
0
0
Fig. 2.7. The position within the compound that can cause skin sensitisation 
and chromosome damage in vitro in mammals.
2.7 DISCUSSION
DEREK was utilised to assess the potential mutagenicity, carcinogenicity and toxicity of 
andrographolide. This computer software utilises toxicological expert knowledge rules in 
predicting the toxicity of chemicals by identifying the structural alerts that may contribute 
to its activity. Andrographolide was predicted to be able to cause peroxisome proliferation 
and nephrotoxicity in rats, mouse and other rodents whereas the a-alkylidene y- 
butyrolactone moiety, detected as a, p-unsaturated ester or thioester by DEREK was 
considered to be able to cause chromosome damage in mammals in vitro. Indeed, Nanduri 
et al. (2004) reported that four positions in the andrographolide chemical structure are 
responsible for its in vitro cytotoxic activity. As shown in Figure 2.8, these positions are (1) 
the intact a-alkylidene y-butyrolactone moiety, (2) the C-14 hydroxyl or its ester moiety, 
(3) the A12(13) double bond and (4) the A8(17) double bond or epoxy moiety.
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Fig 2.8. The chemical structure of andrographolide with the positions responsible for its cytotoxic 
activity. Modification was made by the author to the original picture adopted from Nanduri et al. 
(2004) with coloured stars denoting these positions respectively. (Yellow) the intact a-alkylidene y-
j butyrolactone moiety, (Red) the C-14 hydroxyl or its ester moiety, (Blue) the A12(l3) double bond and
(Green) the A8*1^  double bond or epoxy moiety.
I Whereas the structural alerts define the potential for the chemicals to be carcinogenic or
|
mutagenic, the actual modulation of this potential depends on a series of factors such as
| molecular weight, chemical reactivity, solubility and possible metabolism which can differI
j within each individual class of compounds. In fact, chemicals sharing the same structural 
alert such as aromatic amine for example, can behave in different ways because some are 
active, to a different degree and some are inactive. Such modulating factors can be 
estimated by minor, context-dependent structural alerts for example, the alteration in the 
positions of the skeleton of a chemical with a primary structural alert. However, the 
qualitative approach based on the recognition of structural alerts is rather limited due to thei
| inability to predict the activity of sub-structures which are not in the list of known 
structural alerts or those that possess a combination of alerts.
A powerful generalization is provided by the quantitative structure-activity relationship 
(QSAR) analysis, which is based on a limited number of physical chemical properties with 
general relevance, and produces a mathematical model for the chemical determinants of the 
biological activity. The physico-chemical properties of interest for the biological activity of 
the chemicals are hydrophobic, electronic and stearic effects (Franke & Gruska, 2003). 
QSARs have been generated for a number of individual chemical classes including 
aromatic amines, polycyclic aromatic hydrocarbons and lactones (Benigni, 2005). The 
majority are relative to in vitro mutagenicity. However, a number of QSAR models for the 
animal carcinogenicity exist as well. A great aspect of the QSARs for the individual 
chemical classes, as performed according to the classical Hansch approach and point to the 
physico-chemical determinants of the biological activity of the compounds. Therefore, they
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have appreciably contributed to the comprehension of the mechanisms of chemical 
mutagenicity and carcinogenicity. The other important goal of the use of QSAR analyses is 
the risk assessment of chemicals. Once formulated, the QSARs can be employed for 
estimating the activity of other chemicals not tested experimentally or those lacking 
existing experimental data such as andrographolide.
Natural compounds in general are more structurally diverse with greater complexity than 
synthetic pharmaceuticals and have been shown to be an important source of potential 
pharmacophores (Rowinsky & Donehower, 1995) and others were found to alter biological 
function through interaction with cellular macromolecules and affecting xenobiotic 
metabolism enzymes expression (Chouduri & Valerio, 2005). The fact that natural 
compounds especially phytochemicals, have a wide spectrum of chemical functional 
groups where some are known to be structural alerts for toxicologically-based chronic 
effects such as the induction of carcinogenesis, highlights the need to assess their potential 
toxicity. However, the predicament is that few phytochemicals have been evaluated for 
systemic toxicological effects and even less have been subjected to long-term cancer 
bioassay in vivo. In light of the potential human exposure to the high number of synthetic 
and natural compounds currently in discovery, development or commercialisation phases, 
there is a practical desideratum for the development and validation for an efficiently 
reliable and sensitive methods for screening thousands of untested chemicals for toxicity 
especially crucial endpoints such as genotoxicity. Assessment performed using DEREK 
supports previous findings on cytotoxicity (Siripong et al., 1992; Nanduri et al. 2004; Jada 
et al., 2007) but as highlighted previously, reliable experimental data on possible induction 
of genetic damage is absent.
The current accomplishment of CSAR has been moderate but developing steadily, 
concomitant with their growing importance in compound selection and study duration 
(Johnson & Rodgers, 2006). These expert-knowledge based systems are not free from 
limitations such as inability to predict non-positive structures, does not distinguish between 
target organs for carcinogenicity, inability to predict potential antagonism or synergism of 
substructures and variability in key data quality (Johnson & Rodgers, 2006). Such systems 
is also incapable of accounting for mechanistic considerations such as sex- or species 
specificity and it cannot provide an estimation of dose or time of exposure (acute or 
chronic) essential for carcinogenesis.
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Overall, it can be concluded that predictions for the individual chemicals cannot be taken at 
face value and cannot replace laboratory experiments, when necessary. Their main role is 
to complement the information of different nature and from different sources. At the same 
time, the structure-activity-based methods can have a great role for example in prioritising 
large numbers of chemicals to be studied or in designing better experiments. In the second 
part of this Chapter, the metabolism of andrographolide is predicted using METEOR, 
which is another expert-knowledge rules program and its ability to elicit genomic 
instability will be examined experimentally by employing genotoxicity tests such as the in 
vitro micronucleus assay and the HPRTpoint mutation assay.
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CHAPTER 2
PART 2: IN  SILICO PREDICTION OF ANDROGRAPHOLIDE
BIOTRANSFORMATION
2.8 Biotransformation of Xenobiotics
I
I Biotransformation is the metabolic conversion of endogenous and xenobiotic compounds to 
more water-soluble derivatives. Generally, the physical properties of a xenobiotic are altered 
from lipophilicity to hydrophilicity, thereby reducing its absorbability by tissues and 
favouring its excretion. An exception to this rule is the elimination of volatile compounds by 
| exhalation.
j
I
I Chemical modification of a xenobiotic via biotransformation may also change its biological 
| effects. Some drugs undergo biotransformation to active metabolites that exert their 
pharmacodynamic or toxic effect. However, in most instances, biotransformation terminates
I
j  the pharmacologic effects of a drug and reduces the toxicity of xenobiotics. Enzymes 
| involved in catalysing biotransformation reactions often determine the pharmacokinetics and 
j pharmacodynamics of drugs as well as playing a crucial role in chemical toxicity and
| chemical tumourigenesis. There are two main phases in xenobiotics biotransformation. Phase
t
I mainly involves functionalisation, which is the introduction or exposure of functional 
groups on the chemical structure of a compound. This process provides a chemical ‘handle’ 
for conjugating agents in Phase II to react with. However, rendering a xenobiotic more 
chemically reactive to facilitate their excretion also increases the risk of possible interactions 
with cellular macromolecules such as DNA, ultimately highlighting the existence of a fine 
balance between producing conjugation reactions and more reactive metabolites. The 
functional groups can be either nucleophilic such as carboxyl groups or electrophilic in 
characteristic like the epoxides and these can be injurious to biological systems. Nucleophiles 
can interact with biological receptors while electrophiles have the potential to covalently 
react with electron-rich macromolecules such as RNA, DNA and proteins.
There are two groups of enzymes in Phase I, hydrolases and oxidoreductases. Hydrolases are 
hydrolytic enzymes whose substrates include amides, epoxides, esters and glucuronides. 
Oxidoreductases introduce an oxygen atom into or expel electrons from their substrates and
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cytochrome P450 is the major oxidoreductase enzyme system. Other systems include 
monoamine oxidases (MAO), flavin-containing monooxygenases (FMO) and 
cyclooxygenases (COX). These hydrolysis, reduction and oxidation reactions lead to the 
introduction or exposure of a functional group (-OH, -NH2, -SH or -COOH) which usually 
cause only a small increase in hydrophilicity.
The second phase of biotransformation involves conjugation, where functional groups from 
cofactors are utilised by transferases to react with those present or annexed from Phase I on 
the compound. The resultant conjugates possess increased excretory potential. Although most 
conjugations result in pharmacological detoxification or inactivation, some may end in 
bioactivation. Most of the Phase II enzymes are located in the cytosol except UDP- 
glucuronosyltransferases (UGT) that are microsomal. The consequence of most phase II 
biotransformation reactions is a large increment in xenobiotic hydrophilicity, thus greatly 
promote the excretion of xenobiotic compounds. Figure 2.9 summarises the 
biotransformation process and its main actors.
Phase II reactions are usually faster than Phase I, thus Phase I is the rate-limiting step for 
biotransformation. Phase II metabolism can deal with all products from Phase I with the 
exception of glutathione, which requires a chemically reactive conjugating species. The 
availability of the cofactors during synthesis may have a limiting influence in some Phase II 
pathways as it affects the formation of sufficient conjugating species necessary for reaction 
on a substrate or its metabolites. Due to their reactivity, bio-accumulation of these substrates 
and its metabolites may be harmful.
Various compounds are also capable of causing enzyme induction where they accelerate their 
own biotransformation and excretion. The opposite effect would be the inhibition of the 
process. Other factors that change enzyme levels include age, sex and genetic polymorphism. 
Interspecies differences in biotransformation ability also present a challenge in interpreting 
animal results to humans.
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NADP*
NAOPH
Fig. 2.10. Catalytic cycle o f  cytochrome P450. Cytochrome P450 and NADPH-cytochrome P450 reductase 
are located in the phospholipid bilayer o f  the endoplasmic reticulum. The first part o f  the cycle involves the 
activation o f  oxygen and the final part involves substrate oxidation that entails the abstraction o f  an electron 
or a hydrogen atom from the substrate followed by oxygen rebound. (Pratt and Taylor, 1990).
Cytochrome P450 enzymes are ubiquitous in nature. About one quarter o f the 57 P450s are 
typically regarded to be primarily involved in the metabolism of xenobiotics (Guengerich 
et al., 2005). Unlike P450s that are involved in sterol metabolism which are crucial in 
normal physiology (Nebert & Russell, 2002), the levels of P450 isoforms involved in 
xenobiotic metabolism can vary and some individuals may be completely devoid of certain 
P450 enzymes due to genetics. Figure 2.10 shows the catalytic cycle of cytochrome P450.
The human cytochrome P450 (CYP) superfamily consists of 57 genes (Nelson, 2003) 
contributing to the metabolism of a variety of xenobiotics including carcinogens and 
therapeutic drugs. Although the enzymes is crucial in detoxification to facilitate excretion 
from the body, in some instances xenobiotics are converted to metabolites with greater 
mutagenicity or cytotoxicity potential and a number of human CYPs including CYP1A1, 
1A2, 1B1, 2A6, 2B6 and 3A4 are known to be involved in metabolic activation of pro- 
carcinogens (Guengerich, 2001).
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Fig.2.11. Contribution o f  individual enzyme systems to xenobiotic metabolism. The first bar on 
the left showed the fate o f  drugs upon administration, the second bar showed the proportion o f  
enzymes involved in metabolism and the last bar on the right highlights the relative contribution 
o f  as cytochrome P450 isoforms. CYP refers to cytochrome P450 and UGT stands for uridine 
dinucleotide phosphate glucuronosyl transferase (Wienkers & Heath, 2005).
Cytochrome P450 enzymes are probably responsible for more bioactivation processes than 
other enzymes because several of the reaction products such as epoxides possesses reaction 
chemistry due to their innate instability and P450s collectively have wider substrate 
spectrum than any other enzymes, at least on drugs (Guengerich, 2003) as shown in Figure
2.11
In some cases, the same P450 enzyme catalyses both activation and detoxification 
reactions. For example, CYP3A4 activates aflatoxin B| to the tumorigenic and hepatotoxic 
8,9-epoxide but it also detoxifies the same compound to aflatoxin Qi by 3-hydroxylation 
(Williams & Aruoma. 2000). This shows that complex factors determine the balance 
between xenobiotic activation and detoxification.
2.8.1 Induction of Cytochrome P450
Inducers of cytochrome P450 increase the rate of xenobiotic transformation, lowering 
blood levels and compromising the therapeutic goal of drug therapy but does not cause an 
exaggerated response to the drug. Thus such reaction can lead to pharmacokinetic tolerance 
by which larger drug doses must be administered to achieve therapeutic blood levels 
because o f increased drug biotransformation. Induction of cytochrome P450 may increase
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the activation of pro-carcinogens to DNA reactive metabolites resulting in increased 
tumour formation. There is little evidence from either animal experiments or human 
epidemiologic studies that P450 induction amplify the incidence or multiplicity of tumours 
cavsed by known chemical carcinogens. Most available evidence points to a protective role 
of enzyme induction against chemical-induced damage.
2.8L2 Inhibition of Cytochrome P450
Inhibitory drug interactions generally fall into three categories. The first involves 
competition between two drugs that are metabolised by the same P450 enzyme. The second 
is also competitive in nature but the inhibitor is not a substrate for the affected P450 
emyme. The third type of drug interaction results from non-competitive inhibition of the 
cytochromes by covalent binding to P450.
2.8.3 Phase II Enzyme Reactions
Biotransformation reactions involve in this second phase include acetylation, methylation, 
glucuronidation, sulfonation, glutathione conjugation (mercapturic acid synthesis) and 
conjugation with amino acids such as taurine, glycine and glutamic acid.
Acetylation, methylation, sulfonation and glucuronidation involve reactions with activated 
co-substrates while glutathione or amino acid conjugation concerns reactions with activated 
xenobiotics.
N-Acetylation is a major course of biotransformation for xenobiotics containing an 
aromatic amine (R-NH2) or a hydrazine group (R-NH-NH2) that are transformed into 
aromatic amides (R-NH-COCH3) and hydrazides (R-NH-NH-COCH3) respectively. This 
conversion is catalysed by cytosolic A-acetyltransferases and requires the co-substrate 
acetyl-coenzyme A (acetyl-CoA). N-acetylation masks an amine with non-ionisable group 
rendering the metabolites less hydrophilic than the parent compound. However, N- 
acetylation of certain xenobiotics such as isoniazid assists their urinary excretion.
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Methylation is a minor route of biotransformation and targeting 0-, N- and S-containing 
functional groups. Like N-acetylation, it generally reduces the water solubility of 
xenobiotics by shielding functional groups which otherwise might be conjugated by other 
phase II enzymes. It also requires a co-substrate, which is S-adenosylmethionine that is 
converted to S-adenosylhomocysteine during the methylation reactions.
Uridine diphosphate-glucuronic acid is a co-substrate essential for glucuronidation, a 
biotransformation process that targets electron-rich nucleophilic heteroatom (S, O or N) 
normally present in phenols, aliphatic alcohols, carboxylic acids, primary and secondary 
aromatic and aliphatic amines as well as free sulfhydryl groups. Bilirubin, thyroid and 
steroid hormones are examples of endogenous substrates for glucuronidation. These 
reactions are catalysed by UDP-glucuronosyltransferases and glucuronide conjugates are 
polar, hydrophilic conjugates. These conjugates are also substrates for p-glucuronidase 
present in the intestinal microflora and the intestinal enzyme can liberate the aglycone 
(parent compound or Phase I metabolite) that enters enterohepatic circulation resulting in 
impediment to the xenobiotic elimination. Whether these conjugates are excreted from the 
body in urine or bile is subject to the size of the aglycone.
Many xenobiotics and endogenous substrate are conjugated with sulfate, a reaction 
catalysed by sulfotransferases in the presence of 3 '-phosphoadenosine-5 '-phosphosulfate 
(PAPS), generally producing a highly hydrophilic sulphuric acid ester. Sulfonation 
introduces sulfonate from PAPS to the xenobiotic and these metabolites are excreted 
mainly in urine. Some sulfate conjugates are subjected to further rounds of 
biotransformation. Sulfotransferases is a multigene family of cytosolic enzymes and are 
arranged into gene families (SULT1-SULT5) that share less than 40% amino acid sequence 
homology. Each family tend to work on a specific functional group. Generally, the addition 
of sulfonate to an aglycone reduces the pharmacologic and toxicologic acitivity of 
xenobiotics. However, sulfonation also activates methyl-substituted polycyclic aromatic 
hydrocarbons, aromatic amines and safrole to mutagenic metabolites.
Conjugation of xenobiotics with glutathione includes a huge number of electrophilic 
xenobiotics or those that are convertible to electrophiles. Glutathione is a tripeptide 
consisting of cysteine, glycine and glutamic acid. This reaction is calatysed by a family of 
glutathione S-transferases that are present in most tissues. The substrates for this enzyme
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are compounds that are hydrophobic, containing an electrophilic atom and react non- 
enzymatically with glutathione at a quantifiable rate. Glutathione S-transferase increases 
the rate of conjugation via deprotonation of GSH to GS\ Glutathione conjugates are 
thioethers, formed by nucleophilic attack of glutathione thiolate anion (GS‘) with an 
eletrophilic sulfur, carbon, oxygen or nitrogen in the xenobiotic. There are two types of 
conjugation reactions namely the addition reactions where glutathione is added to an 
activated double bond or strained ring system, and the displacement reactions in which 
glutathione replaces an electron-withdrawing group.
The addition of glutathione to a carbon-carbon double bond is facilitated by the presence of 
a nearby electron withdrawing group, thus the substrate for this reaction normally harbours 
| a double bond attached to -CN, -COR, -COOR or -CHO. The displacement of an electron-
; withdrawing group usually occurs when the substrate contains halide, phosphate, sulfate,
1 sulfonate or a nitro group attached to benzylic or allylic carbon atom. Glutathione is also
j capable of conjugating xenobiotics with an electrophilic heteroatom (S, O and N) where the
I initial conjugate formed between glutathione and the heteroatom is cleaved by a second
molecule of glutathione to form oxidised glutathione (GSSG). The initial reactions are 
catalysed by glutathione S-transferase, whereas the second reaction that leads to GSSG 
formation typically occurs non-enzymatically.
ii
| Last but not least, amino acid conjugation of xenobiotics involves two main pathways and
i
the substrates for conjugation process is limited to certain aromatic, aliphatic, cinnamic, 
heteroaromatic and arylacetic acids. The ability of xenobiotics to go through amino acid 
conjugation depends on stearic hindrance around the carboxylic acid group and by 
substituents on the aliphatic side chain or aromatic ring.
Most Phase II biotransformation enzymes are mainly found in the cytosol and generally 
progress faster than Phase I reactions. Thus, the rate of elimination of xenobiotics whose 
excretion hinges on biotransformation by cytochrome P450 followed by Phase II 
conjugation is generally influenced by the first reaction.
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2.9 Introduction to METEOR
METEOR is another computer program developed by Lhasa Ltd. that utilises expert 
knowledge rules in metabolism to predict the metabolic fate of various chemicals, which 
can be useful in the absence of experimental data. Prediction is made based on the 
chemical’s molecular structure and physicochemical properties. The program contains a 
knowledge base of structure-metabolism relationships and each describes a metabolic 
reaction, characteristic of xenobiotics with a common structural feature. METEOR 
reasoning rule-base contains 841 rules, 217 mammalian Phase I and II biotranformations 
allowing the program to evaluate the relative probabilities of various metabolic pathways 
(Langowski & Long, 2002). Results are accompanied by comments and literature citations 
as evidence that is specific, making evaluations easier. The strength of METEOR lies in its 
ability to predict the metabolites that are likely to be generated rather than all possible 
candidates (Greene et al., 1999).
In certain circumstances, experimental data from metabolism studies discloses empirical 
formula of metabolites and not their molecular structure, which effectively impair a 
thorough assessment of the possible chemical properties such as toxicity possess by the 
metabolites since different molecular structure denotes different activities. The program is 
capable of recommending the most likely molecular structure and even anticipates different 
promising structures from the same empirical formula. Figures 2.12, 2.13 and 2.14 
highlights the main steps involved in a METEOR search.
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METEOR works in the same principle as DEREK and the main steps are outlined as 
below.
’ F [^ T [3 0 E 0 0 E 0
Fig. 2.12. Inserting a chemical structure using ISIS/Draw.
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2.10 METHODS
METEOR version 8.0.1 ISIS/Draw was used to draw the chemical structure of 
andrographolide. Main parameters to the query were set as listed below:
1. Testing against all biotransformations.
2. Absolute reasoning used: True.
3. Phase: Do not grow from phase II products.
4. Species: mammals
5. Likelihood at least: Plausible.
6 . Hydrogen options: perceive implicit and explicit hydrogens.
2.11 RESULTS
| The METEOR programme predicted plausible andrographolide metabolites in Phase I and
| II biotransformation and the possible routes are summarised as a metabolic tree in Figure
j 2.15. The data used for the tree construction were generated by METEOR and various
reactions that contributed to this process are also stated. Figure 2.17 is the same metabolic
i
j tree but instead of empirical formula, the tree shows molecular weight. As thei
| biotransformation pathway progresses, the molecular weight of the metabolites predicted
| increased. Another metabolite tree shown as Figure 2.18 is essentially the same as the one
i
| depicted in Figure 2.15 but highlighted the Phase II reactions in blue while those that can
i
| be achieved by cytochrome P450 are shown in other lighter colours.
Although the empirical formulae of all possible metabolites were shown in Figure 2.15, 
various different chemical structures can be derived from the same chemical formula, a 
task METEOR was equipped to handle. Due to the large size of information generated, 
examples of selected reactions involving the metabolism of andrographolide are shown in 
Figures 2.16a to 2.16f.
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0
Fig. 2.16a. Glucuronidation o f  primary aliphatic alcohol. Area in bold print is the reaction substrate 
whereas the blue ring denotes structural transformation.
0
0
0
Fig. 2.16b. Glucuronidation o f  alicyclic alcohols. Area in bold print is the reaction substrate whereas 
the blue ring denotes structural transformation.
0
0
0
Fig. 2.16c. Conjugation o f  a,P-unsaturated compounds with glutathione. Area in bold print is the 
reaction substrate whereas the blue ring denotes structural transformation.
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0
0
0
Fig. 2 .16d. Hydroxylation o f  methyl carbon adjacent to an aliphatic ring. Area in bold print is the 
reaction substrate whereas the blue ring denotes structural transformation.
0
0
0
Fig. 2.16e. Allylic hydroxylation. Area in bold print is the reaction substrate whereas the blue ring
denotes structural transformation.
0
0
0
Fig. 2 .16f. Epoxidation o f  alkenes. Area in bold print is the reaction substrate whereas the blue ring
denotes structural transformation.
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2.12 DISCUSSION
The metabolic tree suggested by METEOR is useful in the initial prediction of possible 
metabolites of andrographolide especially when there is currently a paucity of sufficient 
data. Figure 2.15 shows all possible metabolites derived from andrographolide, the parent 
compound. Various functional groups attached to the aglycone provide many possible 
substrates for Phase I and Phase II enzymes. The progression of the metabolic tree also 
showed steady increment in molecular weight and polarity of the metabolites by the 
addition of other groups such as glutathione and glucuronide as shown in Figure 2.17. The 
resultant metabolites possess higher polarity and hydrophilicity mainly attributed to the 
high molecular weight of the conjugates, hence facilitates their excretion from the body. As 
depicted both in Figures 2.17 and 2.18, the molecular size of the metabolites produced by 
Phase II reactions were higher that those subjected to Phase I metabolism. Indeed, the 
Phase II biotransformation reactions with the exception of acetylation and methylation, 
result in a large increase of xenobiotic hydrophilicity (Gibson & Skett, 2001). The extract 
of Andrographis paniculata including andrographolide and its analogues have been shown 
to affect hepatic biotransformation enzymes such as anilinehydroxylase, N- and O- 
demethylase (Choudhary & Poddar, 1984), alanine aminotransferase and aspartate 
aminotransferase (Trivedi & Rawal, 2000) as well as glutathione S-transferase and DT- 
diaphorase (Phase II biotransformation enzymes) (Singh et al., 2001).
Several metabolites of andrographolide have also been identified in rats and humans. Ten 
metabolites of andrographolide mainly in the form of sulfonic acid conjugates and sulfate 
compounds were isolated and identified in urine, feces as well as contents of small intestine 
after the compound was orally administered to rats (He et al., 2003a, b, c). Cui et al. (2004) 
also reported structural identification of four urinary metabolites of andrographolide from 
human volunteers, of which three of the metabolites were categorised as 3-O-sulfate 
conjugates and the remaining one as 3-O-sulfate-12-S-cysteine conjugate. An additional 
seven Phase II metabolites were isolated from human urine and all were characterised as 
glucuronide conjugates, where four were found to be two pairs of geometric isomers (Cui 
et al., 2005). All these findings are in line with the predictions made by METEOR in terms 
of plausible reactions that might be involved in andrographolide metabolism where 
different functional groups such as primary aliphatic alcohols and epoxides are being 
targeted by UDP-glucuronosyltransferases and glutathione S-transferases respectively.
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Indeed, assessment of andrographolide structure by DEREK identified the a, p-unsaturated 
ester position as capable of educing chromosome damage and METEOR also suggested 
that this position is susceptible to conjugation with glutathione as illustrated in Figure 
2.16c. Furthermore, compounds containing the a, p-unsaturated ester has been known to be 
metabolised via conjugation with glutathione and hydrolysis (Frederick et al., 1992; Greim 
et al., 1995; McCarthy & Witz, 1997). Glutathione conjugates formed in the liver can be 
excreted intact in bile or they can be transformed to mercapturic acids in the kidney and 
excreted in urine. The conversion of glutathione conjugates to mercapturic acids requires 
sequential cleavage of glycine and glutamic acid from glutathione moiety subsequently 
followed by N-acetylation of the resulting cysteine conjugate (Gibson & Skett, 2001). 
Glutathione conjugation of metabolites is an important detoxification step because 
electrophiles for example, are known to be potentially genotoxic species and can bind to 
critical nucleophiles such as DNA and proteins leading to genetic mutations and cellular 
damage. However, in some cases, conjugation with glutathione amplifies the toxicity of a 
xenobiotic by being inherently toxic or being degraded into a toxic metabolite (Williams & 
Aruoma. 2000).
As shown in Figure 2.18, andrographolide can be converted into four possible metabolites 
via 7 different reactions and these metabolites in turn can also be further transformed into 
various different metabolites. However, cellular conditions and the amounts of cofactors 
present for Phase II metabolism dictate the direction of biotransformation pathway. Thus, 
there will be major and minor andrographolide metabolites being produced depending on 
the circumstances. The cellular concentrations of PAPS for example (approximately 
75pM), are significantly lower than those of glutathione (~10mM) and UDP-glucuronic 
acid (~350pM) and the relatively low concentration of PAPS limits the capacity for 
xenobiotic sulfonation (Gibson & Skett, 2001). The availability of UDP-glucuronic acid 
can also limit the rate of glucuronidation of endogenous as well as exogenous compounds 
especially if they are in high doses and being extensively conjugated such as 
acetaminophen. Figure 2.19 shows one example of possible routes for andrographolide 
biotransformation yielding a glutathione-conjugate.
Before the Phase II biotransformation, andrographolide is susceptible to Phase I enzymes 
as suggested by the metabolic tree (Figure 2.18). Hydroxylation and epoxidation of double
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bonds are two main reactions of andrographolide metabolism attributed to cytochrome 
P450. Even though the aglycone was predicted to be metabolised by these reactions, one 
cannot really ascertain whether the metabolites are more or less reactive by referring to the 
metabolic tree. Andrographolide is shown to be susceptible to epoxidation of the double 
bonds and as shown in Figure 2.16f, this epoxide group resides close to the butyrolactone 
moiety of the phytochemical. Although, epoxides have been known to be potentially 
mutagenic (Guengerich, 2003; Benigni, 2005) per se, the reactivity of epoxy- 
andrographolide can only be determined experimentally. Alternatively, another double 
bond exists within the structure at the A8(17^ position as highlighted in Figure 2.8 and is also 
susceptible to epoxidation according to METEOR assessment. However, the half-lives of 
relatively simple epoxides are known to be usually on the order of hours in the absence of 
added nucleophiles. Many of these simple epoxides are carcinogens when administered to 
rodents at high doses (Dunkelberg, 1979) whereas the evidence for human carcinogenicity 
such as styrene is probably equivocal at best (Yeowell-O’Connell et al, 1998). 
Functionalisation of epoxides with the addition of certain groups lead to enhanced 
reactivity such as 2 -cyanoethylene oxide that is more reactive than propylene oxide and is 
mutagenic (Recio et al., 1988; 2001). Butadiene diepoxide is much more reactive and 
genotoxic than would be expected on the statistical basis of having two epoxides (Cochrane 
& Skopek, 1994). A comparable example on epoxide generation in herbs is that observed 
in Teuchrium chamaedrys (Germander), which was once promoted as slimming products in 
the 1990s until hepatotoxicity cases were reported in France. The hepatotoxicity has been 
attributed to the diterpenoids in T. chamaedrys namely teucrin A and teuchamaedryn A.
The furan ring of these diterpenoids is susceptible to oxidation by CYP3A4, which has a 
wide substrate spectrum, to reactive epoxides that react with proteins such epoxide 
hydrolase and CYP3A (Loeper et al., 1994; Lekehal et al., 1996; Fau et al., 1997; Loeper 
et al., 2001). The presence of these reactive epoxides led to mitochondrial membrane 
permeability transition and apoptosis in rat and mouse hepatocytes (Loeper et al., 1994;
Lekehal et al., 1996; Fau et al 1997). It was revealed that teucrin A binds covalently to 
hepatocyte proteins and the furano diterpenoid part of the compound increased cytosolic
^ I
levels of Ca but decreased cellular glutathione (GSH) and cytoskeleton-associated protein 
thiols resulting in the formation of plasma membrane blebs and apoptosis (Lekehal et al.,
1996; Fau et al 1997).
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Futhermore, the epoxide functional group in andrographolide can be further converted into 
vicinal diols, another functional group that can be mutagenic, which may or may not 
increase the reactivity of andrographolide and can only be assess in laboratory studies. 
However, this prediction is made on the probability that these metabolic routes are the one 
favoured by the cellular or systemic conditions since there were other relatively safer 
pathways such as glucuronidation. The possibility that these metabolites are produced as 
minority products cannot be ruled out too. It is also important to note that the unsaturated 
butyrolactone site of andrographolide was predicted by DEREK as able to cause 
chromosome damage in mammals and whether structural transformation to this moiety will 
enhance or reduce the potency of such effect is not deducible without experimental data, 
which currently is inadequate.
Recently, Jarukamjom et al. (2006) studied the impact of aqueous and alcoholic extracts of 
A. paniculata on mouse hepatic cytochrome P450 enzymes and found the extracts to 
significantly elevate the activities of ethoxyresorufin O-dealkylase (EROD) and 
pentoxyresorufin O-dealkylase (PROD) but not methoxyresorufin O-dealkylase (MROD).
It was also suggested that CYP1A1 and CYP2B10 were the P450 isoforms responsive to A. 
paniculata extracts (Jarukamjom et al., 2006). However, the utilisation of crude extracts in 
the study cannot provide valuable qualitative data on the effects of individual components 
in the extracts on specific P450 isoforms, especially andrographolide which is a major 
diterpenoid present (Kleipool, 1952; Siripong et al., 1992). Furthermore, one must take into 
account that individual substances in the extract, as it is the case with many plant extracts, 
may act in an antagonistic or synergistic manner in the expression of bioactivation and 
detoxification pathways. Thus, another study into the effects of andrographolide on 
cytochrome P450 isoenzymes activities showed that the phytochemical significantly 
evoked the expression of CYP1A1 and CYP1A2 but not that of CYP1B1 in mouse 
hepatocytes in a concentration-dependent manner (Jaruchotikamol et al., 2007). The 
mRNA expression of CYP1A1 induced by andrographolide is higher compared to CYP1A2 
but lower than that stimulated with typical CYP1A agonists such as benz(a)anthracene and 
p-naphthoflavone (Jaruchotikamol et al., 2007). It is known that the mechanisms of 
transcription regulation differ between CYP1A1, CYP1A2 and CYP1B1 (Guengerich & 
Shimada, 1998) hence the dissimilarity in the expression levels observed (Jaruchotikamol 
et al., 2007). However, further studies involving major cytochromes such as CYP3A4 is
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needed. This recent study could possibly shed more light into the reported hepatoprotective 
effect modulated by andrographolide.
Andrographolide has been reported to be the major anti-hepatotoxic compound present in 
A. paniculata extract conferring protection to liver cells against toxicity induced by carbon- 
tetrachloride, galactosamine and acetaminophen (Handa & Sharma, 1990a; Handa &
Sharma, 1990b). Since the mode of action and hence toxicity induced by galactosamine 
and acetaminophen are different, it was suggested that a non-specific hepatoprotective 
activity may be attributed to this phytochemical (Handa & Sharma, 1990b). It may be 
possible that andrographolide is involved in cytochrome P450 activity manipulation, 
effectively shielding the liver cells from cytotoxicity. After all, cytochromes 1A2, 2E1,
2A6 and 3A4 have been shown to oxidise acetaminophen (paracetamol) into A-acetyl-/?- 
benzoquinone imine (NAPQI) that in turn is detoxified by glutathione (GSH) resulting in 
the formation of acetaminophen-GSH conjugate (Patten et al., 1993; Chen et al., 1998)
Although metabolic predictions made by CSAR programme such as METEOR is useful, 
there are several caveats to this finding. Any predictions made cannot overrule 
experimental data. Mammals was the chosen parameter for METEOR where no distinction 
was made between human and animals, thus the metabolic tree generated was not 
representative of any particular species but mammals in general plus there are inter- and 
intra-species variability in metabolic capacity. This might explain the absence of 
sulfonation process from the metabolic tree generated in contrary to experimental findings 
where sulfate conjugates were isolated (He et al., 2003a, b, c; Cui et al. 2004). Secondly, 
METEOR is able to suggest the most plausible molecular structure of possible metabolites 
but it cannot exactly determine their reactivity and toxicity, which can only be proven 
experimentally. This involves extraction and identification of the metabolites using high 
performance liquid chromatography (HPLC) or gas chromatography-mass spectrometry 
(GC/MS) to name a few. Subsequently, various genotoxicity studies whether in vitro and 
subsequently followed by in vivo if necessary, can be performed on the isolated metabolites 
to assess its genotoxic potential. For example, butyrylactone moiety of andrographolide 
was suggested to contribute to its activity but this functional group is susceptible to 
conjugation with glutathione and one can never be certain whether andrographolide will be 
more or less reactive. Finally, all of the metabolism studies cited previously merely 
elucidate the type of metabolites being produced by a rather small sample of healthy male
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human volunteers and rats. Although the studies did not report any adverse effects 
experienced by the human volunteers during the study period, this does not necessarily 
means that more subtle form of injury such as mutagenesis and cellular damage can be 
mled out despite successful extraction of more hydrophilic metabolites. Furthermore, 
human metabolism studies may produce metabolites from the compound of interest, which 
may not be observed in in vitro or animal studies and therefore may not have been 
thoroughly assessed for possible risk to humans. In a case where the metabolites were
considerably high in humans, additional testing with the metabolites or the pathways
involved would be essential to properly evaluate the potential of the compound to cause 
genotoxicity in humans (US FDA, 2005).
Therefore, METEOR was useful in determining the most plausible routes of
biotransformation for a compound based on the application of structure-activity
relationships and meant to complement experimental data or assisting in better 
experimental designs. In this study, many similarities were observed between the results 
generated via in silico assessment of possible andrographolide metabolism pattern using 
METEOR and in vitro/in vivo experiments conducted previously, thereby granting the 
opportunity to appreciate the strengths and weaknesses of such approach. Furthermore, 
semi-quantitative information on metabolic fate of this phytochemical along with SAR 
study conducted using DEREK gave a better picture.
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CHAPTER 3
ASSESSMENT OF ANDROGRAPHOLIDE GENOTOXICITY POTENTIAL 
USING THE IN VITRO CYTOKINESIS BLOCK 
MICRONUCLEUS ASSAY
3.1 Micronuclei as Genotoxicity Biomarker: A Historical Perspective
The most often used assay in routine genotoxicity testing of xenobiotics in vitro is bacterial 
mutation (Ames test). However, the detection of natural and synthetic carcinogenic 
substances that act through a non-direct mode of DNA alteration and are negative in bacterial 
mutation assays requires additional test systems. Another often-used endpoint in routine 
testing is the induction of chromosomal aberrations in mammalian cells. Alternatively, the in 
vitro micronucleus assay is easier to perform and is suitable to monitor genotoxicity of such 
compounds in mammalian cells.
Micronuclei were described as “corpuscules intraglobulaires” by Jolly in the late 1800s and 
early 1900s or known as “fragment of nuclear material” in the cytoplasm of erythrocytes by 
Howell about a century ago hence these structures are known to hematologists as “Howell- 
Jolly bodies”. Similar intracellular structures were described in other cell types, for example 
in rat and mouse embryos by Brenneke in 1937 or in Vicia faba by Thoday in 1951, and are 
known as “fragment nuclei” or “micronuclei”. These micronuclei were consistently found 
after radiation exposure of cells and it was assumed that they originated from acentric 
fragments that were excluded from the two daughter nuclei at the late stages of mitosis. The 
instrumental application of micronucleus as biomarkers for cytogenetic damage was 
discovered by Evans et al. in 1959, while comparing the efficiency of neutrons to y-rays in 
Vicia faba roots.
Boiler and Schmid’s work paved the way for the utilisation of micronuclei as an assay 
system for elucidating genotoxicity potential and were first to suggest the term 
“micronucleus”. Studies on bone marrow erythrocytes by Heddle also contributed to the
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decisive development. Subsequently, Countryman and Heddle introduced lymphocytes as 
another useful cellular system for detection of chromosomal damage by the determination of 
micronucleus induction. They also recommended the utilisation of micronuclei as a 
biomarker in testing schemes.
3.2 The In Vitro Cytokinesis Block Micronucleus Assay and Its Application
The simplicity of scoring and wide applicability of the in vitro micronucleus test in various 
cell types makes it an appealing method in cytogenetic abnormality assessment. However, 
incomplete comprehension of micronuclei induction mechanisms and the absence of 
sufficient methods to concurrently assess cell proliferation and micronucleus formation, 
inevitably delayed the validation of the in vitro micronucleus test for genotoxicity testing.
Micronuclei are small, membrane bound extranuclear bodies that arise in dividing cells from 
whole chromosome/chromatids or acentric chromosome/chromatid fragments that lag behind 
in anaphase and remained outside of the daughter cells’ nuclei in telophase. Micronuclei are 
only formed during cell division regardless of the location of the actual damage that occurred 
during the cell cycle, either by damage to the DNA or damage to the mitotic apparatus.
In the in vitro cytokinesis block micronucleus assay (CBMA) developed by Fenech and 
Morley (1985), cytochalasin-B is added to the cells in culture. Cytochalasin-B is a metabolite 
of the fungus Helminthosporium dematioideum that blocks cytokinesis but not karyokinesis 
and results in the formation of binucleated cells from cells that have undergone one nuclear 
division (Carter, 1967; Ridler & Smith, 1968). Cytochalasin-B prevents cytokinesis by 
binding to high-molecular-weight complexes in the plasma membrane, which is responsible 
in inducing actin polymerisation to form microfilaments that governs the cleavage of the 
dividing cell into two daughter cells. This allowed the identification of once-divided nuclei in 
binucleated cells and granted an efficient approach to study the mechanism leading to 
micronuclei formation as illustrated in Figure 3.1. With restriction on micronuclei scoring 
only in cells that had undergone one cell cycle, the cytokinesis-block micronucleus assay
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(CBMA) solved the technical predicament of possible variation in micronucleus frequency 
caused by modifications in the proportion of dividing cells that may occur either due to sub- 
optimal culture conditions or exposure to genotoxic agents (Fenech, 2000). Table 3.1 
compares the in vitro CBMA and chromosomal aberration assay, which is widely used 
previously to assess genotoxicity.
A micronucleus that contains a whole chromosome mainly results from defects in the 
chromosome segregation machinery such as failure of the mitotic spindle, kinetochore, or 
other parts of the mitotic apparatus, deficiencies in the cell cycle governing genes or by 
damage to chromosomal substructures, mechanical disruption (Albertini et al., 2000) as well 
as centromeric DNA hypomethylation (Fenech et al., 2005). An acentric or a lagging whole 
chromosome that is not included into the main nucleus after nuclear membrane reformation, 
may become enveloped by separate membrane producing a micronucleus due to the inability 
to migrate towards the opposite microtubule organising centres (MTOCs) (Lynch & Parry, 
1993; Schuler et al., 1997; Fenech, 2000). On the other hand, micronuclei harbouring 
chromosomal fragments may arise from direct double-strand DNA breakage, inhibition of 
DNA synthesis or conversion of single strand breaks into double strand breaks after cell 
replication. Misrepair of two chromosome breaks may cause asymmetric chromosome 
rearrangement generating a dicentric chromosome and an acentric fragment. Usually, the 
centromeres of the dicentric chromosomes are pulled towards the MTOCs of the cells during 
anaphase producing a nucleoplasmic bridge (NPB) between the daughter nuclei and an 
acentric fragment that lags behind to form a micronucleus (Thomas et al., 2003; Fenech, 
2005). Micronuclei can also be formed by gene amplification via breakage-fusion-bridge 
(BFB) cycles when amplified DNA is selectively placed to specific sites at the periphery of 
the nucleus and extrude via nuclear budding at the S-phase of the cell cycle (Fenech, 2002).
For almost two decades, the in vitro CBMA has evolved into a comprehensive technique in 
assessing cytostasis, chromosome loss, chromosome breakage, non-disjunction, apoptosis 
and necrosis. New developments also indicated that this assay could be employed to measure 
nuclear buds, a biomarker for gene amplification and changes in gene dosage as well as the 
measurement of nucleoplasmic bridges, which is an indicator for dicentric chromosomes
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resulting from telomere end-fusions or DNA mis-repair (Haaf et al., 1999; Umegaki & 
Fenech, 2000). Figure 3.2 shows the possibility of various outcomes in cytokinesis-blocked 
cells upon exposure to genotoxic and/or cytotoxic agents.
Table 3.1. Comparison o f  strengths and weaknesses o f  chromosomal aberration assay and in vitro CBMA.
Methods
Chromosomal 
aberrations assay
Advantages
Endpoint: chromosome mutations.
Combined with FISFf-painting 
permits the detection of 
numerical and structural 
chromosomal aberrations.
Possible co-detection of mitotic 
indices.
Able to identify the nature of the 
clastogenic damage being 
examined, strand breaks 
against base damage.
Sensitive method.
Interactive scoring possible but not 
full automation.
Disadvantages
• Labour-intensive and
requires in vitro cell 
cultivation.
Requires highly qualified 
skills and experience.
In vitro CBMA
Endpoints: chromosome and 
genome mutations.
Combined with suitable antibodies 
(e.g. CREST) allows the 
identification of aneugen and 
clastogen; detection of 
chromosome loss and non­
disjunction.
Detection of other useful endpoints 
such as apoptotic, necrotic 
cells, NPB and NBUD.
Simple and fast.
Economical to perform and the 
possibility of automation.
Sensitive method with statistical 
power.
Requires cell division for 
micronucleus 
expression.
Effect of cytochalasin-B on 
micronucleus frequency.
Not able to detect all 
chromosomal damage 
events e.g. symmetrical 
reciprocal translocations.
N.B. NPB= nucleoplasmic bridges; NBUD= nuclear budding.
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Genotoxic
insult
Parent cell
Two daughter cells with 
micronuclei after successful 
cytokinesis
(B)
Parent cell
Genotoxic
insult
+ cytochalasin-B
A binucleated daughter cell 
with two micronuclei after 
one cell cycle
Fig. 3.1. In (A), a cell that has been subjected to a genotoxic insult may produce micronuclei in daughter cells 
but they are not suitable for scoring as one cannot ascertain whether the cells has gone through only one cell 
division. However, the addition o f cytochalasin-B such as shown in (B) allows micronuclei in a binucleated cell 
to be quantified since cytokinesis is prevented in a cell that is going through one cell cycle.
One obvious advantage of the in vitro CBMA lies in its capability in detecting both 
aneugenic and clastogenic events, resulting to numerical and structural chromosomal 
aberrations respectively (Fenech, 2000) making the assay more mechanistically enhanced. 
Distinguishing the two different events is achievable even at low doses of genotoxin
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exposure. For example, the sensitivity of this assay in detecting damage induced by ionising 
radiation is 0.2Gy for micronuclei (aneugenic and clastogenic events) and 0.1 Gy when 
combined with pan-centromeric FISH (fluorescence in situ hybridisation) probes when 
detecting clastogenic events (Vral et al., 1997; Touil et al., 2002).
NecrosisApoptosis
o
o°o
Non- Centrosome
v _ jr C h rom o so m e
disjunction* Dicentric bre^ ? 90 <??net- abnormality1 chromosome and amplification
loss
Fig. 3.2. The possibility o f  various outcomes in cytokinesis-blocked cells upon exposure 
to genotoxic and/or cytotoxic agents. The application o f  these biomarkers within the 
CBMA allows the quantification o f chromosome breakage, chromosome loss, gene 
amplification, chromosome rearrangement and cell death (apoptosis and necrosis). 
Furthermore, cytostatic effects can be elucidated by the ratio o f  mono-, bi- and 
multinucleated cells. The CBMA has not been used previously in measuring centrosome 
abnormalities incidence but this is possible in theory by quantifying the frequency o f  tri- 
and/or tetranucleated cells and confirming that their DNA content is 4N. (Adopted from 
Fenech, 2002).
3.2.1 CBMA in Combination with Kinetochore Labelling
Auto-antibody present in the sera of patients suffering from a specific type of the 
autoimmune disease scleroderma, CREST (Calcinosis, Raynaud phenomenon, esophageal 
dismotility, sclerodactyly and telangiectasia) syndrome, possess a high affinity to 
kinetochore proteins present at the centromere of chromosomes (Moroi et al., 1980). It was 
later suggested that the CREST antibody could be utilised in distinguishing between 
micronuclei that contain fragmented (Kinetochore negative; K-) and whole chromosomes
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(Kinetochore positive; K+) (Parry & Parry, 1987). Subsequently, application of the CREST 
antibody in determining whether structural (clastogenic) or numerical (aneugenic) 
chromosomal changes was involved in micronuclei induction rapidly ensued (Degrassi & 
Tanzarella, 1988; Eastmond & Tucker, 1989; Bonassi et al, 1992) as illustrated in Figure 3.3 
below.
Fig. 3.3. Shows how micronuclei harbouring kinetochore positive and negative can be differentiated by 
by employing the CREST antibodies against chromosomal kinetochore proteins. Kinetochore positive 
micronuclei denotes whole chromosome(s) whereas chromosomal fragments detected as 
kinetochore negative micronuclei.
A micronucleus that harbours a centromeric region arise from whole chromosomes or 
chromosomal fragments containing a centromere, whereas those that do not contain a 
centromeric region results from the formation of nuclear membrane around acentric 
fragments or whole chromosomes that have lost the kinetochore from the centromere. As it is 
assumed that random kinetochore loss, chromosome breakages and fragments containing 
centrosomes are not common, regular events, the occurrence of either kinetochore positive or 
negative micronuclei with 70% frequency or higher indicates aneugenic or clastogenic nature
Introduction o f CREST 
antibodies
A binucleated cell with 
kinetochore positive 
m icro n u c le i
A binucleated cell with 
two micronuclei after 
one cell cycle
A binucleated cell with 
kinetochore negative 
m ic r o n u c le i
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i of the compound tested respectively (Antoccia et al., 1991; Antoccia et al., 1993; Stopper &
Muller, 1997).
3.3 Cellular Toxicity in Genotoxicity Assessment
Every genotoxicity tests employed for regulatory submission must be accompanied by 
relevant cellular toxicity data where the agent must be subjected to the tests involving 
; maximum concentrations (10mmol/l or 5000pg/ml), the highest level permissible by
cytotoxicity or the limit of solubility in solvent or growth medium. Thus, the cytotoxicity 
| assessment is not only critical for the elucidation of possible mode of action but also crucial
! for assay validity.
A toxic compound is capable of initiating two characteristic forms of cell death with clearly
!
distinct biochemical and morphological features namely apoptosis and necrosis (Wyllie et al.,
1980). Other forms of cell death include autophagy and senescence. The consequent cell 
death type hinges heavily on the stimulus and cellular context since every cell death 
mechanism is a net result of self-propagating signals and others that negate the alternative 
j  cell death programs (Clarke, 2002). Typical feature of apoptosis are fragmented nuclei with
; condensed chromatin, organised DNA degradation (Wyllie et al., 1980; Duke et al, 1983)
and shrunken cytoplasm within an intact plasma membrane. In contrast, necrosis features 
severe loss of membrane integrity and leakage of cellular components (Wyllie et al., 1980).
The same chemical in different concentrations is capable of triggering both type of cell death 
due to various factors such as increased physical cellular damage, alterations to cellular 
biochemical homeostasis or intolerable disruption to cellular repair mechanisms. For 
example, less than lpM cadmium chloride would activate apoptotic response but higher 
concentrations caused necrosis in cells. Therefore, classical apoptotic and necrotic cell death 
represent only the extreme end of a wide spectrum of possible biochemical and 
morphological deaths that can occur simultaneously in tissues or cell cultures exposed to the 
same agent (Nicotera et al., 1999). Apoptosis may also progress to secondary necrosis when 
dying cells are not removed by heterophagy (Kroemer et al., 1998).
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Once a xenobiotic enters the cell, it may directly interact with various receptors and inducing 
positive or negative effect via signalling pathways manipulation. Alternatively, the 
xenobiotics are subjected to biotransformation yielding reactive metabolites or become 
inactive, which is a common fate. However, some of these compounds or their products can 
have undesired effects. Therapeutic compounds may also possess unrelated effects other than 
its intended purposes and target sites. For example, an oral fluoroquinolone broad-spectrum 
antibiotic temafloxacin (Omniflox™) was found to cause allegic reactions in some patients 
as well as haemolytic anemia, liver and kidney dysfunctions (FDA, 1992) whereas 
Fansidar™ (pyrimethamine-sulfadoxine) that has been used against malaria and 
toxoplasmosis was reported to induce micronuclei as well as sister chromatid exchanges 
(Abou-Eisha & Afifi, 2004). Direct-acting genotoxins will target the DNA causing damage 
such as adducts formation, where they interact with proteins, other macromolecules such as 
DNA or small molecules such as glutathione (GSH). Depletion of the oxidative defences can 
cause changes in cellular redox status resulting in disturbances to regulatory systems affected 
by redox homeostasis, ultimately leading to cell death via apotosis or necrosis as illustrated 
in Figure 3.4 overleaf.
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Fig. 3.4. Shows some o f  the events related to genotoxicity and toxicity o f  xenobiotics. (Adopted from Liebler & 
Guengerich, 2005).
3.3.1 Methods in Cytotoxicity Measurement
Various methods as well as measurement endpoints are employed in assessing cytotoxicity 
exerted by a compound of interest. Thus each of the method employed might differ in the 
terms of the data generated.
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Vital dyes such as trypan blue or fast green are usually excluded from viable cells but can 
enter through damaged cell membranes to stain the cytoplasm, and they have long been used 
as indicators of non-viable cells. Trypan blue was used to study the cytotoxicity of anti­
tumour drug in a variety of tumours and a good correlation was found between the in vitro 
responsiveness and the in vivo chemotherapy results in both animals and humans (Durkin et 
al., 1979). The limitation of vital dye exclusion tests is that these type of assays measure 
dead necrotic cells with damaged membranes and may not measure dying or apoptotic cells 
with intact membranes.
Viable cells can be measured with colourimetric assays utilising a substrate whose colour is 
modified by living but not dead cells. One example was the development of a rapid 
colourimetric assay based on the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) (Mosmann, 1983), which is cleaved and converted to a 
blue formazan by the mitochondrial dehydrogenase in active mitochondria. Thus, cellular 
metabolic activity is utilised to distinguish between viable and non-viable cells. Good 
correlation was observed between MTT and clonogenic assays for drug exposures in some 
cell lines (Carmichael et al., 1987).
Activation of the caspase cascade is an integral event in the apoptotic pathway (Atkinson et 
al, 1998) and caspase-3 activation is frequently accepted as a reliable marker for apoptosis 
(Nicholson et al., 1995). Caspase 3 is part of the caspase cascade which initiates the cleavage 
of various proteins resulting in an ordered breakdown of the cell (Tewari et al, 1995).
Determining cell viability is important in assessing mutagenesis, malignant transformation, 
cellular pathology, toxicity and apoptosis. Furthermore, delineating mechanisms of 
carcinogenesis would be incomplete without cell viability assessment as tumours may only 
arise from abnormal living cells. The methods to be employed in cellular toxicity assessment 
and the advocated levels to be attained are defined in ICH and OECD guidelines (ICH 1995; 
OECD 1997a; OECD 1997b) that differ between test systems. Cloning efficiency or relative 
total growth (RTG) are required to be reduced by 80-90% whereas for cytogenetic assays 
including CBMA, the parameters needed is at least 50% reduction in binucleate index
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(Kirsch-Volders et al., 2003) or mitotic index, cell number and confluency (OECD 1997a). 
Subjecting compound of interest excessively cytotoxic doses may cause artefactual false 
positive data or difficulties in data interpretation (Kirkland, 1992; Galloway, 2000).
3.4 The Objective of the Study
The objective of this study was to assess the potential of andrographolide to induce 
genotoxic damage in V-79 as well as metabolically competent cell lines of AHH-1 and 
MCL-5 using the in vitro cytokinesis-block micronucleus assay. This assay was 
accompanied by kinetochore labelling using the CREST antibodies in order to determine the 
type of damage induced whether it is clastogenic or aneugenic in nature. Along with other 
methods of measurement, the cytotoxicity potential of andrographolide was also assessed 
using trypan blue-exclusion assay.
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3.5 MATERIALS AND METHODS
3.5.1 Safety Aspects.
Disposable latex gloves were worn for every laboratory work conducted. Sterile conditions 
were achieved using Class II Cryomat Pharmaceutical lamina flow hoods which were 
routinely cleaned with 70% ethanol. Experiments involving toxic and dangerous chemicals 
were performed with extra gloves in the Class II lamina flow hood. The staining, fixation and 
mounting of the microscope slides were always conducted inside a flow hood. All items used 
for the experiments were routinely cleaned with 70% ethanol.
Andrographolide and other toxic compounds in solid form were weighed in the toxic 
handling room and dangerous substances were carefully disposed of in multi-layered toxic 
bags destined for incineration. Deionised water used for all experiments was UV-purified and 
filtered with the Milli-Q PF Ultrapure Water Purification System.
3.5.2 Annual Mycoplasma Testing.
Mycoplasmas are considered as serious contaminants of cell cultures. They are prokaryotes 
without cellular walls, belonging to the class Mollicutes, order Mycoplasmatules (McGarrity, 
1984). They are amongst the smallest of self-replicating prokaryotes, approximately one- 
sixth the size of an Escherichia coli bacterium. They are capable of altering cellular functions 
like chromosomal arrangements, uptake of nucleic acid precursors, cell responses to 
mitogens and secretions of interferon by the cells. Mycoplasma may also deplete arginine or 
glutamine from the culture medium (Kouri et al., 1983). It as been reported that they produce 
chromosomal and numerical aberrations of cultured cells (Fogh and Fogh, 1965; Paton et al., 
1965; Aula and Nichols, 1967) and for a review of the cytogenetic effects see McGarrity et al. 
(1984).
The annual screening of mycoplasma in the laboratory was achieved using MycoAlert® 
mycoplasma detection based on bioluminescence assay. Basically, the screening experiment 
was conducted in a two-step process where the reagent containing a substrate for specific 
enzymes secreted into the culture media by mycoplasma leading to the phosphorylation of
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adenosine diphosphate to adenosine triphosphate. The addition of another reagent containing 
luciferase and luciferin, where the enzyme catalyses a light-generating reaction between ATP, 
oxygen and luciferin. Initially, 2ml of cell culture was centrifuged at 1500rpm for 5 minutes 
and lOOpl of cleared supernatant was transferred into a sterile 96-well plate. Subsequently, 
lOOjxl of MycoAlert® was added to the 96-well plate and left at room temperature for 10 
minutes. The luminometer was programmed to take one second integrated reading and the 
first reading was taken (reading A). Then, 100pi of MycoAlert Substrate solution was added 
to the same plate and left at room temperature for another 10 minutes before a second reading 
was taken (reading B). Finally, a ratio between the two readings was calculated and a ratio of 
less than 1, indicates uninfected cell line as the concentration of ATP in the sample is 
proportionate to light intensity. None of the cell lines used in the experiments were found to 
be positive of mycoplasma contamination in the annual screening process.
3.5.3 Introduction to AHH-1 and MCL-5 Cell Lines.
The AHH-1 TK+/‘ is a human B lymphoblastoid cell line that is derived from the RPMI-1788 
cell line isolated from a healthy male donor. This culture was spontaneously transformed 
probably by the Epstein-Barr virus (Gentest Corporation manual, 1994), and the AHH-1 cell 
line was subsequently derived. The cell line has stable aryl hydrocarbon hydroxylase (AHH) 
activity, expressing mixed-function oxygenase (MFO) activity that is essential in oxidative 
xenobiotic metabolism. Mediated gene transfer of cytochrome P450 (CYP450) genes/cDNAs 
is a preferred method in the construction of metabolically competent cells (Crespi et al.,
1990). AHH-1 is homogenous, clonal derivative designed to be constitutively expressing a 
relatively high level of CYP1A1 (Crespi & Thilly, 1984) which is an isoform of cytochrome 
P450 that is involved in the oxidation of polycyclic aromatic hydrocarbons (PAH) hepatically 
in humans.
The MCL-5 cell line is a derivative of AHH-1 which has been transfected with five cDNAs 
namely CYP1A1, CYP1A2, CYP2A6, CYP3A4 and CYP2E1 as well as microsomal epoxide 
hydrolase that are carried on a vector (Crespi et al., 1991). MCL-5 has been demonstrated to 
be more sensitive than the parent AHH-1 cell line and had been used successfully in
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detecting genotoxic properties of many pro-mutagens and pro-carcinogens (Crespi et al.,
1991; Doherty et al., 1996).
Human lymphoblastoid cell lines were chosen over rodent cell lines with metabolic 
activation (S9 liver extract) for several reasons. In comparison to rodent cells, human cells 
are known to be 1000 times more sensitive to some cytotoxic antibiotics, twice as sensitive to 
radiation and six times more sensitive to hydrogen peroxide (Cox et al., 1977a; Cox et al., 
1977b; Hoffman et al., 1984; Gupta & Prasad, 1992). AHH-1 and MCL-5 cell lines possess 
genetically enhanced levels of metabolising enzymes as stated before and they are known to 
be sensitive to chemically active agents and those which require metabolism to manifest their 
effects.
These cell lines are heterozygous for p53 but undergoes normal DNA repair and apoptotic 
responses upon genotoxins exposure (Guest & Parry, 1999). Both lymphoblastoid cell line 
possess a modal chromosome number of 48 with isochromosomes i(3q) and i(9p) (Doepker 
et al., 1998; Corso & Parry 1999).
Furthermore, both cell lines which were chosen for micronucleus assay are also applicable in 
forward mutation assays (HPRT locus) allowing better data comparisons and illuminating 
mechanistic information.
3.5.4 Thawing Frozen AHH-1 and MCL-5 Cells.
The cryovial containing the cells were removed from the liquid nitrogen freezer; thawed in a 
water bath at 37±1°C for a few minutes and decontaminated by spraying with 70% ethanol.
The growth medium used was RPMI-1640 that has been supplemented with 9% horse serum 
and 1% L-glutamine. The thawed cell suspensions were transferred to two 80cm2 plastic 
tissue culture flasks with 50ml of growth medium, which was pre-warmed at 37±1°C for 40 
minutes. The flasks were then gassed with 5% CO2 in air and incubated at 37±1°C. After 24 
hours, the flasks were examined under the Nikon TMS phase contrast microscope proceeding 
from low, then to higher magnification, observing the condition of the cell cultures and any
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sign of contamination. Sub-culturing procedure began approximately after four days of 
growth with 60-75% cell confluency.
The same procedure was employed for MCL-5 cells except 200pg/ml hygromycin-B was
t
I added to 50ml of growth medium. Hygromycin-B is an aminoglycosidic antibiotic produced
| by Streptomyces hygroscopicus and the recombinant vectors in MCL-5 are maintained as an
extrachromosomal plasmids that confer resistance to hygromycin-B.
i
3.5.5 Sub-Culturing Procedure for AHH-1 and MCL-5 Cells.
The 80cm tissue culture flasks were shaken to dissociate loose cell aggregates that were 
growing exponentially and the cell suspension were dispensed into centrifuge tubes. The cell 
cultures were centrifuged at 1500rpm for 8 minutes and a Neubauer haemocytometer was 
used to determine the number of cells. Cell density was maintained at 1.5xl05 cells per ml
and the cells were cultured for a maximum period of three weeks to ensure a stable karyotype 
(Doherty et al., 1996). Prior to treatment, the cell cultures were seeded into several 25cm 
tissue culture flasks to achieve a final concentration of 1.5xl05 cells per ml. The cells were 
then gassed with 5% CO2 in air and incubated at 37±1°C for 24 hours.
The same procedure was employed for MCL-5 cells except 200pg/ml hygromycin-B was 
added to the growth medium.
3.5.6 Introduction to V-79 Cell Line.
V-79 cells are an immortal cell line derived from male Chinese hamster (Cricetulus griseus) 
lung fibroblasts. It has a long history in its application for mutagenicity assays due to 
several properties. The cell line possesses a high cloning efficiency at 75-95%, able to 
grow rapidly from a small inoculum with a doubling time of 12 to 16 hours (Bradley et al.,
1981). It also has short lag period. V-79 cells have a relatively stable karyotype with a 
modal chromosome number of 22±1 that is relatively large, making this cell line suitable 
for aneuploidy studies (Bradley et al., 1981).
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V-79 cells were first grown in 80cm flasks in a monolayer, with Dulbecco’s Modified 
Eagles Medium (DMEM), supplemented with 10% foetal bovine serum. The cells were 
gassed with 5% CO2 in air and incubated at 37±1 °C.
Routine sub-culture of V-79 cells involved re-suspension of cells at lxl 05 cells/ml every 2- 
3 days with fresh growth medium, depending on the culture confluency. Detachment of 
cells from culture flask surface was achieved using 3ml of 2.5% trypsin-EDTA followed by 
brief incubation at 37±1 °C for one minute and gentle tapping.
None of the cell lines used were cultured continuously for more than three weeks and cells 
from new cryovials were used for each replicate of experiments. Cells were sub-cultured 
routinely but not to exceed 10 passage numbers.
3.5.7 Cell Doubling Time Determination.
The cell doubling times for AHH-1, MCL-5 and V-79 were determined beforehand. Even 
though the doubling times for these cell lines can be found in the literature, the author 
conducted a short experiment to determine the cells doubling time. The cells were seeded at
r
the initial concentration of 1.5x10 cells/ml in different 25cm culture flasks containing the 
necessary components to suitable growth media as stated previously. Each of the 25cm2 
culture flasks were labelled to correspond to different time-points between 16 to 24 hours, 
where the cell number were determined using a Neubauer haemocytometer at the desired time- 
points. The result for this experiment was then used for subsequent experiments where the cell 
doubling time for V-79, AHH-1 and MCL-5 were established to be 18, 19 and 23 hours 
respectively and was considered to be comparable to those described in the literature (Gentest 
Technical Manual; Crofton-Sleigh et al., 1993). However, a treatment time of 24 hours for all 
cell lines were adopted instead. The experiments were conducted in three replicates and the 
raw data can be found in Table Al of the Appendix.
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3.5.8 Treatment with Andrographolide.
Andrographolide (CAS no.5508-58-7; molecular weight 350.45) with 98% purity was stored 
in cool and dry place. Andrographolide to be used at various concentrations was prepared by 
dissolving the crystals with DMSO (CAS no.67-68-5, >99.5% purity) as solvent and 
administered to AHH-1/MCL-5/V-79 cell cultures within two hours of preparation. Fresh 
stocks were always prepared for each experiment replicates. Flasks containing healthy- 
looking, evenly distributed cells were selected and labelled according to doses. Less 
confluent flasks were allocated for negative control and low dose treatments while more 
confluent flasks were allocated for high dose treatments. After serial dilutions, the labelled 
25cm2 flasks containing 10ml of cell cultures were treated with increasing doses 
andrographolide in DMSO to give 10-90pM final concentrations respectively. Two 25cm 
flasks were allocated for each dose and at the top dose of 90pM andrographolide, there was
0.9% DMSO. Four 25cm2 flasks were assigned as untreated negative control. Subsequently,
40pl of cytochalasin-B in DMSO was added to each flask giving a final concentration of 
6pg/ml as suggested by Parry et al. (2002). The addition of cytochalasin-B was performed 
under subdued lighting as the compound is light sensitive. The final concentration of DMSO 
in the culture medium was less than 1 %.
The cell cultures were then gassed with 5% CO2 in air for approximately 10 seconds and 
incubated at 37±1°C for 24 hours. The possibility of andrographolide precipitation occurring 
in the growth medium pre- and post-incubation was determined earlier and at these 
concentrations, no precipitations were observed.
Positive control slides were obtained by treating the AHH-1 and MCL-5 cells with 25jig/m 1 
Mitomycin -C (CAS no.50-07-7). Mitomycin-C (MMC) is a known cross-linking agent in 
the absence of exogenous metabolic activation which had demonstrated to be genotoxic in all 
in vivo and in vitro test systems using mammalian cells, including the in vitro micronucleus 
test (Gupta & Singh, 1982; Ishidate et al., 1988; Mavoumin et al., 1990; Sofuni et al., 1996; 
Matsushima et al., 1999; von der Hude et al., 2000). The Ames test also showed that MMC is 
a genotoxicant (Quillard et al., 1985) and the compound was proven to be carcinogenic
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(Ishidate et al., 1988). DMSO at 90jiM final concentration was also use as a second negative 
control since it was used as a vehicle for andrographolide.
In the initial phase of the study, a dose-setting assay was conducted where AHH-1 cells were 
treated with andrographolide between 10 and lOOpM. However, the number of doses was 
later reduced.
3.5.9 Cell Harvesting and Slides Preparation.
After 24 hours, the cell suspensions were dispensed into correspondingly labelled 10ml 
centrifuge tubes and centrifuged at 1500rpm for 8 minutes. The supernatant was safely 
disposed and the cell pellets were re-suspended into clean and clearly labelled centrifuge 
tubes containing 3ml PBS (pH 7.4); they were vortexed using a Whorlimixer for one minute 
to achieve a suspension of single cells. 120pl of the each treated cell suspension were added 
into the wells of the cytospin and spun at lOOOrpm for 5 minutes. Subsequently, slides were 
fixed in 90% ice-cold methanol for 10 minutes as described by Fenech (2000) and air-dried 
before storage at -20°C.
3.5.10 Staining Techniques.
Staining with Giemsa.
The air-dried slides were immersed in 20% Giemsa solution for 8 minutes but the slides were 
examined after 6-7 minutes to ensure appropriate staining intensity, which is important for 
the scoring procedure. After 8 minutes, the slides were removed, rinsed twice in PBS (pH 
6 .8) for 5 minutes and air-dried. Subsequently, the slides were briefly dipped in Xylene 
(99.99%) and coverslips were immediately but carefully placed over the cells mounted with 
DPX. Care was taken to avoid the formation of air bubbles underneath the coverslips. Slides 
were viewed using the Olympus BH-2 light microscope.
Staining with Acridine orange.
Prepared slides were also stained with acridine orange. Fixed slides were placed in coplin jar 
containing 1.25pg/ml acridine orange for 10 seconds. The slides were then placed in 
phosphate buffer (pH 6 .8) for 10 minutes and then transferred to fresh buffer and left for one
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hour. The slides were air-dried in the dark and stored away from light. Olympus BH2-RCF 
fluorescence microscope with triple band-pass filter was used to view the slides, which 
involved placing a few drops of PBS (pH 7.4) onto the cytodots of the slides.
3.5.11 Cell Scoring Procedures.
The Giemsa-stained slides were coded and scored at 1000X magnification under oil 
immersion using an Olympus BH-2 light microscope. The scoring procedure was performed 
as described by Fenech et al. (2003) as shown in Figures 3.5, 3.6 and 3.7 respectively. The 
cells were categorised into mono-, bi-, tri-, tetra-, and multinucleated cells. In this study, 
micronuclei were scored in at least 2000 binucleated cells per dose; micronuclei in other cells 
were not taken into account.
As suggested by Fenech et al. (2003), the binucleated cells selected for scoring micronucleus 
frequency must possess the following characteristics.
1. The cells should be binucleated.
2. The presence of two nuclei with intact nuclear membranes and located within the 
same cytoplasmic boundary.
3. The two nuclei in a binucleated cell should be approximately equal in size, staining 
pattern and intensity.
4. The two main nuclei in a binucleated cell may touch but ideally should not overlap 
each other. A binucleated cell with two overlapping nuclei can only be scored if the 
nuclear boundaries of each nucleus are distinguishable.
5. The presence of intact cytoplasmic boundary or cell membrane and clearly 
distinguishable from the membrane of neighbouring cells.
The criteria adopted for classifying micronuclei in binucleated cells were as suggested by 
Fenech et al. (2003):
1. Micronuclei are oval or round in shape.
2. The diameter of micronuclei in human lymphocytes usually varies between 1/16th and 
l/3rd of the mean diameter of the main nuclei which, corresponds to 1/256* and 1/9* 
of the area of one of the main nuclei in a binucleated cell respectively.
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3. Micronuclei are not linked or connected to the main nuclei.
4. Micronuclei may touch but must not overlap the main nuclei and the micronuclear 
boundary should be distinguishable from the nuclear boundary.
5. Micronuclei usually have the same staining intensity as the main nuclei but 
occasionally staining may be more intense.
6. Micronuclei are non-refractile and they can therefore be readily distinguishable from 
artefacts such as staining particles.
Nucleoplasmic bridges (NPB) are sometimes observed in binucleated cells following 
exposure to clastogens and are believed to originate from rearranged chromosomes with 
more than one centromere, e.g. dicentric chromosomes. The criteria used for scoring 
nucleoplasmic bridges as suggested by Fenech et al. (2003):
1. NPB are a continuous nucleoplasmic link between the nuclei in a binucleated cell.
2. The width of a nucleoplasmic bridge may vary considerably but usually does not 
exceed lA of the diameter of the nuclei within the cell.
3. NPB should have the same staining characteristics of the main nuclei.
4. NPB are preferably scored in binucleated cells with clearly separated nuclei because 
it is usually difficult to observe an NPB when the nuclei are touching or overlapping.
5. A binucleated cell with a nucleoplasmic bridge may or may not contain one or more 
micronuclei and on rare occasions more than one nucleoplasmic bridge may be 
observed within one binucleated cell.
(A) (B) (C) (D)
Fig. 3.5. Displays different binucleated cells that can be scored for micronuclei in the cytokinesis-block 
micronucleus assay. (A) is the ideal binucleated cell to be scored while (B) has a touching daughter nuclei. 
Nucleoplasmic bridges between the two daughter nuclei, as shown in (C) and (D), with (D) possessing a relatively
wider bridge. (Adopted from Fenech et al., 2003).
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Fig. 3.6. Four examples where micronuclei presence in binucleated cells that are suitable for scoring. The relative 
sizes o f the micronuclei is also shown. In (A), the cell contains two micronuclei with different sizes whereas in (B) 
the micronuclei touched but did not overlapped with the main nuclei. Nucleoplasmic bridge is observed in (C) and
multiple micronuclei is shown in (D), a rare occurrence in cells. (Adopted from Fenech et al., 2003).
The guidelines followed for scoring necrotic and apoptotic cells were as recommended by
Fenech et til. (2003).
Necrotic cells:
1. Early necrotic cells can be identified by the presence of a pale cytoplasm with 
numerous vacuoles (mainly in the cytoplasm and some in the nucleus) and damaged 
cytoplasmic membrane with a fairly intact nucleus.
2. Late necrotic cells exhibit loss of cytoplasm and irregular/damaged nuclear 
membrane with only a partially intact nuclear structure and often with nuclear 
material leaking from the nuclear boundary.
3. Staining intensity of the nucleus and cytoplasm is usually less than that observed in 
viable cells.
Apoptotic cells:
1. Early apoptotic cells can be identified by the presence of chromatin condensation 
within the nucleus and intact cytoplasmic and nuclear boundaries.
2. Late apoptotic cells exhibit nuclear fragmentation into smaller nuclear bodies within 
an intact cytoplasm/cytoplasmic membrane.
3. Staining intensity in the nucleus, nuclear fragments and cytoplasm is usually greater 
than in viable cells.
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apoptotic cells necrotic cells Fig. 3.7. Shows different stages o f apoptotic 
and necrotic cell death. The mono- and 
binucleated cells shown experienced an early 
stage o f  apoptotic response where chromatin 
condensation occurred without disintegration of 
the plasma membrane, whereas the third 
example shows cells in late apoptosis with 
apoptotic bodies in the absence o f nuclear 
membrane. In comparison, cells suffering from 
necrotic cell death show the presence of 
vacuoles, cytoplasmic loss and damage to the 
cell membrane. The first two examples are 
mononucleated cells in the early stage of 
necrosis and the third example is necrotic cell 
in late stage evident from the absence of 
cytoplasm and damaged nuclear membrane 
(Adopted from Fenech et al., 2003).
3.5.12 Replication Index Calculation.
Apart from utilising the frequency of necrotic and apoptotic cells as biomarkers for 
cytotoxicity, assessment of toxicity was performed by determining cell proliferation in both 
treated and control cultures using the replication index (RI) values which denotes the relative 
number of nuclei in cell cultures exposed to test agent compared to negative control cultures 
as described by Kirsch-Volders et al. (2004):
^  (Number o f  binucleates + 2 x number o f  multinucleates)T / Total number o f  cellsT  ^^
(Number o f  binucleates + 2 x number o f  multinucleates\ / Total number o f  cellsc
 ( 1)
where T: test agent treatment culture; and C: solvent control culture.
Therefore, the measurement of reduction in treated cultures due to the presence of test agent; 
Cytotoxicity = 100 — RI. .....(2)
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3.5.13 Trypan Blue Exclusion Assay for Cell Viability.
AHH-1, MCL-5 and V-79 cells were grown in 25cm culture flasks as described previously 
in Section 3.5.5; 3.5.6 and treated with various doses of andrographolide as mentioned in 
Section 3.5.8 respectively. After 24 hours, the cells were treated with various doses of 
andrographolide; gassed with 5% CO2 and incubated for another 37±1°C for 24 hours. 
Subsequently and as described by the manufacturer, 0.5ml of 0.4% Trypan Blue solution was 
transferred into centrifuge tubes containing 0.3ml HBSS. Cells that were floating and 
attached to the flask surface were collected; washed by centrifugation at 1500rpm for 5 
minutes and re-suspended in HBSS in correspondingly labelled tubes. Then, 0.2ml of cell 
| suspensions in HBSS that were prepared earlier, were transferred into each of those
| centrifuge tubes and mixed thoroughly (5 dilution factor). The cell number were counted
i
I using Neubauer haemocytometer; the ratios of viable and non-viable cells (blue-stained) in 
I treated and untreated cells were determined.
Cell growth to determine any changes in cell counts was calculated as;
1
i
„ „ , (Cell number in treated cultures)Cell growth = \  x 100
(Cell number in untreated cultures)
| 3.5.14 Kinetochore labelling.
1
| The indirect immunofluorescent labelling of kinetochore proteins was performed as
| described by Ellard et al. (1991) with some minor modifications. The prepared slides were
removed from storage and were rehydrated in PBS at room temperature for one minute. The 
slides were then dipped in a primulin solution (0.005pg/ml) for 10 seconds in order to stain 
the cytoplasm. This was subsequently followed by washing and rewashing the slides in PBS 
and any excess PBS was removed.
CREST antibody was diluted in PBS with a 1:1 ratio and 50pl of the diluted antibody were 
applied onto the cytodots of each slide. Plastic cover slips were applied and the slides were 
incubated in humidified chambers at 37°C for 45 minutes.
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After the incubation, the cover slips removed; slides were washed three times for 3 minutes 
in PBS with 1% bovine serum albumin (BSA) followed by washes in PBS for 3 minutes. The 
slides were left in PBS to prevent drying out while a second antibody was prepared. A 
second antibody, FITC-conjugated goat anti-human IgG with PBS in 1:100 ratio and 50pl 
of the diluted antibody were applied onto the cytodots of each slide. Cover slips were added 
and the slides were incubated for 45 minutes in humidified chambers. Again, the slides were 
washed twice with PBS+1% BSA followed by a final wash with water to remove salt. The 
slides were then left to air-dry in the dark and kept at 20°C until needed.
To visualise the signals, 20pl DAPI/Antifade (lpl + 9jnl water + 990pl vectashield) solution 
were added and the slides viewed using Olympus BH-F Fluorescence microscope. The DAPI 
and fluorochrome signals of the kinetochore can be visualised through the triple band filter.
3.5.15 Statistical Analyses.
The t-test was employed to assess whether the means of two groups examined were 
statistically different from each other and the 95% (p<0.05) confidence limits were adopted. 
Dunnett’s test is a multiple comparison post-hoc test performed after an ANOVA or t-test, 
which compares all treatment data against the control. A sample size formula was included 
guaranteeing the possibility of correctly detecting each treatment with mean value. Again, a 
95% level of confidence was applied (p<0.05 significance) to reject the null hypothesis. The 
SPSS® statistical analysis software was employed in performing the analyses.
Figure 3.8 shows a flow chart that briefly summarised the materials and methods employed.
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Fig. 3.8 The flow chart for materials and methods employed in CBMA.
CELLS CULTURED
AHH-1, MCL-5 and V-79 cells were cultured at 37"C in 
their respective growth media and gassed with 5% CO2 in
air.
ANDROGRAPHOLIDE TREATMENT
The cultured cells were treated with andrographolide. 
doses ranging from lOpM to 90pM (the highest dose).
Subsequently. 40pl cytochalasin-B were added to the 
andrographolide-treated cells and incubated at 37°C 
for 24 hours.
Positive controls were prepared by treating the cultured 
cells with 50ng mitomycin-C in separate culture flasks 
and then incubated at 37°C for 24 hours.
CELL HARVESTING
After 24 hours incubation period, the treated cells were 
harvested and prepared on microscope slides with 
replicates.
STAINING AND SCORING PROCEDURES
The slides were stained with 20% Giemsa solution and 
acridine orange.
The stained slides were coded and blindly scored at lOOOx 
magnification under oil immersion according to Fenech et
al. (2003).
Slides of MCL-5 cells were also subjected to kinetochore 
labelling with CREST antibodies.
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3.6 RESULTS
The dose-setting experiment for in vitro CBMA was conducted on AHH-1 cells treated with 
andrographolide and the results tabulated in Table 3.2. Andrographolide induced micronuclei 
and cytotoxicity at the concentrations as indicated in Table 3.2. In further experiments, the 
number of andrographolide doses used was reduced from 10 to 5 since no significant 
difference was observed between the 10 doses adopted initially. Subsequently, the same 
dose-range selected for AHH-1 was used in treating V-79 and MCL-5 cell lines respectively.
Table 3.2. A summary o f  CBMA data on AHH-1 cells treated with andrographolide for dose-setting assay.
0 56.61 0.15 100.00 0.00
10 51.48 0.33* 91.45* 8.55*
20 50.23 0.33* 89.36* 10.64*
30 44.36 0.40* 79.03* 20.97*
40 42.05 0.35* 75.40* 24.60*
50 35.67 0.35* 64.52* 35.48*
60 34.44 0.18 61.84* 38.16*
70 22.00 0.18 38.95* 61.05*
80 21.92 0.13 38.54* 61.46*
90 16.85 0.05* 29.55* 70.45*
100 15.84 0.03* 27.80* 72.20*
Notes: Mn/Bi: Micronuclei in binucleates; RI: Replicative index, in dicates statistically significant difference 
against the negative control (p<0.05).
V-79, AHH-1 and MCL-5 cells were employed in determining the genotoxicity potential of 
andrographolide using the in vitro cytokinesis block micronucleus assay. The results obtained 
are tabulated and the raw data are available in the Appendix. As shown in Tables 3.3, 3.4 and
3.5 respectively, the mean percentage of binucleated cells decreased with increasing dose of 
andrographolide in all three cell lines tested. Figure 3.12 shows an example of a binucleated 
AHH-1 cell harbouring two micronuclei stained with acridine orange. The frequency of 
micronuclei in binucleated cells exhibit the same pattern in all three cell lines where the 
values accrued steadily with dose before beginning to decrease at 70 and 90pM doses 
respectively. As shown in Tables 3.3 and 3.5, andrographolide was capable of inducing 
micronuclei in binucleated cells with statistically significant difference to the negative 
control between the doses of 10 and 50pM in AHH-1 and V-79 cells respectively. In
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comparison, 30 to 50pM of the same phytochemical were required to cause the same effect in 
MCL-5 cells. For both V-79 and AHH-1, 30pM of the compound caused the highest 
statistically significant induction of micronuclei in binucleated cells. As for MCL-5, which 
has five cytochrome CYP450 isoforms compared to AHH-1 cells, the highest statistically 
significant value (p<0.05) of micronuclei occurrence was observed at 5 0 jiM  of 
andrographolide as tabulated in Table 3.4. Graphs in Figures 3.9, 3.10 and 3.11 each 
illustrated the steady reduction of binucleated cells and the frequency of micronuclei induced 
by andrographolide in AHH-1, MCL-5 and V-79 cells during 24 hours treatment period.
Table 3.3. A summary o f CBMA data on AHH-1 cells treated with andrographolide.
0 57.10 0.16 100.00 0.00
10 51.21 0.30* 90.27* 9.73*
30 44.19 0.40* 78.31* 21.69*
50 35.20 0.33* 62.83* 37.17*
70 22.05 0.18 38.56* 61.44*
90 16.92 0.05* 29.29* 70.71*
MMC 50.16 1.90* 90.47* 9.53*
Notes: Mn/Bi: Micronuclei in binucleates; RI: Replicative index. ^Indicates statistically significant difference 
against the negative control (p<0.05). MMC refers to mitomycin-c.
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Fig. 3.9 Binucleated cell frequency and the incidence o f micronuclei in AHH-1 cells treated with
andrographolide for 24 hours.
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Table 3.4. A summary o f  CBMA data on MCL-5 cells treated with andrographolide.
0 54.79 0.14 100.00 0.00
10 50.42 0.15 93.95* 6.05*
30 40.53 0.33* 74.78* 25.22*
50 34.82 0.40* 64.57* 35.43*
70 22.34 0.13 40.37* 59.63*
90 18.66 0.08 33.59* 66.41*
MMC 49.74 2.30* 92.91* 7.09*
Notes: Mn/Bi: Micronuclei in binucleates; RI: Replicative index. ^Indicates statistically significant difference 
against the negative control (p<0.05). MMC refers to mitomycin-C.
(A 50
<■> 40 'a> $
s 30 0.20 o o
0 10 30 50 70 90
Andrographolide (pM)Mean % Binucleates 
Mean % Mn/Bi
Fig. 3.10 Binucleated cell frequency and the incidence o f micronuclei in MCL-5 cells treated with
andrographolide for 24 hours.
Table 3.5. A summary o f  CBMA data on V-79 cells treated with andrographolide.
Dose (pM Mean % Mean % Mn/Bi Mean Relative RI Mean %
Binucleated cells Cytotoxicity
0 45.44 0.14 100.00 0.00
10 41.29 0.33* 92.66* 7.34*
30 38.20 0.50* 83.60* 16.40*
50 28.88 0.43* 66.07* 33.93*
70 19.63 0.15 42.68* 57.32*
90 17.11 0.08 36.92* 63.08*
MMC 41.08 2.20* 91.91* 8.09*
Notes: Mn/Bi: Micronuclei in binucleates; RI: Replicative index. ^Indicates statistically significant difference 
against the negative control (p<0.05). MMC refers to mitomycin-c.
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Fig. 3.11 Binucleated cell frequency and the incidence o f  micronuclei in V-79 cells treated with
andrographolide for 24 hours.
Although, the presence of nucleoplasmic bridges in binucleated cells were also examined, 
there were only random and very rare incidence of this particular endpoint (data not shown). 
Nucleoplasmic bridge is an indicator for the occurrence of dicentric chromosomes resulting 
from DNA mis-repair or telomere end-fusions (Haaf et al., 1999; Umegaki & Fenech, 2000). 
The incidence of micronucleated mononucleate counted in AHH-1 and MCL-5 cells also did 
not exhibit a statistically significant difference between the doses of andrographolide except 
at 90pM where the compound was clearly cytotoxic as shown in Table 3.6.
Table 3.6. The frequency o f  mononucleate AHH-1 and MCL-5 cells harbouring micronuclei after treatment 
with andrographolide.
0 0.10 0.08
10 0.13 0.13
30 0.12 0.12
50 0.11 0.12
70 0.05 0.04
90 0.03* 0.02*
Notes: Mn/Mono: Micronuclei in mononucleates; ^Indicates statistically significant difference against the 
negative control (p<0.05).
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Fig. 3.12 A binucleated AHH-1 cell with two micronuclei stained with 
acridine orange (1 OOOx magnification)
T able 3.7. Comparison o f  the incidence o f micronuclei in binucleated cells between different cell lines.
0 0.16 0.14 0.14 None
10 0.30* 0.15* 0.33* 1 vs. 2; 2 vs. 3
30 0.40 0.33* 0.50* 2 vs. 3
50 0.33 0.40 0.43 None
Notes: *Indicates statistically significant difference (p<0.05) against the mean Mn/Bi values between the cell 
lines. Each value were tested against each other as shown above and unless stated otherwise, the difference 
were regarded to be insignificant. The numbers in brackets represent the cell lines.
Linear regression analysis on the incidence o f micronuclei revealed that the probability of 
dose-response relationship for the doses tested to be not significant, thus higher doses of 
andrographolide may not induce more micronuclei.
The data obtained also demonstrated that these three cell lines exhibited different frequency 
of micronuclei indicating that the properties of these cell lines may be attributed to such 
incidence. Table 3.7 compares the micronuclei values for the cell lines tested where 
andrographolide at lOpM caused significant incremental increases of micronuclei frequency 
in AHH-1 and V-79, with the values registered for these cell lines were significantly lower 
than that observed in MCL-5, hence MCL-5 was capable of tolerating the presence of 
andrographolide at this dose. At 30pM of the phytochemical, there was significant difference 
between micronuclei induction in MCL-5 and V-79 but not between MCL-5 and AHH-1 nor
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those of AHH-1 and V-79. No difference was observed at 50pM of andrographolide. It can 
be proposed that MCL-5 superior metabolic capacity plays a role in this observation.
The levels of andrographolide cytotoxicity were measured using different methods. Mean 
cytotoxicity percentages tabulated in Tables 3.3, 3.4 and 3.5 were calculated using the 
equation (1) that measured cell replicative index (RI) and cytotoxicity values were derived 
from equation (2) as stated in Section 3.5.9. Andrographolide cytotoxicity in all cell lines 
tested upon, exhibited a steady increase in tandem with dose where 70 and 90jliM of the 
phytochemical caused cell death and reduced cell viability in more than 50% of cells.
Apart from RI calculations on cytotoxicity, cell death was also measured via microscopical 
identification of necrotic and apoptotic cells. The results obtained were tabulated and the 
significant difference (p<0.05) against the negative controls for necrotic and apoptotic cells 
were shown in Tables 3.8, 3.9 and 3.10 respectively. It was found that the trend witnessed in 
RI cytotoxicity calculations was mirrored in the incidence of necrotic and apoptotic cells in 
all cell lines. The data also revealed that the cells died primarily via necrosis compared to 
apoptosis. There was significant dose-dependent accruement of necrotic cells and 
comparable to the RI cytotoxicity values, the concentration of 70 and 90pM of 
andrographolide induced more than 50% of cell population to die via necrosis. The 
percentage of apoptotic cells in all cell lines increased with dose until 30pM but beginning 
from 50pM to the highest concentration of andrographolide tested, the values started to 
dwindle. None of the concentrations tested cause apoptosis more than 2% of the cell 
populations in the cell lines tested. However, 30 and 50jjM andrographolide produced higher 
number of apoptotic response in AHH-1 and MCL-5 cells relative to other concentrations 
and statistically significant against the negative controls. In V-79 cells, 30jnM of 
andrographolide produced 1.38% of apoptotic cells which is statistically significant 
compared to negative controls. More than 50% of AHH-1, MCL-5 and V-79 cells died via 
necrosis compared to less than 0.45% of apoptotic cells at the top doses of 70 and 90pM, a 
value that was generally less than those observed in negative control. Reduced cell number 
was also observed on the scored slides as the concentration of andrographolide increased.
The dose of andrographolide that caused more than 1% of apoptotic cells were observed to 
be those that caused micronuclei induction, which were 30 and 50pM respectively.
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Table 3.8. A summary o f cell death data on AHH-1 cells challenged with andrographolide for 24 hours.
0 8.44 0.41
10 12.20* 0.90*
30 35.85* 1.15*
50 41.93* 1.13*
70 49.65* 0.83*
90 66.05* 0.35
* Indicates statistically significant difference against the negative control (p<0.05).
■  % Mean Apoptotic cells Andrographo,ide (llM) 
31% Mean Necrotic cells
Fig. 3.13. A graph to show the induction o f  necrotic and apoptotic cell death in AHH-1 cells 
treated with andrographolide for 24 hours.
Table 3.9. A summary o f cell death data on MCL-5 cells challenged with andrographolide for 24 hours.
0 7.75 0.46
10 15.28* 0.75*
30 35.55* 1.27*
50 46.51* 1.02*
70 61.15* 0.83*
90 65.88* 0.45
* Indicates statistically significant difference against the negative control (p<0.05).
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Fig. 3.14. A graph to show the induction o f necrotic and apoptotic cell death in MCL-5 cells 
treated with andrographolide for 24 hours.
Table 3.10. A summary o f  cell death data on V-79 cells challenged with andrographolide for 24 hours.
0 8.16 0.40
10 15.43* 0.88*
30 24.73* 1.38*
50 41.80* 0.80*
70 50.48* 0.35
90 69.00* 0.30
*Indicates statistically significant difference against the negative control (p<0.05).
=  40
I % Mean Apoptotic cells 
I % Mean Necrotic cells
10 30 50 70 90
Andrographolide (pM)
Fig. 3.15. A graph to show the induction o f necrotic and apoptotic cell death in V-79 cells 
treated with andrographolide for 24 hours.
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Determination of the influence of treatment duration on andrographolide exposure was also 
conducted with the aim of determining the prevalent mode of cell death preformed using only 
MCL-5 cell line. As tabulated below in Table 3.11, MCL-5 cells incubated for 8 hours in the 
presence of andrographolide showed a similar trend to longer duration treatment of 24 hours.
The data were presented graphically in Figure 3.16.
Table 3.11. A summary o f cell death data on MCL-5 cells exposed to andrographolide for 8 hours.
0 7.58 0.39
10 10.82 0.83
30 18.08* 1.30*
50 20.35* 1.43*
70 33.70* 0.43*
90 41.40* 0.35*
*Indicates statistically significant difference against the negative control (p<0.05).
0 10 30 50 70 90
M% Mean Apoptotic cells A n d r o g r a p h o l id e  (pM)  
m% Mean Necrotic cells
Fig. 3.16. A graph to show the induction o f necrotic and apoptotic cell death in MCL-5 cells 
exposed to andrographolide for 8 hours.
The cells died mainly via necrosis as opposed to apoptosis. However, the percentage of 
necrotic cells was lower than those of apoptotic cells, particularly at 30 and 50juM which 
were also the dose that induced high micronuclei in MCL-5 cells. For example, in reference 
to Tables 3.9 and 3.11 at 30pM of andrographolide, 35.55% of cells were necrotic compared 
to 18.08% during 8 hours incubation but the value for apoptotic cells were not different from 
each other at 1.27%(24 hours) and 1.30%(8 hours) respectively. This data demonstrated that
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the induction of necrosis in MCL-5 cells was time-dependent apart from relying on the 
concentration of the compound administered whereas apoptotic response was not. The 
percentage of apoptotic cells was similar between short and longer treatment periods.
Cellular viability was also assessed using the trypan-blue exclusion assay and three replicate 
experiments were performed on AHH-1 and MCL-5 cells whilst retaining the same dose 
range used in CBMA studies. The results are tabulated in Tables 3.12 and 3.13 for the two 
cell lines respectively. Correspondingly, cell count data revealed that cell growth was also 
reduced when the dose increased. MCL-5 cells exposed to andrographolide for one cell cycle 
also exhibited a same trend as observed in AHH-1. There was a reduction in both cell 
viability and cell growth. Figures 3.17 and 3.18 compares the values of non-viable cells and 
cell growth inhibition in AHH-1 and MCL-5 cells. Andrographolide seemed to have a 
relatively more profound effect (p<0.05) on MCL-5 cell growth than on AHH-1 cells evident 
from cell growth inhibition values at the same concentration of the phytochemical due to 
cytotoxicity as shown in Table 3.14.
Therefore, cumulatively all the data generated on the cytotoxicity of andrographolide using 
RI calculation, microscopical identification and trypan-blue exclusion assay painted a similar 
picture where this diterpene lactone phytochemical affects cell growth and caused cell death 
primarily via necrosis in a dose-dependent manner. However, apoptotic response was 
observed to be highest at 30 and 50pM, which also elicit high micronuclei formation.
Table 3.12. Cell viability data summary assessed by Trypan-blue on AHH-1 cells treated with andrographolide.
0 2.55 97.45 100.00
10 6.89* 93.11 98.69
30 21.54* 78.46 97.06
50 31.97* 68.03 91.61
70 54.40* 45.60 68.88
90 66.22* 33.78 53.23
*Indicates statistically significant difference against the negative control (p<0.05).
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Table 3.13. Cell viability data summary assessed by Trypan-blue on MCL-5 cells treated with andrographolide.
0 3.10 96.90 100.00
10 5.54 94.46 88.98
30 20.53* 79.47 79.91
50 40.27* 59.73 74.15
70 59.90* 40.10 48.09
90 69.86* 30.14 41.47
in d icates statistically significant difference against the negative control (p<0.05).
</>
o 50 a>
5 30
10 30 50 70
|MCL-5 Andrographolide (pM)
I AHH-1
Fig. 3.17. A bar graph comparing the mean percentage o f  non-viable cells in MCL-5 and AHH-1 cells treated 
with andrographolide for one 24 hours as measured using the trypan-blue exclusion assay.
Table 3.14. Effect o f andrographolide on the growth o f MCL-5 and AHH-1 cells.
0 100.00 100.00
10 88.98 98.69
30 79.91* 97.06
50 74.15* 91.61
70 48.09* 68.88
90 41.47* 53.23
* Denotes significant difference against the values in AHH-1 cells (p<0.05).
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Fig. 3.18. A line graph comparing the effect o f increasing concentration o f  andrographolide at various 
concentrations on the growth o f  MCL-5 and AHH-1 cells exposed to the phytochemical for 24 hours.
In order to elucidate the mechanism through which andrographolide induces micronuclei, 
kinetochore labelling utilising CREST anti-kinetochore antibodies was performed on treated 
MCL-5 cells. A total of 60 binucleates harbouring micronuclei were scored for the presence 
or absence of kinetochore within the micronuclei. Three replicates of experiment with new 
stocks of andrographolide were performed yielding a grand total of 180 micronuclei scored 
per dose. The data obtained were tabulated and graphically presented in Table 3.15 and 
Figure 3.19 respectively. Clearly, andrographolide possesses the propensity to cause the loss 
of whole chromosomes with increasing dose indicated by the increasing frequency of 
kinetochore positive micronuclei compared to untreated cells. Andrographolide induced 
0.40% micronuclei in MCL-5 cells at 50pM, which was the highest value recorded and more 
than 70% of the micronuclei scored were positive indicating the presence of chromosomes 
with centromere. Thus, this phytochemical acts in aneugenic manner causing the loss of 
whole chromosomes that were later manifested as micronuclei. Figure 3.20 overleaf shows 
images of kinetochore-positive micronuclei and a kinetochore-negative micronucleus 
observed using the Olympus BH2-RCF fluorescent microscope.
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Table 3.15. Data summary showing the mean results o f kinetochore labelling in MCL-5 cells treated with 
andrographolide in cytokinesis-block micronucleus assay.
0 48.33 51.67
10 52.78 47.22
30 63.89 36.11
50 72.22 27.78
80
70
60<u
°  50 o
2 40<D
|  30
sO5-  20 
10
10 30 50
I Mean % kin +ve
I Mean % kin -ue Andrographolide (pM)
Fig. 3 .19 Bar graph comparing the induction o f kinetochore positive against kinetochore negative in MCL-5 
cells treated with andrographolide in cytokinesis-block micronucleus assay.
Fig. 3.20 Shows two examples o f binucleated cells with micronuclei subjected to kinetochore labelling. 
In (A), the micronucleus is kinetochore positive whereas in (B) both kinetochore positive and negative 
micronuclei were detected. (lOOOx magnification).
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| 3.7 DISCUSSION
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Realising the medical potential of Andrographispaniculata especially andrographolide based 
on previous publications and the paucity of genotoxicity information on the compound, 
determining the genotoxicity potential of the phytochemical was deemed to be imperative.
As discussed previously, in silico assessment of a compound of interest utilising CSAR was 
very useful but insufficient in drawing a reliable conclusion. The author showed that toxicity 
assessment of andrographolide employing an expert knowledge-based system DEREK, 
which anticipated the compound to be capable of causing chromosome damage in vitro due 
to the presence of a-alkylidene y-butyrolactone moiety. Furthermore, the author also 
employed METEOR, another knowledge-based program harnessing QSAR concept to 
predict biotranformation routes of andrographolide and its possible metabolites. As 
elaborated earlier in Chapter 2, andrographolide can be subjected to various Phase I/II 
reactions and the a-alkylidene y-butyrolactone moiety of the phytochemical is also a 
metabolism target. Thus, a genotoxicity test will augment such findings.
The in vitro cytokinesis-block micronucleus assay was used to assess the genotoxicity 
potential of andrographolide on three cell lines namely V-79, AHH-1 and MCL-5 where the 
latter two are metabolically competent with MCL-5 being more sensitive due to the presence 
of cDNAs for four human cytochromes plus microsomal epoxide hydrolase (Crespi et al.,
1991). To the best of the author’s knowledge, this is the first study utilising in vitro CBMA, 
which is a recommended Stage I assay (COM, 2000) in examining the genotoxicity potential 
of andrographolide.
Andrographolide Induced Aneugenicity in Vitro,
The phytochemical caused statistically significant (p<0.05) incidence of micronuclei between 
10 and 50pM in AHH-1 and V-79 cell lines and the values decreased between 70 and 90pM.
In MCL-5 cell line, which is metabolically superior to both AHH-1 and V-79 cells, exposure 
of the cells to lOpM for one cell cycle did not elicit substantial genotoxic damage.
Copy I 139
Y. Sharifuddin
Chapter 3
Statistically significant (p<0.05) inductions of micronuclei were only observed in MCL-5 
cells challenged with 30 and 50pM but the two top doses tested did not cause increases in 
micronuclei frequency. The lower incidence of micronuclei witnessed in all cell lines at 
higher andrographolide concentrations of 70 and 90pM was primarily due to high 
cytotoxicity exerted by the phytochemical.
The interesting part of the data obtained concerns the difference in micronuclei frequency 
between the cell lines tested. As summarised in Table 3.7, MCL-5 cells were capable of 
tolerating lOpM of andrographolide evident in the absence of significant micronuclei 
frequency unlike in AHH-1 and V-79 cells, where there was significant difference in values 
between AHH-1 and MCL-5, as well as V-79 against MCL-5. At 30pM, metabolically- 
deficient hamster lung fibroblast V-79 cells possess the highest percentage of micronuclei 
recorded which was significant against that observed in MCL-5 but not in AHH-1. All three 
cell lines harbour significantly different (p<0.05) micronuclei frequency at 50pM against 
untreated cells but there were no difference between them at the 50jiM dose. Thus, the 
metabolic capacity possesses by AHH-1 cell line may be insufficient in reducing the 
genotoxic activity of andrographolide compared to MCL-5 cells, which boast CYP1A1, 
CYP1A2, CYP2A6, CYP3A4 and CYP2E1 as well as microsomal epoxide hydrolase 
activities (Crespi et al., 1991). Furthermore, there were no significant difference observed in 
the incidence of micronuclei at 10, 30 and 50pM andrographolide between metabolically- 
deficient V-79 cells and AHH-1 cells that has stable aryl hydrocarbon hydroxylase and 
CYP1A1 activities. As MCL-5 cells began to exhibit increased incidence of micronuclei at 
30jliM and upwards, it can be proposed that the intrinsic metabolic capacity was 
overwhelmed and the cells were no longer able to tolerate the accumulation of 
andrographolide molecules between 30 and 90pM concentrations. The absence of a 
statistically significant increase of micronuclei frequency in mononucleated AHH-1 and 
MCL-5 cells ruled out the possibility of accumulation in mitotic slippage incidences.
Mitomycin-C, a direct-acting clastogen was employed as a positive control in. As shown in 
Tables 3.3, 3.4 and 3.5 previously, mitomycin-C induced statistically significant micronuclei
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against the negative control and these figures are within the range normally used in the 
laboratory.
As shown in Tables 3.3, 3.4 and 3.5, the number of micronuclei and binucleated cells 
decreased at higher doses of andrographolide, in agreement with elevated level of 
cytotoxicity elicited by the phytochemical. It is conceivable that the higher cytotoxicity 
imposed a greater selective pressure on the cells and cell cycle kinetics where the scored 
binucleated cells might be the subpopulations that survived.
Apart from disparity in metabolic potential, these cell lines also differ in p53 status. Both 
AHH-1 and MCL-5 are heterozygous for p53 but able to conduct normal DNA repair 
(Doherty et al., 1996) whereas V-79 is deficient in p53 (Chaung et al., 1997). p53 has been 
described to accumulate into micronuclei although its role has not been determined (Granetto 
et al., 1996; Sablina et al., 1998). Referring to the data generated, there were no indications 
that p53 may affect cellular response in concordance to previous findings that 
andrographolide activity is independent of a cell’s p53 status (Rajagopal et al., 2003). 
Clearly, the Phase I biotransformation capacity exhibited by MCL-5 cell line may have 
played a role in reducing the genotoxic impact of andrographolide at lOpM concentrations.
These data provided valuable insights into andrographolide biotransformation in human cell 
lines that also complement the in silico predictions derived from DEREK and METEOR.
The incidence of mitotic slippages was absent based on the frequency of micronucleated 
mononucleate cells that did not change significantly.
MCL-5 cells that were challenged with 10, 30 and 50pM of andrographolide and then 
labelled with anti-kinetochore CREST antibodies to determine the presence of kinetochores, 
revealed that the phytochemical induced mainly kinetochore positive micronuclei. This 
method identifies the presence of kinetochore protein associated with the centromeres of 
chromosomes or its absence from acentric chromosome fragments (Brinkley et al., 1985).
This discovery suggest that andrographolide behaves primarily in an aneugenic manner in 
which whole chromosomes are lost as opposed to breakage producing chromosomal 
fragments that were manifested as kinetochore negative micronuclei. The ratio of kinetochore
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positive/kinetochore negative micronuclei in MCL-5 cell line was within the range normally 
observed in the laboratory and comparable to those observed in the literature (Parry et al.,
2002; Kayani & Parry, 2008) as well as the percentage of kinetochore positive/negative 
induced by andrographolide against known clastogen and aneugen reported in Parry et al., 
(2002).
The induction of damage by aneugenic compounds may involved the chromosomes and 
various other cellular components crucial for cell division including the signal transduction 
pathways which ensure the fidelity of the whole process (Parry & Parry 1989), hence the rise 
of aneuploidy may not always be attributed to direct chromosome aberration or gene 
mutation, both of which have DNA as primary target for chemical action. Since indirect 
mechanisms of a genotoxin involve interactions with non-DNA targets leading to a genotoxic 
effect (Kirsch-Volders et al., 2003), various cellular targets would have to be damage before 
any manifestation of scorable biological effects can be observed. Therefore, aneugens exhibit 
threshold concentration-effect response curve (Aardema et al., 1998; Kirsch-Volders et al.,
2003). Potential thresholds have been elucidated for aneugens which are spindle inhibitors 
such as benzonitrile, nitrobenzene (Bonacker et al., 2004) benomyl and its active metabolite 
carbendazim (Bentlery et al., 2000), colchicine, mebendazole and nocodazole (Elhajouji et 
al., 1995; 1997; 1998) using the in vitro micronucleus assay in combination with kinetochore 
labelling and fluorescence in situ hybridisation (FISH).
Andrographolide Primarily Evoked Necrotic Cell Death in vitro.
Genotoxicity assessment would be incomplete without the cytotoxicity level determination. 
Cytotoxicity of andrographolide was determined using replicative index calculation, 
microscopical identification of cell death and trypan-blue exclusion assay. Replicative index 
(RI) measures the relative number of nuclei in cells exposed to andrographolide compared to 
negative control cultures and the mean relative RI values for all cell lines significantly 
(p<0.05) decreased with dose, concomitant with a consistent increase in cytotoxicity values 
where the top two doses caused more than 50% cytotoxicity. It transpired that lOpM of
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andrographolide was sufficient to significantly affect the replicative index but the caveat to 
this was the assumption that untreated cells possess 100% viability.
The same trend was also observed in the incidence of necrotic cells where lOpM of the 
phytochemical initiated statistically significant and unfluctuating increases with the top two 
doses caused more than 50% necrotic death in the cell population, close to the 60% 
cytotoxicity mark. This was in stark contrast to apoptotic cells where the highest percentage 
of occurrence was lower than 2% of the cell population in all cell lines where 30 and 50pM 
of the phytochemical always induced the highest frequency of apoptosis in AHH-1 and 
MCL-5 cell lines. However, these figures were still low in comparison to population of cells 
that were primarily greeted by necrosis. The generally low frequency of apoptotic response at 
the two top doses compared to other treatment concentrations was due to profound damage to 
the cells and possibly the apoptotic machinery. Furthermore, andrographolide was found to 
trigger necrosis in a time- and dose-dependent manner, the longer duration of incubation 
from 8 to 24 hours increased necrotic cell frequencies but not apoptotic cells. The incidence 
of apoptosis in MCL-5 cell population remained almost constant between those exposed for 8 
and 24 hours respectively, where less than 2% of cells experienced apoptosis. The dose of 30 
and 50pM of andrographolide that induced high and significantly different apoptotic cells 
against negative controls also elicit significant micronuclei induction indicating possible 
correlation between the two. However, the prevalence of apoptosis amongst cells was low to 
affect micronuclei induction and cells mostly died via necrosis.
Therefore, all cell lines treated with andrographolide exhibited one common trait in terms of 
cell death despite their differences in metabolic capacity and p53 status, that the cells died 
primarily via necrosis in a dose-dependent fashion as compared to programmed cell death. 
Furthermore, cell viability assessment performed using the trypan-blue exclusion method, 
which primarily measures cellular membrane integrity shows that the majority of cells died 
in a dose-related fashion. Since only cells with damaged membrane would be susceptible to 
the dye, it can be safely assumed that the dead cell population measured by this method 
experienced necrosis because apoptotic cells normally possess intact cellular membrane.
Even though the dye itself is toxic, the exposure time for all samples were limited to 9
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minutes, well below the maximum 15 minutes limit recommended by the manufacturer. The 
replicative index, the necrotic and apoptotic cells frequency determination as well as trypan- 
blue exclusion assay indicated the same trend of dose-dependent cytotoxicity exerted by 
andrographolide. Furthermore, trypan-blue exclusion assay and cellular replicative index 
measure different cytotoxicity endpoints, the cumulative effects are additive where 
andrographolide reduced the population of viable cells and caused inhibited cellular 
proliferation of the surviving cell population. The adoption of either measurement on its own 
negates accurate assessment of cytotoxicity.
Exposure of HepG2 cells to andrographolide was reported to lead to the collapse of 
mitochondrial membrane potential (MMP) (Li et al., 2007). The damage caused to the 
glutathione (GSH) system in the mitochondria by andrographolide was found to be in a dose- 
dependent fashion with corresponding depletion of glutathione. Glutathione plays a crucial 
role in the maintenance of cellular function and defence against oxygen free radicals. The 
presence of andrographolide changed the normal intracellular redox status and the collapse of 
mitochondrial membrane potential but failed to elicit a potent apoptotic response in HepG2 
cells (Li et al., 2007). As mentioned previously in the second Chapter, teucrin A was 
considered a comparable example since it is a diterpene-containing phytochemical and in the 
presence of CYP3A4, formed reactive epoxides that interacts with proteins and also caused 
mitochondrial membrane permeability and caspase activation. Teucrin A was also shown to 
reduced cytoskeleton-associated protein thiols, cellular glutathione levels but increased 
cytosolic concentration of Ca2+. Indeed, moderate accumulation of Ca2+ concentration leads 
to caspase activation and increase FasL expression that would initiate apoptosis. In contrast, 
higher levels of cytosolic Ca2+ can activate calpains, endonucleases and phospholipase A2, all 
of which have been implicated in necrotic cell death (Trump & Berezesky, 1995; Kass & 
Orrenius, 1999; Berridge et al., 2000). The chemical structure of teucrin A in comparison to 
andrographolide is shown in Figure 3.21. The MCL-5 cell line carries CYP3A4 cDNA, 
amongst other P450 cytochromes and CYP3A is known to possess wide substrate spectrum 
(Wienkers & Heath, 2005) as well as epoxide hydrolase. It can be proposed that 
andrographolide may behave in the same manner. Furthermore, predictions by METEOR 
demonstrated that andrographolide is capable of forming epoxides.
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OH
Teucrin A Andrographolide
Fig. 3.21. Chemical structure comparison between teucrin A  and andrographolide. 
Both phytochem icals contain b icyclic diterpene.
Glutathione is a ubiquitous tripeptide consisting of glycine, cysteine and glutamate. One of 
the prediction made by METEOR was the conjugation of glutathione with andrographolide 
at the a,p-unsaturated moiety, where the cysteine part of GSH directly attached to 
andrographolide abolishing the A,2(13) double bond as shown in Figure 2.16c. Furthermore, 
Cui et al. (2004) reported the presence of 3-O-sulfate conjugates and 3-0-sulfate-12-S- 
cysteine conjugate metabolites in human urine, that were not within the list of possible 
metabolites suggested by METEOR. It may be possible that andrographolide is capable of 
reacting to cellular proteins that contains the thiol group. Its ability to attenuate inflammation 
was suggested via the inhibition of NF-kB activation by forming a molecular adduct with 
reduced cysteine62 of p50, hence blocking the binding of NF-kB oligonucleotide to nuclear 
proteins (Xia et al., 2004). Andrographolide was demonstrated to reduce cyclooxygenase-2 
(COX-2) expression, which is an example of pro-inflammatory proteins also via binding to 
NF-kB (Hidalgo et al., 2005). Thus, it can be speculated that higher concentrations of 
andrographolide caused depletion of cellular proteins with thiol group such as GSH, 
changing redox status.
These results might explain the observation made by Akbarsha & Murugaian (2000), where 
Sertoli cells in rats treated with andrographolide were highly vacuolated, indicating cell 
death. Indeed the presence of vacuoles within the cytoplasm is a mark of necrotic cell death. 
The seminiferous epithelium was also thoroughly distorted and disorganised with the 
epithelium and/or lumen contained multinucleated giant cells with several nuclei harbouring
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marginalised chromatin in rats subjected to andrographolide treatment (Akbarsha & 
Murugaian, 2000). These anomalies were observed to be more profound in rats given higher 
doses of andrographolide (Akbarsha & Murugaian, 2000). Sperms were also found to 
possess no or little motility with tail abnormalities (Akbarsha & Murugaian, 2000). 
Furthermore, all the female rats mated with control males delivered litters, whereas none of 
the females mated with andrographolide-treated males delivered any offspring. Whether this 
is due to abnormal sperms itself or development deficit at conceptus level are not entirely 
clear but aneuploidy is known to cause reproductive failure. Andrographolide it seemed 
affects cell growth by causing chromosome malsegregation, disrupting the mitotic machinery 
and caused necrotic cell death in a dose-dependent fashion.
Thus, necrosis was a prevalent mode of cell death after andrographolide exposure, which was 
a surprise considering aneugens are known to primarily elicit programmed cell death 
(Decordier et al., 2002). Necrosis has long been considered as a consequence of physico­
chemical stress and thus as accidental and uncontrolled event. There are increasing number 
of evidence supporting the existence of caspase-independent cell death pathways responsible 
in a well-controlled cell death induction as observed in apoptosis (Zong & Thompson, 2006) 
and providing an alternative suicide mechanism in the event of apoptotic machinery failure 
(Fiers et al., 1999; Leist & Jaattela, 2001). For example, Salmonella and Shigella can cause 
necrosis of infected neutrophils and macrophages (Brennan & Cookson, 2000; Francois et al.,
2000) as well as CD4+ T lymphocyte destruction by HIV-1 (Borthwick et al, 1999; Plymale 
et al., 1999; Lenardo et al, 2002). Caspase-independent death is also implicated in 
myocardial infarction, ischemia-reperfusion injury after cerebral ischemia, glutamate 
excitotoxicity (Eliasson et al., 1997; Cipriani et al., 2005; Schwabe & Brenner, 2006), 
diseases such as Alzheimer’s (Akiyama et al., 2000), epilepsy (Fujikawa, 2000) and other 
inflammatory injuries (Kaplowitz, 2000) also involves necrosis.
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Menage-a-Trois: Micronuclei Induction by Andrographolide and Possible Connections 
to Apoptosis and Caspase-3 Activity
The effect of andrographolide on apoptosis is still debatable. It was reported to protect 
human endothelial cells from growth factor deprivation-induced apoptosis via the activation 
of phosphatidyl inositol-3-kinase/Akt pathway (Chen et al., 2004). Apoptosis induced using 
hydrocortisone and phorbol 12-myristate 13-acetate in thymocytes were also shown to be 
attenuated by andrographolide (Burgos et al., 2004). However, a relatively high 
concentration between 40 to 100pM of the phytochemical could induce apoptotic cell death 
in human leukaemic HL-60 cells (Cheung et al., 2005) and human prostatic adenocarcinoma 
PC-3 cells (Kim & Milner, 2005) where in both cases, the activation of the caspase cascade 
was proposed. In contrast, Li et al. (2007) recently suggested apoptosis only occur late in 
HepG2 cells and did not require the caspase cascade. Caspase-3 activity was significantly 
up-regulated in andrographolide-treated cells between 24 and 48-hours of in vitro exposure 
with the absence of potent apoptotic response despite diminishing cell growth and viability 
(Li et al., 2007). Furthermore, cell death cannot be prevented using neither the caspase-3 
specific inhibitor, Ac-DEVD-CHO nor vZAD-fmk which is a pan-caspase inhibitor, 
indicating that cell death elicited by andrographolide was not relying on cellular caspases 
activities (Li et al., 2007) and as shown here, necrotic cell death which does not require 
caspases was the prevalent mode of cell demise.
It is still to be ascertained whether the caspase cascade was not initiated or andrographolide 
is directly inhibiting the apoptotic machinery despite caspase-3 activation. Thus, it is still not 
clear whether andrographolide is an anti- or pro-apoptotic agent and the detailed molecular 
mechanism(s) is still largely uncharted. Even if it does promotes programmed cell death in 
cells, it is still not known whether such an induction is a direct effect of the phytochemical on 
cellular apoptotic machinery or indirectly via other pathways and/or as a consequence of 
other events such as severe damage to mitotic apparatus. It was demonstrated that different 
treatment times with andrographolide, namely for 8 and 24 hours did not show any difference 
in apoptotic cells induction even though necrosis incidence was lower in shorter treatment 
duration. Hence, the possibility that apoptosis might be provoked earlier than 24 hours can be 
ruled out and even at 8 hours, apoptotic response was still lower than the incidence of
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necrosis. As andrographolide exerts its influence primarily as an aneugen, which suggest the 
possibility of perturbations on the mitotic machinery, the absence of significant apoptotic 
response relative to necrosis is intriguing. Furthermore, the revelation that the majority of 
cell death occurs via necrosis begs the question whether cells adopt this mode of cell death 
because of disruptions to apoptotic components or other factors. The percentage of apoptotic 
cells in V-79, AHH-1 and MCL-5 were significantly higher at 30 and 50pM respectively and 
as pointed out earlier, these concentrations also caused micronuclei induction. Disruption to 
the mitotic apparatus might have a stake in apoptosis induction.
Aneugens are known to be good micronuclei inducer and also possess high propensity to 
initiate programmed cell death. It was demonstrated that spindle poisons such as 
carbendazim and nocodazole induced both apoptosis as well as micronuclei, which were later 
preferentially eradicated via apoptotic cell death (Decordier et al., 2002). The occurrence of 
apoptosis can eradicate micronucleated cells and leads to the alteration of micronuclei 
frequency, ultimately negate an accurate damage assessment due to genotoxins exposure that 
can also act as apoptogens. Thus, the inhibition of apoptosis may increase micronucleated 
cells ratio in cytokinesis-block micronucleus assay (Kirsch-Volders et al., 2003). Quite 
recently, it was demonstrated that the inhibition of apical caspases-8 and -9 caused increases 
in the frequency of nocodazole-induced micronuclei but remarkably, caspase-3 which is 
regarded to be an effector caspase for apoptosis execution was not involved in the 
elimination of micronucleated cells (Decordier et al., 2005). Instead, caspase-3 activity was 
hypothesised to play a direct role in micronuclei formation (Decordier et al., 2005). In this 
study, the highest incidences of micronuclei were observed to occur at the same 
concentrations where andrographolide also induced significant apoptotic response in the cell 
lines tested. Furthermore, the micronuclei scored within the binucleated cells were primarily 
one micronucleus per binucleated cells and since the cells were examined using both Giemsa 
and acridine orange, the possibility of mistakenly identifying these cells as containing 
apoptotic bodies were reduced. Apoptotic cells harbouring apoptotic bodies also possess 
other features such as visible chromatin condensation within the nucleus as described by 
Fenech et al. (2003).
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Caspase-3 has been suggested to be involved in cell cycle control and cell growth 
modulation. For example in proliferating lymphoid cells, caspase-mediated cleavage of the 
cyclin-dependent kinase (CDK) inhibitor p27KIP1 contributes to the induction of cell cycle 
progression (Frost et al., 2001) whereas Carlile et al. (2004) reported the involvement of 
caspase-3 in normal erythroid differentiation. Yan et al. (2001) showed the presence of 
active caspase-3 in the nuclei of dividing cells within the proliferative regions of rat 
forebrain and it was also reported to be involved in embryonic keratinocytes differentiation 
(Okuyama et al., 2004). However, caspase-3 is also known to inhibit B-cell proliferation 
(Woo et al., 2003), hence this caspase can mediate a paradoxical proliferative or pro- 
apoptotic roles. Since apoptosis regulation is closely affiliated to cell cycle and cell division 
fidelity, where the proteolysis of different substrates is crucial for a spectrum of processes in 
both non-apoptotic and apoptotic conditions. The exact mechanism(s) of caspase 
involvement in micronucleation is yet to be elucidated but lamin B may be involved, a 
nuclear membrane component that has been demonstrated to be associated with micronuclei 
formation due to DNA replication impairment (Tanaka & Shimizu, 2000; Kottke et al., 2002) 
and other possible nuclear-mitotic apparatus proteins that are required in mitotic assembly as 
well as nuclei formation after mitotic completion (Hirata et al., 1998; Decordier et al., 2005).
As will be discussed in the following Chapter, andrographolide is capable of inducing 
microtubule organisation centres (MTOCs) aberration that can lead both to micronuclei 
formation and/or multinucleated cells.
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INDUCTION OF CENTROSOME AMPLIFICATION AND ITS 
CONSEQUENCES IN CELLS CHALLENGED WITH 
ANDROGRAPHOLIDE
4.1 Introduction to Microtubules
Many important cellular processes in higher eukaryotic cells including motility, 
intracellular organelle trafficking, cell growth and division rely on the cytoskeleton which 
is a complicated network of protein filaments. The functional diversity of the cytoskeleton 
depend on three kinds of protein filaments namely:
• Microfilaments that are also known as actin filaments, dictate cell shape and 
topography. They are also crucial for cell motility and polarity as well as for being 
indispensable during cytokinesis.
• Intermediate filaments that grant mechanical strength and resistance to physical 
stress.
• Microtubules that manage intracellular trafficking of proteins and organelles, and 
involve in chromosome segregation during mitosis.
iij
| Despite their differences in dynamic and mechanical properties, these protein filaments
i
possess some identical fundamental characteristics, especially the fact that they exist as 
polymers consisting of helical assemblies of specific protein subunits which self-associate 
through side-to-side or end-to-end non-covalent interactions and their dynamic nature to 
disassembly/reassembly. The functions of these cytoskeletal filaments hinge on various 
accessory proteins.
Therefore, polymerised microtubules remain in a dynamic steady state, alternating between 
a phase of growth and recession in a situation known as dynamic instability (Mitchison & 
Kirschner, 1984; Erickson & O’Brien, 1992).
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Microtubules consist of 13 parallel protofilaments. The subunit of each protofilament is a 
tubulin heterodimer constructed from a very tightly linked pair of alternating a-tubulin and 
P-tubulin monomers arranged along the longitudinal axis of the microtubule. There are 6 
isotypes of each a- and p-tubulin in human cells, possessing cell- and tissue-specific 
patterns of expression as well as differences in drug binding abilities (Khan et al., 2000; 
Hallworth & Luduena, 2000; Burkhart et al., 2001). Microtubules also possess polarity 
with distinct ‘plus’ and ‘minus’ ends.
Even though both microtubule ends alternately lengthen and shorten, it is known that net 
growing occurs at the ‘plus’ end, which are often free in the cytoplasm or situated near the 
plasma membrane, whereas net shortening occurs at the ‘minus’ ends. The ‘minus’ ends of 
the microtubules are frequently associated with the microtubule organising centres 
(MTOCs) or centrosomes, the specific site in the cytoplasm from which microtubules are 
nucleated.
The protein y-tubulin, is the main component of the MTOC and possesses a 28-35% 
homology with a- and P-tubulins but are being expressed at lower values than these latter 
isoforms (Moudjou et al., 1996)
4.2 Introduction to Centrosomes and Its Functions
The centrosome is a small non-membraneous organelle, approximately l-2pm in diameter 
and is normally located at the periphery of the nucleus. It contains at least 150 proteins 
(Andersen et al., 2003) that change in abundance through the cell cycle, essential to its 
main function in nucleating microtubules to determine the spatial organisation of the 
microtubule network, hence it is often referred to as a major microtubule organising centres 
(MTOCs). During interphase, the network involves in a number of crucial cellular 
processes, such as cell growth and division, cell shape determination, polarity, intracellular 
organelle trafficking and the ability to interact with the environment. The function of the 
centrosome is equally important during the interphase as well as in mitotic cell.
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S phase
G1
1 centrosome
( ?  centrioles)
G2
2 centrosomes
(4 centrioles)
Fig. 4.1. In G|-phase o f  the cell cycle a single centrosome consisting o f  two structurally- 
distinct centrioles, where the mother centriole possesses appendages (denoted in black) that 
are crucial in microtubule anchoring. Both centrioles are situated inside an electron-dense 
matrix known as the pericentriolar material, PCM (grey). Subsequently in S-phase, both 
centrioles produced a progeny and by G2-phase o f the cycle, the cell contains two 
centrosomes with each consisting o f  two closely associated centrioles. Also in late G2, the 
pericentriolar material achieved maturation (dark grey) in a phosphorylation-dependent 
process. This augments y-TuRC recruitment and permits increased microtubule anchoring 
activity essential for spindle formation. (Adopted from Nigg, 2007).
The centrosome consists of three major domains with the most prominent being the 
centriolar and pericentriolar areas with an average diameter of approximately 1 pm in most 
animal cells. The centriolar domain defines the centre of centrosome and contains either a 
single centriole or a pair of centrioles, depending on the stage of the cell cycle and each 
centrioles are composed of characteristic nine parallel triplets of microtubules. The pair of 
centrioles structurally differ from each other where one with a set of appendages at the 
distal ends (maternal centriole) and one without appendages (daughter centriole). The 
daughter centriole acquires these appendages, which appear to be essential for anchoring 
microtubules, in late G2 phase of the cell cycle. Figure 4.1 shows the changes that occur 
during normal centrosome duplication between Gi and G2 phases of the cell cycle.
The pericentriolar domain encircles the centriole as a cloud of protein meshwork known as 
pericentriolar material (PCM) containing a large number of coiled-coil proteins and 
functions as the site for microtubule polymerisation (Bomens, 2002). This matrix provides 
a scaffold for proteins that are important for regulating centrosome duplication and 
function, containing the basic unit for microtubule nucleation, the y-tubulin ring complex
(y-TuRC) (Moritz et al., 1995a; 1995b), a complex of six proteins in humans that includes 
y-tubulin and GCP2-6 (Fava et al., 1999; Murphy et al., 2001). The y-tubulin is a
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conserved, ring-shaped multi-protein complex of all microtubule organising centres that 
apparently serve as a template for microtubule polymerisation from the closely-associated 
a- and p-tubulins (Moritz et al., 1995a). The centrosome extends out of the pericentriolar 
domain by integrating with the surrounding organelles and cytoplasm through microtubules 
and microfilaments as depicted in Figure 4.2 below. These outer extensions of the 
centrosome are called the outer centrosomal domain.
Centrosome
Q  y-TuRC 
° Centrosomal
Fig. 4.2. The centrosome is crucial in nucleating microtubules. The y-TuRC (shown as 
green circles) initiates the polymerisation o f  a- and P-tubulin promoters into microtubules 
(depicted as red rods). Maturation o f  the centrosome in G2 controls the y-TuRC content in 
the pericentriolar material. (Adopted from Sankaran & Parvin, 2006).
During mitosis as well as meiosis, centrosomes are the primary organising centre for 
microtubule in most eukaryotic cells, become the core structures of spindle poles and 
dictate the formation of mitotic spindles. Each of the daughter cell inherits only one 
centrosome upon cytokinesis, hence the centrosome must duplicate once prior to the next 
cell division. Therefore, at any particular time of the cell cycle, cells possess either one 
unduplicated or two duplicated centrosomes. Since DNA and centrosome are the only 
organelles that undergo semi-conservative duplication once every single cell cycle, animal 
cells are equipped with a mechanism that coordinates these two events, ensuring only one 
duplication step takes place at any one time.
In late Gj -phase, the centrosome triggers duplication via physical separation o f the paired 
centrioles and losing their orthogonal orientation with respect to each other but remained 
attached via a fiber. Tsou and Steams (2006) proposed that this disorientation step permits
proteins M TO C
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the following duplication steps. In early S-phase, pro-centrioles (daughter centrioles) 
formed close to the proximal end of each centriole, perpendicular to each pre-existing 
mother centriole. Pro-centrioles can appear anywhere in the cytoplasm but a regulatory 
mechanism which is not well understood limits the sites of synthesis to the base of mother 
centrioles (reviewed in Hagan & Palazzo, 2006). The nascent pro-centrioles elongate 
through S and G2 phase of the cell cycle and two centrosomes continue to mature by 
recruiting pericentriolar material.
At the G2/M-phase, the centrosomes undergo a dramatic increase in size due to 
accumulation of several proteins including y-TuRC and the influx of y-TuRC into the 
pericentriolar material is associated with a higher level of centrosomal microtubule 
nucleation activity (Khodjakov & Rieder, 1999). The new mother centriole also matures 
via the binding of specific proteins and in M-phase both centrosomes have acquired the 
maximal amount of pericentriolar material.
Maturation
y-TuRC influx 
centriole modification
Centrioles
o o „
Separation
Disorientation
PCM
Elongation Duplication
Fig. 4.3. The centrosome cycle. Centrosomes consisting o f  paired centrioles (depicted as light 
blue cylinders) surrounded by pericentriolar material (yellow in Gi/S-phases and green, upon 
maturation in G2/M-phases). Appendages o f  the mother centrioles are also shown (red and 
orange). Different stages o f  the centrosome cycle are shown corresponding to the cell cycle and 
with temporal scale o f  activity for kinases (red arcs), ubiquitin ligases (blue arc) and poly- 
(ADP)-ribosylation or PAR (green arc) that are known to influence centrosome duplication and 
maturation. Finally, in mitosis the two pairs o f  centrioles split o ff  the centrosome and migrate to 
the opposite poles o f  the nucleus. (Adopted from Sankaran & Parvin, 2006).
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Subsequently, the two mature centrosomes move to the opposite poles of the nucleus to 
form the mitotic spindle regulated by a slew of kinases. It has become increasingly clear 
that other protein modifications, including ubiquitination and ADP-ribosylation, regulate 
this process and Figure 4.3 illustrated the centrosome duplication cycle in relation to 
different phases of the cell cycle.
The centrosomes have three important roles. It nucleates the polymerisation of tubulin 
subunits into long microtubule polymers, it manages nucleated microtubules into functional 
arrays and it duplicates once per cell cycle, hence legitimising cell cycle progression from 
Gi into S phase, including exit from cytokinesis. After nucleation in the pericentriolar 
material by y-TuRC, microtubules are liberated from their nucleating sites and translocated 
to the anchoring sites situated at the sub-distal appendages of the maternal centrosomes that 
contain centriolin and ninein as anchor proteins but lack microtubule-nucleating proteins 
(Doxsey et al., 2001).
Centrosomes play a pivotal role in bipolar spindle formation during mitosis and therefore 
exert a strong influence on karyokinesis and cytokinesis. Cells of higher plants and eggs of 
many animal species are capable of forming bipolar spindles through centrosome- 
independent mechanisms (Heald et al., 1996; Schmit 2002, Basto et al., 2006). However in 
their presence, centrosomes usually adopt a domineering role in determining the orientation 
and bipolarity of the mitotic spindle (Brinkley, 2001). The presence of two MTOCs during 
mitosis is critical for the formation of bipolar mitotic spindles because chromosomes are 
pulled in opposite direction towards each spindle pole and this bipolarity is essential for 
accurate chromosome segregation into two daughter cells during cytokinesis, hence they 
are vital for both the fidelity of chromosome segregation and the positioning of the 
cleavage plane during cell division. Thus, numerical homeostasis of centrosomes is a 
highly controlled process and abrogation of this control leads to abnormal amplification of 
centrosomes, which in turn increases the frequency of aberrant mitoses and chromosome 
segregation errors.
4.3 Centrosome Abnormalities
Centrosome abnormalities can be classified in two, namely structural and numerical 
aberrations. Although these aberrations often occur together, their origins as well as their
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consequences may differ. Both type of centrosomal anomalies have been considered to 
present diagnostic and/or prognostic values (Deusberg, 2001).
Structural centrosome anomalies are most likely to arise from deregulated expression of 
genes coding for centrosomal proteins or alteration in post-translational modifications, 
such as phosphorylation defects of the corresponding proteins. Consequently, altered or 
imbalanced protein levels caused the centrosomal structural modification, for example 
in size due to PCM accumulation around the centrioles. Furthermore, centrosomal 
coiled coil proteins have the tendency to form intracellular assemblies and this can be 
manifested as centrosome-related bodies at ectopic sites (Fry et al., 1998, Casenghi et 
al., 2003). The exact protein compositions of the structurally altered MTOCs and 
centrosome-related bodies have an impact on function, for example the recruitment of 
y-TuRCs may be either reduced or enhanced and microtubule nucleation is either 
suppressed or stimulated (Lingle & Salisbury, 2001; Lingle et al., 2002), which in turn 
influence the polarity, shape and motility of cells.
Numerical centrosome abnormalities are usually linked to genome instability and loss 
of tissue differentiation (Ghadimi et al., 2000; Lingle et al., 2002,). There are several 
mechanisms that lead to centrosome amplification. Firstly, centrosomes replicate more 
than once in a single cell cycle and may not always undergo re-duplication process, 
hence the final centrosome number can be either odd or even. Cytokinesis failure, 
resulting in genome and centrosome doubling in even numbers is the second well- 
known mechanism. There has been a debate as to whether centrosome multiplication is 
a cause or consequence of chromosome instability and most incidence of centrosome 
amplification involves deregulated replication and cytokinesis failure. Consequently, 
the existence of abnormal centrosome number abrogates centrosomal numerical 
homeostasis, disrupts normal mitotic process and increases the frequency of aberrant 
mitoses and chromosome segregation errors. Other mechanisms that can cause 
centrosome multiplication but less frequent than those described previously includes 
improper splitting of the paired centrioles, de novo formation of acentriolar centrosomes 
and cell fusion via fusogenic viruses as illustrated in Figure 4.4 overleaf.
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4.4 Centrosome Amplification, Aneuploidy and Cancer
Centrosome defects are observed in many types of carcinomas including gall bladder, 
breast (Lingle et al., 1998), pancreas (Sato et al., 1999), colorectal (Ghadimi et al., 2000), 
prostate (Pihan et al., 2001), head and neck cancers (Doxsey, 2001; Carroll et al, 2000).
For example, almost 80% of invasive breast tumour cells possess amplified centrosome 
numbers (Lingle et al., 2002) and centrosomal changes are strongly associated with
!
I aneuploidy and chromosomal instability in various studies (Lingle et al., 1998; Pihan et
! al., 2001; Ghadimi et al., 2000; Pihan et al., 2003). Furthermore, MTOCs defects are
; known to increase in severity during tumour development (Doxsey, 2001; Pihan et al.,
\ 2001; Pihan et al., 2003). The prevalence of centrosomal multiplication in cervical
[ carcinoma cells for instance, progressively accrued to approximately 20% of the cell
|
; population in grade 1 tumours to nearly 70% in grade 3 tumours (Pihan et al., 2003) and
i
| genetically unstable aneuploid breast tumours exhibit around 6.8 centrosomes per cell
j compared to 1.5 in normal tissues (Lingle et al., 2002).IIi\l
j Due to karyotypic shuffling, aneuploidy could disrupt global transcription process
i
! resulting in down-regulation of genes involved in growth control and up-regulation of!
growth promoting genes. Indeed, previous finding suggests that aneuploidy due to the
i
| addition of one single chromosome lead to misregulation of 100-200 genes and only 5-
I 20% of misregulated genes were contained on the trisomic chromosome (Upender et al.,
2004)
Figure 4.5 shows the effects of abnormal MTOCs on chromosome segregation fidelity 
and the scenarios resulting from such amplification. Most cells harbouring amplified 
MTOCs will be primarily ushered towards programmed cell death due to deleterious 
chromosome missegregation. However, some cells may survive after gaining favourable 
chromosome complement that permits further growth and propagation, usually leading to 
neoplasms propelled by autocatalytic karyotype shuffling.
Most centrosome abnormalities can be allocated into three groups namely abnormal 
centrosome number, aberrant microtubule nucleation and inability to correctly segregate 
during mitosis. Centrosomes of tumour cells display different structural alterations 
including an increase in centrosome number and volume, supernumerary centrioles,
Copy 1 158
Y. Sharifuddin
Chapter 4
accumulation of excess pericentriolar material and inappropriate phosphorylation of 
centrosome proteins (Pihan et al., 1998; Lingle et al., 1998). Furthermore, centrosomes in 
tumour cells exhibit functional abnormalities characterised by increased microtubule 
nucleation activity (Lingle et al., 1998; Salisbury et al., 1999). There can be at least two 
detrimental consequences of centrosome defects that may contribute to neoplastic 
transformation and tumour progression. First, centrosome duplication anomaly may 
severely affect maintenance of cell polarity in interphase cells due to disorganisation in 
cytoplasmic architecture and directional vesicular trafficking in a cell with multiple 
MTOCs. Second, centrosome defects may intensify the incidence of multipolar mitoses 
leading to chromosomal segregation abnormalities and aneuploidy.
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Fig. 4.5. The presence o f  supernumerary centrosomes bears different tidings to the cells affected depending 
on the circumstances. Abnormal MTOCs (red dots) numbers lead to multipolar division where the MTOCs 
nucleate abnormal number o f  microtubule (green lines), consequently the chromosomes are pulled to 
different poles. Chromosomes missegregation caused genomic instability that primarily courts apoptotic 
response. Sometimes, daughter cells might gain a chromosome complement favourable to survival. In 
deamplification scenario, all but two dominant centrosomes are eliminated or deactivated thus reverting to 
a more manageable ability in nucleating microtubule. Alternatively, in coalescence, the amplified MTOCs 
formed a pseudo-bipolar segregation. Both routes lead to neoplastic growth. (Adopted from Brinkley, 
2001 ).
The observation that centrosome abnormalities are very common in tumour cells 
considering supernumerary centrosomes rendered a clear disadvantage to the affected 
cells’ ability to proliferate is currently a bewildering paradox especially when the 
definitive long-term data on the cellular fate is limited. Only a sub-population of tumour 
cells observed to possessing multiple MTOCs and tumour-derived cell lines usually 
contains around 5-25% of cells with the same feature when cultured in vitro (Lingle et 
al., 2002; Pihan et al., 2003). Notably, this population seemed to remain roughly constant 
as the culture is propagated and it is conceivable that cells with aberrant MTOCs number 
were generated de novo through any of the mechanisms mentioned previously and the 
majority subsequently died due to chromosomal instability, although some will survive. 
Therefore, the population size of cells with multiple MTOCs is determined by the 
generation, elimination and survival rates of these cells.
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4.5 The Objective of the Studies
This study was initiated to elucidate the influence of andrographolide on MTOCs, 
microtubules, mitotic index and cell fate upon removal of the compound in V-79 cells in 
vitro. Mitotic machinery aberrations have been shown to lead to aneuploidy and 
multipolar mitosis is known to be a mechanism for micronuclei induction (Parry et al.,
2002). The determination of possible mechanism of action for micronuclei induction by 
andrographolide does not require a high statistical power since only mechanistic 
information is needed. The cell fate study was intended to complement the MTOCs 
studies in determining the outcome of mitoses in the presence of abnormal MTOCs 
number. The fate of cells after pro-longed exposure to the phytochemical was also 
examined and intended to determine the frequency of daughter cells with more than one 
nucleus. The cell recovery study was necessary to assess whether V-79 and MCL-5 cells 
are capable of recovering from exposure to andrographolide at various concentrations 
since threshold level of damage is suspected and to determine if damage to mitotic 
machinery will affect subsequent mitoses.
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4.6 MATERIALS AND METHODS
4.6.1 Introduction to V-79 cell line.
As stated in section 3.5.6 in Chapter 3.
4.6.2 Sub-culturing V-79 cells for treatment.
The cells were seeded at 8xl04 cells/ml onto sterile glass microscope slides. The slides 
were placed in Petri dishes with a total volume of 12ml medium in each Petri dish and 
incubated at 37±1°C for 24 hours with circulated 5% CO2 in air prior to treatment.
4.6.3 Treatment of cells with andrographolide.
Andrographolide with 98% purity was stored at room temperature. Andrographolide to 
be used at various concentrations was always freshly prepared by dissolving the crystals 
with DMSO as solvent and administered to V-79 cell cultures within two hours of 
preparation. The cells were then incubated for another 24 hours at 37±1°C in the 
presence of andrographolide inside the incubator with circulating 5% CO2 in air.
The experiments were accompanied by negative and positive controls. The negative 
control preparations were essential for monitoring spontaneous incidence of aberrations 
in the cell culture and to validate DMSO, the solvent used in formulating 
andrographolide, was not itself affecting the cells and hence the outcome of the 
experiments. Colchicine (CAS no. 64-86-8) was chosen as positive control in this study 
at 0.5pg/ml as used in the laboratory. It possesses the typical profile of a non- 
carcinogenic aneugen and was shown to be positive in the in vitro and in vivo 
micronucleus tests (Heddle et al., 1977; Mavoumian et al., 1990; Miller et al., 1998; 
Matsushima et al., 1999) but negative in gene mutation assays (Heddle et al., 1977; 
Honma et al., 1999a) except for the mouse lymphoma assay when a 24-hour treatment 
was adopted (Honma 1999b). Colchicine is known to cause numerical aberrations due 
to metaphase-blockage by the inhibition of tubulin polymerisation (Galloway et al, 
1987; Miller et al, 1998) and have been tested positive for aneuploidy induction in a 
number of test systems (Liang & Brinkley, 1985), including somatic cells in vivo 
(Miller & Adler 1989) and mammalian germ cells (Mailhes & Zhin, 1987; Russo & 
Pachierotti, 1988).
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For each set of experiment, different andrographolide stock solutions were used and a 
total of three sets of replicate experiments were conducted for this study.
4.6.4 Harvesting the slides.
After 24 hours, the growth medium removed and the slides gently washed with cold 
PBS twice. Subsequently, the slides were fixed in two different fixatives depending on 
the staining purposes as stated below.
4.6.5 Spindle staining using conventional dyes.
The slides were fixed in methanol and acetic acid with 3:1 ratio in the presence of 
MgCh and CaCb for three washes; 14 minutes for each wash. The additions of 
magnesium ions were to enhanced protein staining while calcium ions were to decrease 
spindle solubility, resulting in irreversibly stabilised spindles and prevented their 
possible shrinkage. The slides were air-dried thoroughly and placed in 5% perchloric 
acid at 4°C for 24 hours for RNA removal. This was followed by washing the slides 
thoroughly in distilled water for three times; 4 minutes for each wash. Subsequently, the 
slides were stained with 0.5% Brilliant blue and 0.5% Saffanin O in 15% acetic acid for 
12 hours at room temperature. Brilliant blue stains the spindle fibres blue while 
Saffanin O stains the chromosomes red in colour. Finally, the slides were gently washed 
with distilled water; air-dried and mounted in DPX. The spindle staining procedure was 
originally described by Wissinger et al (1981).
4.6.6 p~ and y-tubulin immunofluorescence staining.
The prepared slides were fixed in ice-cold 90% methanol and air-dried (alternatively, 
they can be stored at -20°C until needed). The slides were then washed once in ice-cold 
phosphate-buffered saline (PBS), then fixed in 90% methanol at -20°C for 30 minutes, 
followed by 20 seconds in acetone at -20°C. The slides were then rinsed in PBT (PBS 
plus 0.1% Tween 20). Subsequently, the cells were incubated with a diluted 1:200 
mouse monoclonal anti-y-tubulin (T6557) in a humidified chamber at 37±1°C for two 
hours. Then they were rinsed again in PBT followed by incubation with diluted 1:32 
anti-mouse IgG Fab specific TRITC conjugate (T7782) in a humidified chamber at 
37±1°C for two hours. After another rinse in PBT, the slides were later incubated with 
diluted 1:100 monoclonal anti-a-tubulin conjugate (F2168) in a humidified chamber at
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37±1°C for one hour. After another extensive rinsing in PBT, DNA was counter-stained 
with diluted DAPI.
4.6.7 Slides Scoring Criteria.
Mitotic index.
For mitotic index measurement, slides were coded and 1000 cells per slide were scored 
to obtain the interphase:mitotic cells ratio according to the formula;
Mitotic index (M.I.) = number of mitotic cells 
number of interphase cells
x 100
Scoring was performed under 1000X magnification with oil immersion using Olympus 
BH-2 light microscope.
Cell division aberrations (fluorescent microscopy).
The immunofluorescence-stained slides were also coded and scored at 1000X 
magnification under oil immersion using an Olympus BH2-RCF fluorescence 
microscope. 100 cells per slide were analysed for a- and y-tubulin alterations, y-tubulin 
is a centrosome protein and involves in microtubule nucleation whereas a-tubulin is a 
microtubule monomer.
• a-tubulin (microtubules) stained green.
• y-tubulin (centrosomes) stained red.
• chromosomes stained blue.
Characteristics employed for identification:
• Bipolar: cells with normal metaphase and bipolar microtubule organising centre 
(MTOC) division.
• Tripolar: cells exhibiting abnormal metaphase with three MTOCs.
• Tetrapolar: cells with abnormal metaphase due to four MTOCs and relatively 
more extensive aberrations.
• Multipolar: More than four MTOCs present in a cell at the metaphase stage.
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• Abnormal mitotit cells were scored as lagging chromosome (attached to
microtubules), telophase bridge, multipolar whereas condensed chromatin were 
considered as dead cells.
Figure 4.6 shows a flow chart highlighting all the necessary steps involved in 
elucidating the effects of andrographolide exposure on MTOCs and chromosomal 
aberrations in V-79 cells.
4.6.8 Trypan Blue exclusion assay for cell viability.
The assay was conducted as described in Section 3.5.13 in Chapter 3.
4.6.9 Studies on Mitotic Fate and Cell Recovery
4.6.9.1 MCL-5 cells
Culturing and treatment procedures employed for MCL-5 in these cell fate and cell 
recovery studies were the same as those described in Sections 3.5.4 and 3.5.6 but without 
the addition of cytochalasin-B. The cells were grown in carefully labelled, 25cm flasks 
and subjected to andrographolide treatment for 24 or 48 hours. After the treatment phase, 
cells intended for cell fate assessment were promptly harvested as described in Section
3.5.7 and on the other hand for cell recovery experiments, the cells were harvested via 
centrifugation at 1500rpm for 5 minutes.
For the continuous treatment of MCL-5 cells with andrographolide, the cells were left in 
the presence of andrographolide for 5 cell cycles (120 hours) before being harvested as 
conducted previously.
4.6.9.2 V-79 cells
For V-79 cells, the same culture and treatment procedures were followed as described in 
Sections 4.6.1 and 4.6.3. After exposure to andrographolide for 24 hours, the cells were 
harvested according to the aim of the experiments. For assessing aberrations in MTOCs 
and chromosomes, the slides that were grown in Petri dishes were carefully and gently 
washed twice with pre-warmed PBS in a sterile Petri dish. Autoclaved forceps was used 
when handling the slides and the tips of the forceps were briefly dipped into 90% ethanol
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then dried before the next slides are handled. New Petri dishes were used for each slide.
Washed slides were promptly placed in new Petri dishes with fresh growth medium and 
incubated at 37±1°C with 5% CO2 in air for another 24 and 48 hours respectively. After 
these recovery periods, the slides were harvested as described in 4.6.4. Staining 
procedures were the same as those stated in Sections 4.6.5 and 4.6.6.
For cell fate study involving V-79 cells, the cells were grown in 25cm flasks rather than 
Petri dishes as described in Section 3.5.5 and treatment was performed as in Section 3.5.6 
in the absence of cytochalasin-B. The method employed was similar to that of MCL-5 as 
described previously but both floating and cells that were attached to the flasks were 
collected for harvesting using the cytospin as described in Section 3.5.7.
Three replicate experiments were conducted for each study. Figure 4.7 displays the 
important steps employed in studies for cell fate, cell recovery and continuous treatment 
with andrographolide.
4.6.10 Statistical analysis
The Fisher’s Exact test was used for the analysis of cell division aberrations and 95% 
confidence limits were accepted as the measure of significant difference unless otherwise 
stated. Analysis was performed via the Simple Interactive Statistical Analysis website 
accessible via http://home.clara.net/sisa/
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Fig 4.6 Flow chart for important steps involved in assessing MTOCs, mitotic index 
and chromosome aberrations in V79 cells.
ANDROGRAPHOLIDE TREATMENT
After 24 hours, the cultured cells were treated with 
andrographolide at selected concentrations; then incubated 
for another 24 hours.
CELLS CULTURED
V-79 cells were cultured at 37±1°C in DMEM which was 
supplemented with 10% horse serum and gassed 
with 5% CO-).
CELLS SEEDED
The cells were then seeded at approximately lxl(T 
cells/ml onto sterile microscope slides in Petri dishes 
and incubated at 37±1°C with COt for 24 hours.
SLIDE HARVESTING
After one cell cycle, the growth medium removed and the 
slides were washed with cold PBS twice; fix with ice-cold 
90% methanol and air-dried. The slides were kept 
at-20°C  until needed.
CONVENTIONAL STAINING
The slides were stained with:
• Brilliant blue
• Safranin O
IMMUNOFLUORESCENCE
STAINING
The slides were stained with:
• T6557
• T7782
• F2168
• Counter-staining with DAP I
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4.7 RESULTS
Cell division aberrations due to andrographolide exposure were investigated in Chinese 
| hamster lung fibroblasts V-79 cell line. The mitotic spindle fibres and chromosomes were 
| stained with Brilliant blue and Saffanin O respectively; visualised using light microscopy 
| to assess cell cycle irregularity and shifts in mitotic index value. Abnormalities in
ii
! microtubule organising centres (MTOCs) were qualitatively evaluated using fluorescent
i
I microscopy for better accuracy against using conventional dyes. The effect of
I
| andrographolide on MTOCs integrity in interphase and mitotic cells were investigated 
using immunofluorescence of y-tubulin, a centrosomal protein whereas microtubule 
j organisation was examined by means of a-tubulin immunofluorescence. Quantification of 
multiple MTOCs actuation was performed by establishing the relationship between the 
number of tubulin signals with different concentrations of andrographolide.
In untreated interphase cells the microtubule network was constructed all over the cells 
and centrosomes were detected as a one-spot signal of y-tubulin as shown in Figure 4.8.
In untreated mitotic cells, two spots of y-tubulin signals co-localised with spindle poles. 
Incubation of the cells with andrographolide for 24 hours induced abnormal tripolar, 
tetrapolar and multipolar spindles that co-localised with three, four and multi-spots of y- 
tubulin signals respectively. In contrast, the presence of andrographolide did not 
influence the microtubule architecture and the number of y-tubulin signals in interphase 
j cells. Data as shown in Table 4.1 revealed a pattern of steady and significant (p<0.05)
i
: dose-dependent accruement in multiple MTOCs with tripolar mitosis being the most 
prominent. Tetrapolar and multipolar mitoses also increased significantly with reduction 
in normal bipolar spindle ratio in scored mitotic cells respectively. Concomitantly, mean 
percentage mitotic index also accrued in a dose-dependent fashion. Figures 4.9 and 4.10 
shows examples of a bipolar, tripolar, tetrapolar and multipolar V-79 cells.
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(A) (B)
Fig. 4.8. Showing untreated interphase V-79 cells stained with immunofluorescence probes. Chromosome 
was stained blue with DAPI, y-tubulin observed as orange/yellow spots whereas a-tubulin, a microtubule 
monomer clearly visible in green. In (A), the microtubule network was clearly constructed all over in the 
resting cells. In (B), the y-tubulin spots are observed in one position within the cells. (lOOOx magnification)
(A) (B)
Fig. 4.9. Shows different number and MTOCs polarity in V-79 cells. (A) A bipolar cell and (B) a tripolar 
cell. Centrosome observed as orange/yellow spots, microtubule is green and chromosome in blue. (lOOOx 
magnification).
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(A) (B)
Fig. 4.10 Shows different number and MTOCs polarity in V-79 cells. (A) A Tetrapolar cell and (B) a 
multipolar cell. Centrosome observed as orange/yellow spots, microtubule is green and chromosome in 
blue (lOOOx magnification).
(A) (B)
Fig. 4.11. (A) Shows dead V-79 cells challenged with high doses o f  andrographolide where evaluating 
centrosomal integrity was not possible due to the absence o f  endpoints. (B) Compares a two cells. The 
smaller one on the left hand side is a V-79 cell that is bipolar whereas the one on the right hand side 
possesses two pairs o f  spindle poles. This particular type was considered to be pseudo-bipolar.
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Table 4 .1. Induction o f  centrosome and mitotic spindle abnormalities in V79 cells after 24 hours o f  
continuous exposure to andrographolide.
0 95.86 3.02 0.86 0.27 4.65
10 93.33 4.67 1.00 1.00 5.71
30 82.44 11.00 3.67 2.89 6.36
50 76.33 13.89 5.78 4.00 5.52
Colchicine 53.56 31.33 9.67 5.44 6.98
Figure 4.12 shows the incremental increases in tripolar, tetrapolar and multipolar 
centrosomes whereas Figure 4.13 compares the reduction of normal bipolar spindle poles 
ratio with multiplications in MTOCs and increases in mitotic index after 24 hours 
exposure to andrographolide. All cells were observed to possess direct association 
between spindle poles (y-tubulin) and microtubule (a-tubulin) as shown in Figures 4.9 
and 4.10. There were no visible disruptions to the microtubule network. An increase in 
mitotic index was observed at 10pM, continued at 30 before beginning to decrease again 
at 50pM. Between lOpM and 30pM of andrographolide, the increased mitotic index 
value indicated aberrant MTOCs was affecting cellular division and causing mitotic 
arrest that can be followed by cell death. Although, higher MTOCs were observed at 
50pM, the mitotic index began to decrease steadily in tandem with reduced cell viability 
frequency observed at 70 and 90pM of the compound. As shown in Figure 4.11(A), dead 
cells were not scorable for centrosome integrity. The data on the positive control, 
colchicine was also shown in comparison to andrographolide with expected outcome.
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Fig. 4.12 Graph showing the induction o f  aberrations in mitotic spindle and centrosome organisation in 
V-79 cells after 24 hours continuous exposure to andrographolide.
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The cells seemed more able to tolerate the presence of tripolar MTOCs where 3.02% of 
untreated V-79 cell populations possessed this feature as compared to less than one 
percent of cells with tetrapolar and multipolar centrosomes respectively, illustrating that 
higher number of MTOCs are not sustainable and cells are less likely to survive the next 
rounds of mitoses. Furthermore, prior to harvesting, the number of floating and 
unhealthy-looking cells inside the petri dishes was observed to be higher than viable cells 
attached to the slides in a dose-dependent manner, where higher andrographolide 
concentration was affecting cell number.
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Fig. 4.13 Graph to compare and contrast the reduction in normal bipolarity with increases in multiple 
centrosomes (tripolar, tetrapolar and multipolar) and mitotic index accruement.
Andrographolide (pM)
■  Mean % Abnormal mitosis
Fig. 4.14 Shows the incidence o f abnormal mitosis in V-79 cells exposed to andrographolide for
24 hours.
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The incidence o f abnormal mitosis was also determined and as shown in Figure 4.14 and 
the data in Table 4.2 the frequency of aberrant mitoses increased in relation to 
andrographolide concentration. The presence of more than two spindle poles affected 
normal chromosome segregation process.
Table 4.2. Mean % incidence o f  aberrant mitosis in V-79 cells treated with andrographolide for 24 hours.
0 2.56
10 4.33*
30 10.89*
50 10.56*
^Statistically significant values (p<0.05) against the negative controls.
Cell viability assessment using Trypan-blue exclusion assay revealed the number of 
viable cells as well as scorable centrosomal aberrations decreased beginning from 50pM 
to 90pM, which was the highest concentration of andrographolide tested on V79 cells. 
The cells were exposed to andrographolide for 24 as well as 48 hours, evidently the 
frequency of non-viable cells increased steadily with dose, in agreement with cell growth 
reduction. The duration o f andrographolide treatment also affected V-79 cell viability as 
shown in Table 4.3 and Figures 4.15 respectively. Thus, andrographolide cytotoxicity is 
dose- and time-dependent in V-79 cells. Figure 4.16 shows the effect of different 
concentrations of andrographolide with different treatment time on V-79 cell growth.
Table 4.3 Mean percentage o f  non-viable V-79 cells treated with andrographolide for 24 and 48 hours with 
corresponding cell growth values (percentage to negative controls).
0 6.83 26.50 100.00 100.00
10 7.08 44.98 85.64 69.S2*1
30 14.45* 81.41*2 59.12* 26.89*2
50 38.25* 91.08*2 58.39* 15.48*2
70 61.10" 94.91 *2 21.90* 8.34*2
90 75.76" 94.88*2 14.11* 5.66*2
^Statistically significant values (p<0.05) against the negative controls. 2 denotes significant difference 
(p<0.05) between 24 and 48-hours treatment.
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Fig. 4.15 A comparison o f  non-viable cell frequency between 24- and 48-hour treatment o f  V-79 cells with 
different concentrations o f  andrographolide. Longer treatment reduced cell viability.
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Fig. 4.16 The effect o f  different concentrations o f  andrographolide on V-79 cell growth during 24- and 48- 
hour treatment period. Longer treatment significantly reduced cell growth.
In order to determine whether the presence of abnormal centrosome numbers after 
treatment would be continued in subsequent cell divisions in the absence of 
andrographolide, V-79 cells that were exposed to various concentrations of the compound 
were washed with pre-warmed PBS and allowed to grow in fresh medium for a further 
one and two cell cycles.
Table 4.4 and Figure 4.17 shows the data on MTOCs abnormality in V-79 cells growing 
for 24 hours post-treatment whereas Table 4.5 and Figure 4.18 shows the aberrations 
observed after two cell cycles (48 hours) after andrographolide removal respectively.
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Table 4.4 Induction o f  centrosome and mitotic spindle abnormalities in V79 cells 24 hours after the
removal o f  andrographolide.
0 94.38 4.25 0.88 0.50 5.21
10 91.75 5.75 1.25 1.25 5.75
30 84.50 11.00 3.25 2.50 6.31
50 81.75 11.25 3.75 3.25 6.08
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Fig. 4.17 Graph showing the induction o f  aberrations in mitotic spindle and centrosome organisation in 
V-79 cells 24 hours after the removal o f  andrographolide.
Based on both sets of data, MTOCs tripolarity constituted the most prevalent type of 
aberrant multiplication even after andrographolide was removed from the growth 
medium. Tetrapolar and multipolar division also registered an increase against negative 
control but were less than 6% and 4% respectively. It is interesting to note that of the 
MTOCs aberrations induced, tripolarity in particular can be as high as those observed in 
continuous treatment with andrographolide. Figure 4.19 compares the induction of 
MTOCs aberration between the three treatment sets. However, one must also take into 
account that the occurrence of multiple MTOCs (i.e. tripolar, tetrapolar and multipolar) 
were higher in untreated cells for these sets o f experiments as compared to negative 
controls in cells subjected to continuous 24-hour treatment.
Mean % Tripolar
□  Mean % Tetrapolar
BM ean % Multipolar
10 30 50
Andrographolide (pM)
Copy 1
1 7 6
Y. Sharifuddin
Chapter 4
Table 4.5 Induction o f  centrosome and mitotic spindle abnormalities in V-79 cells 48 hours after the 
removal o f  andrographolide.
0 93.13 4.88 1.00 0.50 5.66
10 89.50 7.25 2.25 1.00 6.88
30 81.25 12.25 3.75 2.75 7.30
50 77.50 14.00 5.25 3.25 8.03
As aberrant centrosome multiplication increased with dose, so did the mitotic index 
values. This value was higher in cells treated with various doses of andrographolide and 
allowed to recover for a further two cell cycles as shown in Figure 4.20.
16
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Fig. 4 .18 Graph showing the induction o f  aberrations in mitotic spindle and centrosome organisation in 
V-79 cells 48 hours after the removal o f  andrographolide.
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Fig. 4.19 Graph to compare and contrast the frequency o f  microtubule organising centres (MTOCs) 
aberrations (tripolar, tetrapolar and multipolar) between V-79 cells that were treated continuously for 24 
hours and those that were allowed to recover one and two cell cycles post-treatment. Tripolarity was the 
most common form o f  centrosome multiplication observed.
T3
Treated for 24 hours 
24-hours post-removal 
48-hours post-removal
Andrographolide (pM)
Fig. 4.20 A line graph to compare and contrast the levels o f  mitotic index observed between V-79 cells that 
were treated continuously for 24 hours and those that were allowed to recover one and two cell cycles post­
treatment. The mitotic index for cells treated continuously fell in the presence o f  andrographolide due to
cytotoxicity.
When comparing the data presented in tables 4.1, 4.4 and 4.5, the percentage of cells with 
more than two spindle poles in the negative control remained mostly constant in value, 
although slight increase were observed, they were not statistically significant. There were 
dose-related increases between 10-50pM even after andrographolide removal but these 
were mostly tripolar in nature. Remarkably, the percentage of cells with tripolar MTOCs
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remained similar even in the absence of andrographolide, post-treatment. The same can 
be said about tetra- and multipolar MTOCs values although there was a decrease of 
tetrapolar cells before it increased again when allowed to progress for another one cell 
cycle. The mitotic index values also changed with the values were higher for cells that 
were permitted to proceed through subsequent cell cycles after 24-hour andrographolide 
challenge. Cells that completed two cell cycles (48 hours) post-treatment showed the 
highest mitotic index value.
Table 4.6 The mean percentage incidence o f  condensed chromatin in V-79 cells treated with 
andrographolide for 24 hours and those that were allowed to recover 24 hours post-treatment.
0 0.10 0.12
10 0.16 0.18
30 0.60* 0.69*
50 1.82* 2.07*
70 3.62* 4.38*
90 5.33* 5.29*
^Statistically significant values (p<0.05) against the negative controls.
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Fig. 4.21 A graphic comparison in the mean percentage incidence o f  condensed chromatin observed 
between V-79 cells that were treated continuously for 24 hours and those that were allowed to recover 24 
hours after andrographolide insult. The presence o f  condensed chromatin indicates dead cells.
The incidence of condensed chromatin, which indicates cell death was also quantified 
and andrographolide elicited condensed chromatin frequency in a dose-related fashion as 
presented in Table 4.6 and Figure 4.21. There were no significant difference in condensed
0 10 30 50 70 90
4 24 Hours Andrographolide (pM)
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chromatin frequency between V-79 exposed to andrographolide for 24 hours and those 
that were permitted to grow for another 24 hours period in the absence of the 
phytochemical.
As the induction of multiple MTOCs was observed in a dose-dependent manner between 
10-50pM of continuous exposure to andrographolide, discovering how it affects cell fate 
was deemed an interesting venture. Table 4.7 shows the data of V-79 cells exposed to 
andrographolide in the same concentration range and the data displayed graphically as 
shown in Figure 4.22. Generally, the pattern of the data is supporting the trend observed 
as shown in Table 4.1 earlier. Abnormal centrosome number promoted aberrant mitoses 
and the percentage of cells containing more than one nucleus and failed to complete 
cytokinesis, increased in a dose-dependent fashion with 30pM of the phytochemical.
13.28% and 13.73% of the cell population remained as binucleates whereas 1.55% and 
1.35% of cells were trinucleates, upon treatment with 30 and 50pM of andrographolide 
respectively. Statistically significant values (p<0.05) for difference against the negative 
controls were as shown in Table 4.7. Even though the percentage of tri-, tetra- and 
multipolar cells generated were lower than the percentage of cells that were shown to 
have tripolar, tetrapolar and multipolar MTOCs when treated with the same dose of 
andrographolide, the presence o f more than two spindle poles forced anomalous 
chromosome migration in different directions manifested by trinucleated, tetranucleated 
and multinucleated cells. Whereas, the effects observed at higher doses were closely 
linked to cell viability since most cells challenged with 70 and 90pM of the compound 
died due to necrosis. As demonstrated in the Chapter 3, V-79 cells exposed to 
andrographolide for 24 hours experienced reduced cell viability with most cells died 
primarily via necrosis in a dose-dependent manner.
Table 4.7 Cell fate o f V-79 cells after 24-hour treatment with different doses o f  andrographolide.
0 3.39 0.24 0.13 0.06
10 6.85* 0.30 0.25 0.15*
30 13.28* 1.55* 0.85* 0.28*
50 13.73* 1.35* 0.55* 0.35*
70 9.93* 0.70* 0.35* 0.58*
90 4.45 0.38 0.08 0.18*
^Statistically significant values (p<0.05) against the negative controls.
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Fig. 4.22 Graph showing the cellular division stage o f  V-79 cells after 24-hour continuous treatment
with different doses o f  andrographolide.
The ability o f V-79 cells to recover after andrographolide insult for 24 hours was also 
investigated and the data were presented as Table 4.8 and Figure 4.23 respectively. It 
turned out that there was still significant presence (p<0.05) o f cells harbouring more than 
one nucleus in concordance with the MTOCs abnormality data as demonstrated in Tables
4.4 and 4.5. Trinucleated cells frequency was prominent so did tetra- and multinucleated 
cells. Thus, the presence o f abnormal MTOCs polarity promoted multinucleation of V-79 
cells even after andrographolide removal.
Table 4.8 Cell fate o f V-79 cells after 24-hour treatment with different doses o f  andrographolide and 
subsequently allowed to recover for another 24 hours in the absence o f  the phytochemical.
0 2.55 0.33 0.03 0.04
10 3.08 0.98* 0.20* 0.10*
30 6.13* 1.58* 0.50* 0.15*
50 7.03* 1.78* 0.63* 0.33*
70 3.53* 0.50 0.30* 0.13*
90 2.23 0.38 0.10 0.05
^Statistically significant values (p<0.05) against the negative controls.
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Fig.4.23 Cell fate o f  V-79 cells after 24-hour treatment with different doses o f  andrographolide and 
subsequently allowed to recover for another 24 hours in the absence o f  the phytochemical.
Since the V-79 cell line is p53-deficient, another cell line, MCL-5 that is metabolically- 
competent and capable o f normal DNA repair was also subjected to the same treatment 
for one and two cell cycles. As shown in Tables 4.9 and 4.10 respectively, MCL-5 cells 
were observed to generally experienced less effects of andrographolide challenge evident 
from the percentage of cells harbouring more than one nuclei, especially trinucleates. 
Figures 4.24 and 4.25 graphically displayed the data obtained. There was a steady 
accruement of cells containing more than one nucleus in the order o f binucleates > 
trinucleates > tetranucleates > multinucleates, where binucleated cells were statistically 
significant between 10-50pM of andrographolide against negative control as observed 
after 24 hours treatment. The presence of cells with more than two nuclei (tri-, tetra- and 
multinucleated) were less than 1% of the cell population in all doses tested and again 
30pM of the phytochemical induced the highest number whereas 50pM was required to 
attain statistically significant percentage of multinucleated cells. This suggests that MCL- 
5 may be more able to withstand andrographolide challenge than V-79 cells.
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Table 4.9 Cell fate o f  MCL-5 cells after 24-hour treatment with different doses o f  andrographolide.
0 5.90 0.43 0.37 0.09
10 10.32* 0.65* 0.25 0.13
30 13.38* 0.90* 0.60* 0.18*
50 10.45* 0.65* 0.50* 0.30*
70 6.23 0.30 0.15* 0.15
90 3.90 0.30 0.20 0.15
^Statistically significant values (p<0.05) against the negative controls.
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Fig. 4.24 Graph showing the cellular division stage o f  MCL-5 cells after 24-hour continuous treatment
with different doses o f  andrographolide.
MCL-5 cells that were subjected to 48 hours (two cell cycles) continuous exposure also 
showed that 30pM of andrographolide remained the optimum concentration in arresting 
cells as bi-, tri- and tetranucleates but only at a higher concentration of 50pM that 
multinucleated cells were of significant value, the same trend as observed with 24 hours 
exposure demonstrated earlier in Table 4.9
Table 4.10 Cell fate o f  MCL-5 cells after 48-hour treatment with different doses o f  andrographolide.
0 3.25 0.21 0.10 0.09
10 7.00* 0.30 0.20* 0.05
30 10.18* 0.50* 0.43* 0.13*
50 9.93* 0.45* 0.23* 0.25*
70 8.88* 0.48* 0.23* 0.05
90 7.83* 0.10 0.10 0.05
^Statistically significant values (p<0.05) against the negative controls.
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Fig. 4.25 Graph showing the cellular division stage o f  MCL-5 cells after 48-hour continuous treatment
with different doses o f  andrographolide.
This data sets highlight the fact that even though the treatment time was prolonged by 
another one cell cycle, direct doubling of effects measurable by the percentage of non­
mononucleated cells, in this case the most obvious would be binucleated cells, was not 
observed. In fact, simple direct comparison between data in Tables 4.9 and 4.10 showed a 
slight decrease rather than an expected increment, observed between doses 10 to 50pM. 
Interestingly, the percentage of binucleated cells at 70 and 90pM were higher compared 
to the cells exposed to the same concentrations but at shorter treatment period. However, 
these figures should not be interpreted as a direct effect o f andrographolide but merely 
changes to the number of scorable cells since many cells died due to necrosis.
MCL-5 cells were also exposed to a similar concentration range of andrographolide up to 
50pM but with a longer treatment period of 120 hours (5 continuous cell cycles) and a 
similar result emerged. Referring to Table 4.11 and Figure 4.26, shows the percentages of 
cells arrested with different mitotic outcomes.
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Table 4.11 Cell fate o f  MCL-5 cells after continuous exposure for five cell cycles to different 
concentrations o f  andrographolide.______________________________________________
0 7.05 0.43 0.48 0.03
10 12.18* 0.93* 0.65* 0.30*
30 11.25* 1.84* 1.03* 0.53*
50 10.05* 1.89* 0.91* 0.50*
*Statistically significant values (p<0.05) against the negative controls.
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Fig. 4.26 Graph showing MCL-5 cells at various stages after continuous exposure to andrographolide for five 
cell cycles (120 hours).
Although, generally the numbers were slightly higher when compared to 24- and 48-hour 
exposure, the percentage of binucleated cells in untreated cultures were also higher 
possibly due to stress during the culture period. The percentages of trinucleated cells 
were almost 2% and tetranucleated cells were almost 1% between 30 and 50pM whereas 
the percentage of multinucleated cells was still less than 1% of the cell population. Again 
at these concentrations, andrographolide induced a statistically significant number of 
binucleated cells more than 10% of 4000 cells scored.
Table 4.12 Frequency o f  necrosis and apoptosis in MCL-5 cells treated for five cell cycles to different
concentration o f andrographolide.
0 13.05 0.73
10 24.45 1.00
30 33.15* 1.45*
50 50.95* 1.30*
* Denotes statistically significant difference against the negative controls.
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Fig. 4.27 The incidence o f  necrosis and apoptosis in MCL-5 cells exposed to andrographolide for five cell
cycles (l 20 hours).
Again, MCL-5 cells exposed to the longer treatment period of 120 hours (five cell cycles) 
reproduced the same trend observed previously where andrographolide mainly incited 
necrotic cell death in a dose-dependent manner, rather than apoptotic response. In all 
concentrations tested more than 1% of the cells were apoptotic as demonstrated in Table 
4.12 and Figure 4.27. Thus, subjecting the cells to longer treatment period did not 
increase the incidence of cell death. This can be attributed to the dynamics of cell growth 
and demise, where the values were for the cells scored at that time. Cellular debris and 
remnants were observed on the microscope slides indicating the presence of cells that 
died earlier. It is also to be stated the frequency of necrotic and apoptotic cells in the 
negative control may be related to cell culture stress.
■  Mean % Apoptotic cells 
@ Mean % Necrotic cells
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4.8 DISCUSSION
Chromosomes are segregated by attachment to the highly organised microtubule spindle 
| that only forms during mitosis, replacing the long monoastral array present in the
i
! interphase stage. In normally dividing cell, microtubule organising centres (MTOCs) or 
| centrosomes exist in mirror symmetry at the opposite poles connected by microtubules
I
from each spindle pole. To this highly symmetrical structure, the duplicated chromatids 
attached, then are diametric and equally apportioned during anaphase to each daughter 
cell. Disruption to any actors during this mitotic theatre can lead to dire consequences. 
Indeed, abnormalities of centrosome integrity and mitotic spindle apparatus may have a 
role in the initiation of neoplasia (Yuen et al., 2005).
The exposure of V-79 cells to andrographolide at various concentrations induced aberrant 
mitotic division in a dose-response manner and this is the first study, to the best of the 
author’s knowledge, which provided evidence for the propensity of andrographolide to 
disrupt microtubule organising centres function hence contributing to chromosome 
segregation abnormalities such as those manifested as micronuclei. The data suggested a 
direct correlation between aberrant MTOCs number, cell division and mitotic index upon 
andrographolide challenge, with such an insult inflicted damages that can still be 
observed even after the removal of the phytochemical.
Centrosomes can be indispensable for microtubule polymerisation (Heald et al., 1996; 
Khodjakov et al., 2000) but are crucial for spindle nucleation and thus affect 
chromosome segregation process. Centrosomes also influence other key roles governing 
cell division including cytokinesis initiation and the entry into S-phase of the cell cycle 
| (Khodjakov et al., 2000; Hinchcliffe et al., 2001; Piel et al., 2001). In the absence of the
| centrosome, microtubule polymerisation and chromosome segregation can still occur but
I cell division is usually accompanied by defects in cytokinesis and cell cycle progression
(Khodjakov & Rieder, 2001). For accurate chromosome separation process, each 
daughter cell must receive only a single centrosome and this centrosome must replicate 
only once per cell cycle.
Andrographolide caused significant numerical centrosomal abnormality manifested by 
the presence of the y-tubulin signal in tri-, tetra- and multipolar MTOCs, in a descending
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order of prominence especially between 30 and 50pM doses, with corresponding 
| significant increases in the mitotic index value. This anomalous number of spindle polesi
affects normal chromosome segregation process due to the presence of multipolar mitotic 
| spindles. Unequal chromosome segregation leads to aneupoidy and higher doses of
andrographolide increased the proportion of not only cells with tripolar MTOCs but also 
cells with higher number of centrosomes, suggesting a worse disruption to the 
| centrosome numeral homeostasis and carries more risks to cellular division process. It is
! possible for disruption to normal levels of proteins involved in centriole duplication toi
cause numeral amplification within one cell cycle consistent with increases in pseudo-1
| bipolar and multipolar mitoses frequencies (Duensing et al., 2007).
!j  Indeed, centrosomal anomaly in cultured mammalian cells is associated with the
induction of multipolar spindles, multipolar division and micronucleation (Ochi 2002).
Diazepam for example was shown to induce abnormal anaphases consisted primarily of 
multipolar spindles and a high frequency of kinetochore-positive micronuclei in 
binucleated cells (Izzo et al., 1998). A study on centrosome integrity using a mouse 
model of human breast cancer revealed that 25% of the cells contained micronuclei and 
approximately 60% harbouring aberrant centrosome numbers (Montagna et al., 2002). 
Furthermore, the presence of micronuclei was detected only in 7% of cells with normal 
bipolar MTOCs in contrast to 18% in cells with amplified centrosome numbers 
(Montagna et al., 2002). The statistically significant dose-dependent elevation in aberrant 
MTOCs number in V-79 cells subjected to andrographolide for 24 hours is in 
concordance with the micronuclei frequency induced in AHH-1, MCL-5 and V-79 cell 
lines as discussed in the previous chapter and assists in the elucidation of possible 
mechanism involved in micronuclei induction by this phytochemical. The presence of 
more than two MTOCs affected normal chromosome migration towards opposite spindle 
I poles since the frequency of aberrant mitotic cells accrued with increased 
| andrographolide concentrations. The immunofluorescence staining technique employed 
not only assisted in centrosome numerical aberration assessment but also revealed a 
direct connection between MTOCs represented by y-tubulin antibody (red in colour) and 
microtubules (a-tubulin antibody, green in colour), hence lend credence to the notion that 
andrographolide caused centrosome multiplication as opposed to microtubule disruption 
and disassociation with the MTOCs.
ij
j
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Centrosome duplication is controlled by members of the Aurora/IpII, CDK, NIMA and 
Polo-like families of cell cycle kinases (Fry et al., 1998; Mayor et al., 1999; Hinchcliffe 
et al., 1999; Lacey et al. 1999; Mussman et ah, 2000; Meraldi & Nigg, 2001). CDK2 
bound to cyclins E or A and involves in stabilising the centrosomal kinase hMpsl 
! permitting its maintained association with the centrosome in mice (Fisk et al., 2001) 
while phosphorylating and dissociating nucleophosmin/B23 (Okuda et al., 2000). During 
G2, various additional proteins are recruited including members of CDK1 kinases, Aurora 
and Polo-like families, presumably involves in centrosome maturation (Bailly et al.,
1989; Pockwinse et al., 1997; Jackman et al., 2003). In M-phase, nucleophosmin is again 
present at the spindle poles and associates with the centrosomal organising protein 
NuMA (Zatsepina et al., 2003). Also at this stage, the tumour suppressor proteins p53,
; BRCA1 and TACC are present at the centrosomes (Raff, 2002; Fisk et al., 2002).
I Cells with abnormal centrosome number customarily produce multiple MTOCs such as
tri-, tetra- and multipolar spindles (Fukasawa, 2005). Tripolar MTOCs seems to be more 
tolerable and frequent in occurrence as shown by the results and they are able to complete
I
cytokinesis with some daughter cells from this mitosis are viable but aneuploid in status 
whereas others may not survive due to ruinous karyotypic modifications (Fukasawa,
2005). Cells containing more than three spindle poles frequently fail to undergo 
cytokinesis, subsequently generating either binucleated or arrested as mono-nucleated 
cells. The results generated showed that the presence of multiple centrosomes were 
translated into cells with multiple nuclei. V-79 cells challenged with andrographolide for 
24 hours exhibited significant frequency of bi-, tri-, tetra- and multinucleated cells
between 30 and 70pM doses, which suggest chromosome segregation fidelity was
affected in the presence of andrographolide.
Furthermore, abnormal centrosome number was maintained in the absence of 
andrographolide, after the initial 24-hours exposure period as illustrated in Figure 4.19.
The values remained almost similar and it was expected that should the cells were able to 
recover, the frequency of cells with abnormal MTOCs would be reduced by cell death but 
this was not supported by the data obtained and the mechanism(s) involved is not entirely 
clear. Consequently, the presence of multiple MTOCs lead to abnormal mitoses observed 
in V-79 cells even after the compound was removed from the growth medium and cells
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were subsequently allowed to grow for a further 24 and 48 hours after exposure. 
Anomalous centrosome number can be transferred to daughter cells after division.
After andrographolide removal, the frequency of tri-, tetra- and multinucleated cells were 
still above the untreated samples. At 10pM of the phytochemical, in comparison to cells 
subjected to continuous 24-hours treatment (Table 4.7), the percentage of binucleated 
cells was lower whereas trinucleated cells increased (Table 4.8). The percentages of 
binucleated cells were also lower than those observed in Table 4.8 but were still 
significant against the negative controls. This shows that centrosome amplification 
induced by andrographolide were maintained if not accrued and also affected subsequent 
cell divisions. However, it is also not distinguishable whether such incidence corresponds 
to new daughter cells or existing cells that were not able to divide.
Evidently, the presence of tripolar MTOCs within a cell is more tolerable than those with 
four or more centrosomes, hence the frequencies of trinucleated cells were higher than 
those of tetra- and multinucleated cells. When cells attempt cytokinesis in the presence of 
abnormal MTOCs number, only one cleavage furrow may prevail due to insufficient new 
surface area to complete more than one and constantly resulting in two daughter cells 
containing different chromosome complement (Duesberg & Li, 2003). Division involving 
three or more daughter cells are produced by multiple cleavage furrows and aneuploid 
progeny are generated. When comparisons were made between V-79 and MCL-5, the 
incidence of trinucleated cells were higher in the former than the latter as shown in 
Tables 4.7 and 4.9 respectively. This explained previous findings that male rats subjected 
to andrographolide treatment for 48 days exhibited reduced sperm counts, caused necrotic 
death amongst Sertoli cells and the seminiferous epithelium as well as lumen are 
consisted of multinucleated cells (Akbarsha & Murugaian, 2000). Mating of 
andrographolide-treated rats with untreated females counterparts did not produced any 
offspring (Akbarsha & Murugaian, 2000).
The statistically significant increase of mitotic index value connotes an increase of 
metaphase arrest suggesting a build-up of dividing cells unable to complete mitosis.
There is a correlation between DNA repair and the maintenance of normal MTOCs 
number. Centrosome amplification has been shown to occur during prolonged G2-arrest 
in Rad51 -deficient cells due to G2-M checkpoint activation by DNA damage (Dodson et
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al, 2004). Therefore, DNA damages that are usually repaired, will accrued in the 
presence of defective repair system or genomic injury induced by the detrimental agent 
that essentially overwhelmed the DNA repair mechanisms, consequently triggering the 
G2-M transition checkpoint activation leading to mitotic arrest.
i
j Previous studies showed that andrographolide caused cell cycle arrest at the G0-G1 phase
! of the cell cycle concomitant with decrement of cell populations at the G2-M phase in
1
| human cancer cells (Rajagopal et al., 2003; Satyanarayana et al., 2004). It was further
revealed that there was significant elevation of p27Kipl and reduction in CDK4 protein 
expression levels (Rajagopal et al., 2003; Satyanarayana et al., 2004). However, no 
changes were recorded in cyclins D1 and B1 levels (Satyanarayana et al., 2004).
However, another recent study reported andrographolide induced G2-M arrest with 
treated HepG2 cells possessing a low level p34cdc2, which is a key cyclin-dependent 
kinase for G2-M transition (Li et al., 2007). Both the G2 and the mitotic checkpoints 
possess a restricted capacity in maintaining arrest following cytoskeletal disruptions and 
DNA damage respectively, which means after a period of time in arrest, cells might 
progress to the next stage of the cell cycle in an aberrant manner. Adaptation of the G2 
and mitotic checkpoints can lead to genomic instability. However, there was no clear 
pattern in andrographolide effects on cell cycle arrests since different cell lines including 
cancer cells studied in previous works exhibited a non-specific cell cycle arrest.
Centrosome duplication can become temporally detached from the cell cycle allowing 
multiple centrosomes to materialise in a single cell. Over-duplication is connected with 
decreased activity of the p53 tumour suppressor pathway, commonly via mutational
| inactivation of the TP53 gene (Fukasawa et al., 1996; Carroll et al., 1999). Reduced p53
1
I activity can also be due to over-expression of the p53 inactivating protein MDM2
i
I (Carroll et al., 1999) or reduced activity of p53 downstream targets, Gadd45 (Hollander
et al., 1999; Wang et al., 1999) and p21Cipl/wafl (Mantel et al., 1999; Tarapore et al,
2001a), all of which correlated with centrosome multiplication. The p53 protein localises 
to centrosomes before and after duplication. It is capable of regulating centrosome 
replication independent of its role as transcription regulator (Tarapore et al., 2001b) then 
dissociates from the centrosomes to be stabilised in cytoplasm of cells with mitotic 
defects leading to Gi arrest in the next cell cycle. Whereas, no mitotic arrest occurred in 
cells without p53 (Fisk et al., 2002; Raff et al., 2002). Andrographolide was shown to
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exert its effects independent of a cell’s p53 status (Rajagopal et al., 2003). The V-79 cell 
line used in this study is p53-deficient (Chaung et al., 1997) hence, cells that can escape 
mitotic arrest, customarily generates tetraploid cells (Lanni & Jacks, 1998).
!
Loss of normal p53 activity has been shown to permit polyploid cells to proliferate 
instead of apoptose (Casenghi et al., 1999; Andreassen et al., 2001). It has beent
i
| suggested that p53 is responsible in coordinating the initiation of centrosome duplication
| with DNA replication in addition to its role in preventing centrosome over-duplication. In
i
response to DNA damage, p53 should activates its target genes including for p21, which 
in turn binds to and inhibit the CDK2-cyclin E complex. CDK2-cyclin E complex is 
needed for centrosome duplication but the paradox is centrosome hyperamplification is 
still observed in p53 positive cells in which p21 would be induced and CDK2-cyclin E 
activity would be inhibited. Thus, p53 status alone may not significantly influence normal 
centrosome presence since abnormal centrosome number can be seen in tumours with 
persistent p53 activity (Lingle et al., 2002; D’Assoro et al., 2002; Pihan et al., 2003) 
suggesting that actors other than the ‘guardian of the genome’ might be involved.
The major cell cycle control mechanism that acts during mitosis is the spindle assembly 
checkpoint, also known as the mitotic checkpoint which prevents chromosome 
malsegregation and aneuploidy via inhibition of cell cycle progression into anaphase, 
until all of the replicated chromosomes have attached to spindle microtubules. Mitotic 
checkpoint proteins are recruited to kinetochores of unattached chromosomes leading to 
the generation of an at least partially diffusible signal inhibiting the anaphase promoting 
complex/cyclosome (APC/C). The APC/C is an E3 ubiquitin ligase that ubiquitinates 
substrates whose degradation is essential for anaphase inception (securin) and mitotic exit
I
I (cyclin B). Abolition of securin post-ubiquitination releases its binding partner separase,
i
! whereas simultaneous depletion of cyclin B-dependent CDK1 kinase activity resulting in 
separase dephosphorylation. Both events cause separase activation, which then cleaves 
the cohesins that hold replicated chromosomes together and initiates anaphase. Even a 
single unattached kinetochore can be sufficient to delay anaphase onset (Rieder et al.,
1994; Rieder et al., 1995). A weakened mitotic checkpoint where inability to maintain 
checkpoint signalling process can lead to chromosome loss or non-disjunction concordant 
with decrease length of arrest. Complete absence of the mitotic checkpoint on the other 
hand, results in rapid cell-autonamous lethality due to extensive chromosome
|
i
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missegregation and the cells die within six divisions (Michel et al., 2004; Kops et al.,
2004). Chromosome segregation errors due to microtubules nucleated by multipolar 
MTOCs cannot be prevented by the mitotic checkpoint if the kinetochores made 
productive attachment to the spindles.
iiii
; A large number of gene products are involved in the mitotic checkpoint response
j  including but not limited to MAD2, BUB1, BUBR1 and Aurora B. Direct mutation in
j any of the essential genes could compromise the checkpoint response. Alterations to the 
expression levels of these genes, which apparently occur more frequently in comparison 
to direct mutations, can also jeopardise the mitotic checkpoint. Lower expression of the 
crucial proteins would result in aneuploidy and chromosome instability, at least in 
proteins whose accumulation was rate-limiting for checkpoint signalling at individual 
kinetochores. Indeed, this was shown to be the case for MAD2 and BUBR1 (Michel et 
al., 2001; Baker et al., 2004). The mechanism by which overexpression of individual 
checkpoint proteins can elicit aneuploidy is not fully understood yet but has been 
observed in various human cancers. For example, BUB3 was found to be upregulated in 
breast (Yuan et al., 2006), gastric (Grabsch et al., 2003) and lung (Miura et al., 2002) 
cancers respectively. It is not known whether andrographolide is capable of affecting the 
expression levels of crucial genes involved in checkpoints.
Surprisingly, there is no known checkpoint that terminates mitosis in response to 
abnormal MTOCs accumulation (Sluder et al., 1997). Cells can compensate for having 
multiple MTOCs by clustering them together to bipolar division with equal or almost 
equal chromosome segregation (Ring et al., 1982; Brinkley, 2001; Quintyne et al., 2005).
| Some V-79 cells were observed to possess an ability to form a pseudo-bipolar MTOCs by
i
| clustering or aligning multiple centrosomes by a mechanism still to be understood which
| structurally mimics the normal bipolar spindle poles and is suspected to segregate 
chromosomes equally, at least for that particular division. Figure 4.11(B) shows an 
example of a pseudo-bipolar V-79 cell in comparison to a normal bipolar cell. It is also 
conceivable that some multipolar spindles can transform to pseudo-bipolar spindles 
during mitosis but are not devoid of chromosome segregation errors. Centrosomes spatial 
proximity at the beginning of mitosis may determine the possibility and extent of 
centrosome clustering, where amplified centrosomes close to each other will be grouped 
and those widely apart will nucleate microtubules independently. The centrosome
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clustering dimension in turn may determine whether chromosome separation process is 
equal or almost equal. Centrosomal clustering requires the microtubule motor 
cytoplasmic dynein. In some tumours, it has been speculated that multipolarity is 
correlated to the overexpression of the spindle protein NuMa and that NuMa interferes
i
| with dynein localisation to the spindles (Quintyne et al., 2005). Whether these factors 
contribute to the multipolar spindles observed after DNA damage remains to be 
established. The size of cells with multinucleated MTOCs were also bigger compared to 
| normal cells as shown in Figure 4.10, or even those possessing abnormal censtrosome 
numbers such as tri- and tetrapolar cells as animal cells do not proliferate exponentially 
; and thus would not necessitate the evolution of a cell-size checkpoint (Brooks & Shields,
1985).
An increase in cell number always stems from the balance between cell proliferation and 
cell death, cell viability assessment performed using trypan-blue exclusion assay revealed 
that andrographolide caused cellular toxicity in a dose- and time-dependent manner, in 
agreement with data obtained earlier. There were statistically significant difference in the 
frequency of non-viable cells between 24- and 48- hour exposure with the latter possess 
higher percentage of dead cells as shown in Figure 4.3. Furthermore, the frequency of 
condensed chromatin, which also indicates cell death, accrued with andrographolide 
concentration and remained similar in the absence of andrographolide 24 hours after the 
initial insult (Figure 4.21). This observation indicates that cells challenged with 
andrographolide may not be able to recover from the damage inflicted.
t
Regardless of whether abnormal centrosome number arise due to overduplication, 
cytokinesis failure or any other mechanism, they are unlikely to behave merely as an 
audience to the mitotic dance. A frequent but not inevitable short-term effect of MTOCs 
multiplication is the formation of multipolar spindle, which can be superseded by a 
multipolar division producing more than two daughter cells. Undoubtedly, cells that were 
generated from multipolar division are destined to die due to the lack of essential genes.
Thus, in reference to their proliferative potential, cells harbouring multiple MTOCs are 
expected to be at disadvantage when compared to cells with normal centrosome numbers.
On the other hand, multipolar cell divisions are capable of inducing chromosomal 
instability especially chromosome combination where such occurrence are not only
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compatible with life, it also confers a selective advantage to the surviving but genetically 
abnormal cell.
In the studies conducted, andrographolide was shown to promote centrosome 
amplification, MTOCs multipolarity and aberrant mitotic cells leading to mitotic 
aberration. These effects along with cytotoxicity occurred in a dose-dependent manner 
and may shed more lights into the formation of micronuclei. Hence, andrographolide 
cellular target(s) may include the mitotic machinery. The presence of aberrant 
centrosome number might be transferred to daughter cells after division and can affect 
subsequent mitoses.
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CHAPTER 5 
ASSESSMENT OF ANDROGRAPHOLIDE'S MUTAGENIC POTENTIAL 
UTILISING THE HPRT FORWARD MUTATION ASSAY
5.1 Introduction
iI
A reliable and robust assay that is sensitive in detecting mutations in the low dose region of 
exposure is needed for both the qualitative and quantitative analysis of the dose response 
relationship of genotoxicants.
Usually mutations are detected using mammalian cell test systems with high efficiency. In 
similarity to the microbial-based test systems, testing on mammalian cells are also rapid 
and can be conducted at a relatively low cost. The most common assays for gene mutation 
assessment in mammalian cells depend upon forward mutations that confer resistance to a 
toxic chemical, in contrast to the Ames test which is based on a reverse mutation principle. 
Thymidine kinase (TK) and hypoxanthine phosphoribosyl transferase (HPRT) mutation 
assays are two examples where forward mutations cause the inactivation of a wild type 
gene at heterozygous loci (TK*f~) and sex-linked loci (HPRT*). The mammalian forward 
mutation assays are capable of responding to a wide spectrum of mutagens because any 
mutation interfering with gene expression confers resistance to the toxic chemical 
(McGregor et al., 1989; Morris et al., 1994; Domon et al., 2001; Doak et al., 2007).
The HPRT forward mutation assay employs hemizygous mammalian HPRT gene to 
elucidate genetic damage that is manifested as a loss of phenotypic characteristic. In this 
case it is the loss of cell proliferation in the presence of the lethal analogue 6-thioguanine 
which is cytotoxic to HPRT* but not to HPRT" mutants. In humans, mutations in the HPRT
\
gene leads to a neurological condition known as Lesch-Nyan and partial loss leading to 
gouty arthritis (Gibbs et al., 1990).
1 Three appealing features of the mammalian HPRT gene mutation assay that contributed to 
it being widely used are;
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| • The HPRT gene is encoded on the mammalian X-chromosome thus making it
i
I easier to select for loss of function in mutants in cells derived from males, which
in mammals are heterogametic. On the other hand, in cells from females it could 
I be due to inactivation of one of the X-chromosome.
• Mutations in the same HPRT gene can be compared among cell lines,
experimental animals and humans (Chen et al., 2002).
• The biochemical selection systems for loss of function for cells that survive in the
presence of 6-thioguanine and/or 8-azoguanine are effectively simple (Caskey &
Kruh, 1979).
As large losses in the X-chromosome lead to lethality, detection of small changes such as 
point mutations in the HPRT gene provided valuable insights into possible mechanism of 
action involved.
Further multiple events are required to transform DNA changes into selectable phenotypes 
after a chemical insult and these are fixation of the mutation and reduction of the pre­
existing enzyme to a level with no biological activity. Fixation of a mutation needs the 
initial lesion in the DNA such as strand break or damage to DNA-dependent protein, to be 
translated into change(s) to the DNA sequence such as point mutation or deletion. In the 
case of point mutation, the mutated strand must be separated from the wild type strand by 
cell division resulting in one of the progeny cells no longer able to synthesise active mRNA 
and/or protein. Point mutations can only occur after the completion of the cell cycle as the 
lesion affecting the base may be removed or repaired by DNA repair mechanisms and thus 
such mutation is only relevant in these assays after its incorporation into both strands. For 
selection, the existing enzyme or mRNA must be reduced either by cell division or 
; degradation to non-functional levels, so that the original phenotype can no longer be 
identified. Figure 5.1 shows the principle of the HPRT point mutation assay.
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5.2 Objective of This Study
In this study, the potential of andrographolide to induce point mutations in mammalian 
cells will be examined and determining whether such mutations can occur at concentrations 
used previously in this thesis as well as other published works. The author employed the 
HPRT mutation assay in this study because the method was routinely used in the laboratory 
(Barber et al. 2006, Doak et al., 2007) as compared to the Ames test.
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M utant purification
•  Achieved by culturing cells in 
growth medium with HAT
•  Endogenous pathway is blocked
•  Uridine monophosphate in salvage 
pathway is blocked forcing cells to 
rely upon HPRT for DNA synthesis
E xposure to gen otoxin  
HPRT cells that survived HAT 
treatment, were treated with the test 
compound and subcultured.
H P R T  m utants selection
6-thioguanine, a toxic analogue o f  dGTP 
was employed to select for HPRT' 
mutants.
C ells d ie
Cells incorporated 
6-thioguanine into 
DNA
C ells surv ive  
Mutants are resistant 
to 6-thioguanine 
since it is not 
incorporated into 
DNA
Fig. 5 .1 Shows the main concept o f  HPRT point mutation assay.
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G and T into DNA incorporate G and
T into DNA
HPRT
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5.3 MATERIALS AND METHODS
5.3.1 Thawing Frozen AHH-1 Cells.
This procedure was performed as described in Section 3.5.4 of Chapter 3.
|
5.3.2 Sub-culturing Procedure for AHH-1 Cells.
This procedure was performed as described in Section 3.5.5 of Chapter 3.
5.3.3 HPRT Forward Mutation in Cultured AHH-1 Cells.
5.3.3.1 HPRT mutant purification.
The main working principle of mammalian forward mutation assays is the quantification of 
mutant cells using selective media. Thus the number of mutant cells for each gene such as 
TK_/' and HPRT' were reduced to decrease the background mutation frequency (MF) by 
utilising selective growth media that inhibits the endogenous pathway without affecting the 
salvage pathway, which produces the required dNTP for DNA replication. Cells that are 
incapable of undergoing the replication process through the salvage pathway (i.e. TK'/_ or 
HPRT') will ultimately die. Figures 5.2 and 5.3 illustrate the endogenous and salvage 
pathways.
Initially, during the mutant purification procedure, mutant cells (HPRT') were reduced in 
RPMI 1640 growth medium supplemented with 9% horse serum and 1% L-glutamine.
HAT (Hypoxanthine-aminopterin-thymidine) at 50-times strength was added to the growth 
medium at 1:50 ratio (1 HAT: 50 medium); gassed with 5% CO2 in air and incubated at 
| 37±1°C for three consecutive days. Thus endogenous pathway was blocked and only
allowing DNA synthesis via the salvage pathway during this step.
I
Subsequently, cells were grown at 5x105 cells per ml for 24 hours in growth medium with 
HT solution (HAT without aminopterin) added, also at 1:50 ratio. After 24 hours, the cells 
were washed once by centrifugation at 1500rpm for 8 minutes and grown in normal growth 
medium for 3-4 days in order to obtain optimum cell numbers suitable for treatment.
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Dihydrofolate
NADP
DHFR*Am inopterinii
NADPH + H
Tetrahydrofolate 
*DHFR: Dihydrofolate reductase
Fig. 5.2 Endogenous pathway-direct synthesis o f  nucleotides.
Uridine 
monophosphate
Aminopterin ^
Guanine
HPRT*
Or 1' ------  I Z ^ >  dNMP.I............dNTP 1-— DNA
6-Thioguanine 
(Toxic analogue)
*HPRT: Hypoxanthine phosphoribosyl transferase
Fig. 5.3 Salvage pathway-synthesis from free purines and pyrimidines.
5.3.3.2 Treatment procedures.
Andrographolide with 98% purity to be used at various concentrations was prepared by 
dissolving the crystals with DMSO as solvent and administered to AHH-1 cell cultures 
within two hours of preparation. Fresh stocks were always prepared for each experiment 
replicates. Flasks containing healthy-looking, evenly distributed cells were selected and 
labelled according to doses. Less confluent flasks were allocated for negative control and 
low dose treatments while more confluent flasks were allocated for high dose treatments. 
Cells seeded at 5x106 cells per ml in 10ml medium were challenged with andrographolide
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at the specified concentrations and cultured for 24 hours at 37±1°C. Unlike previous 
studies, the concentrations of andrographolide used in this particular study were slightly 
different where the higher concentrations of 70 and 90pM were replaced with lower doses 
of 1 and 5pM of the compound respectively.
I
| Methylmethanesulfonate (MMS) is a known insecticide and chemotherapeutic agent 
(Fishbein, 1970) with a high Swain-Scott constant (s>0.83). It is an alkylating agent that is
|
| often used a model genotoxin and functions via an Sn2 mechanism targeting adduct
i
| generation at the nucleophilic centres such as N-7 of guanine and to a lesser extent the N-3 
of adenine, both of which are not mutagenic but caused breaks in DNA (Lawley, 1979;
Sega, 1984; Friedberg et al., 1995; IARC 1999). MMS was employed as the positive 
control for this study and administered to the cells at 4pM final concentration, which was 
used previously in the laboratory.
Following andrographolide exposure, the cells were washed twice by centrifugation at 
1200rpm for 5 minutes and re-suspended in fresh growth medium for mutant expression.
The phenotypic expression phase for HPRT mutation assay was 14 days incubation, to 
allow fixation of possible mutations and the degradation of the already expressed HPRT 
proteins. During the expression phase, the cell concentrations were routinely diluted to 
1.00x10 cells per ml with dilutions carried out on 1,3,5,7,9 and 11 days respectively, 
involving centrifugation and re-suspension in fresh growth medium.
Mutant frequency determination followed the phenotypic expression phase where the cells 
| were added to 96-well plates at the concentration of 4xl04 cells per well in fresh growth
i medium. A toxic analogue of guanine, 6-thioguanine at the final concentrations of 0.6
pg/ml was employed as a selection agent.
For the plating efficiency determination, 20 cells per well were plated at each dose in the 
absence of the selecting agent. Plates were scored for colony formation after 14 days of 
incubation at 37±1°C in humidified incubator with circulating 5% CO2 in air.
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5.3.3.3 Scoring Procedures.
After 14 days, the plates were scored using Nikon TMS phase contrast inverted microscope 
under 100X magnification where colonies with a diameter consisting of more than 20 cells 
were scored as viable colonies and ensuring that separate colonies were clearly apart, 
thereby accounting for clonal expansion. The cloning efficiencies and mutant frequencies 
were estimated as described by Furth et al. (1981). Figure 5.4 highlights all the procedures 
followed when conducting this study.
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5.3.3.4 Mutation Frequency and Plating Efficiency Calculations
Plating efficiency, cell viability and mutation frequency were calculated using the formulae 
shown below.
Plating Efficiency % (PE) = -Ln (Xo/N0) x 100 ....(1)
Cell Viability
Cell viability % = PE x 100
PE of control ...(2)
Mutant Fraction
Mutation frequency (MF) =
Dilution factor
-Ln (X«/N5) x dilution factor 
-Ln (Xo/No)
(No. of initial cells per well) Non-selective conditions 
(No. of initial cells per well) Selective conditions
Xs= Number of wells without colonies
Ns = Total number of wells J  Selective conditions
Xo= Number of wells without colonies L
N0 = Total number of wells Non-selective conditions
Worked examples:
HPRT mutation frequency (MF) calculation for untreated cells.
MF = -Ln (296/300) 
-Ln (2/300)
20 = 0.01342302 / 5.01063529 * 0.0005
40000
=1.339x10’6
HPRT mutation frequency (MF) calculation for cells treated with 30pM 
andrographolide
MF = -Ln (236/300) 
-Ln (10/300)
20 = 0.23995067 / 3.40119738 * 0.0005
40000
=3.527x10-5
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5.3.3.5 Statistical Analyses 
Dunnetts and 2-sample t-test.
Dunnetts is a specialised multiple comparison post-hoc test performed after an ANOVA or 
j a t-test by comparing all treatment data against the negative control. A samples size
| formula is proposed that guarantees the probability of correctly detecting each treatment
[ with mean value sufficiently different from the control mean value (Liu 1997). Dunnetts
j alongside t-test statistical analysis provides sufficient confidence in analysing the
significance of the results. The 2 sample t-test is more subjective as it compares each 
sample mean to the control separately, which is why both tests were required.
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Fig. 5.4 Flow chart for necessary steps in the methods employed for HPRT mutation assessment in AHH-1
cells treated with andrographolide.
MUTANT CLEANSING PHASE
Removal o f existing mutants. Growth of cells for 3 days 
in HAT media followed by a further 24 hours in HT media.
Growth of cells in normal media for 3-4 days to obtain 
sufficient cell number.
4
ANDROGRAPHOLIDE TREATMENT
Treatment flasks prepared w ith 5xl06 cells ml"1 in 10ml. 
The cultured cells were treated with andrographolide, doses 
ranging from lpM  to 50pM (the highest dose).
Cells were then incubated at 37±1(,C for 24 hours with 
circulating 5% CCb in air. Subsequently, cells were washed 
by centrifugation and re-suspended in fresh growth media.
4
PHENOTYPIC EXPRESSION PHASE
Cells were then allowed to grow for 14 days and serially 
diluted to l.OOxlO^ cells/ml on alternate days.
ft 4
MUTANT FREQUENCY H  PLATING EFFECIENCY
Cells were added to 96-well plates at Cells were added to 96-well plates with
the concentration of 4x 104 cells per approximately 20 cells added per well
well in fresh growth medium with 6- to measure cell viability
thioguanine at the final concentrations 
of 0.6 pg/ml employed as a selection 
agent.
SCORING FOR MUTANTS
After 14 days, the 96-well plates were scored
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5.4 RESULTS
The data generated for mutation at the HPRT locus in AHH-1 cells treated with 
andrographolide are tabulated in Table 5.1 below. Four sets of experiment replicates using 
freshly prepared new stocks of andrographolide were used with five plates per dose in 
order for suitable statistical analysis to be performed. Only 60 out of 96 wells were 
examined for colony formations as the periphery wells around the 96-well plates were not 
suitable for scoring. The concentrations of andrographolide used in this study were changed 
and are slightly different where the higher doses of 70 and 90pM of the phytochemical 
were discarded because of previous cell viability studies demonstrated that more than 50% 
of the cells subjected to these doses died primarily due to necrosis. Instead, 1 and 5pM of 
andrographolide were used to examine the effect of the compound at lower concentrations 
while retaining other doses used previously.
Table 5.1. Data summary for mutation frequency (xlO'6) o f  andrographolide-treated AHH-1 cells with 6- 
thioguanine selection for HPRT  mutant detection.______________________________________________
0.00 1.45 0.41 1.43 0.39
1.00 3.37 0.85 0.43 1.23
5.00 2.88* 2.32* 3.37* 5.80*
10.00 4.83* 3.97* 5.80* 8.56*
30.00 35.27* 46.93* 47.46* 59.50*
50.00 4.90* 9.62* 7.36* 7.15*
MMS 63.18* 68.93* 71.24* 69.71*
Each set o f  experiment replicates involves 5 plates o f  96-well plates per dose and 60 wells scored per plate. 
*Denotes significant (p<0.05) difference between sample means obtained using the two-tailed two-sample t- 
test and Dunnetts. HPRT=  Hypoxanthine phosphoribosyl transferase. MMS =methyl methane sulfonate.
Data are presented as presence of viable colonies in a series o f 96 well plates and mutation 
frequency values were calculated using formula (3) as described in section 5.2.3.4 
previously incorporating colonies observed both with and without 6-thioguanine selection. 
As shown in Table 5.1, there were statistically significant increases (p<0.05) in the 
frequency of HPRT mutants induced in a dose-response manner between 5 and lOpM of 
andrographolide. Although the incidence of mutant colonies formation was abruptly 
reduced at 50 pM of the compound, the values were still significantly different (p<0.05) 
against the negative control of untreated AHH-1 cells. The statistical analyses were 
conducted using t-test and Dunnetts test where the values were as shown in Table 5.2 
respectively. This finding suggests that andrographolide is mutagenic to the mammalian
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cells AHH-1 in vitro at a concentration as low as 5pM with the maximum induction of 
HPRT  mutants was observed at 30pM of the phytochemical as graphically presented in 
Figure 5.5.
Table 5.2. Two-tailed two sample t-test and Dunnetts test performed on AHH-1 HPRT  data.
0.00 0.707 Not applicable Not applicable
1.00 1.307 0.351 0.891
5.00 1.535 0.002* 0.012*
10.00 1.991 0.000* 0.000*
30.00 9.892 0.000* 0.000*
50.00 1.928 0.000* 0.000*
MMS 3.525 0.000* 0.000*
*Denotes significant (p<0.05) difference between sample means obtained using the two-tailed two-sample t- 
test and Dunnetts.
Mean Mutant 
Frequency
<o
LL
Andrographolide (pM)
Fig. 5.5. Mutation frequency (MF) o f  AFIH-1 HPRT  mutant cells after treatment with various 
concentrations o f andrographolide. Data points derived from mean o f  four experiment replicates.
Plating efficiency (P.E.) is a cell viability count in plates without 6-thioguanine selection 
and viable colonies are regarded as mutants after selection. AHH-1 cell viability after 
andrographolide insult at different doses was calculated using the formulae (1) and (2) that 
were described in section 5.2.3.4 previously with all data values compared to negative 
control of untreated cells as 100% cell viability. The data are tabulated in Table 5.3 and 
graphically displayed in Figure 5.6. Statistical analyses performed using Dunnetts and two- 
tailed two-sample t-test revealed that 5pM of andrographolide was sufficient to induce 
statistically significant difference in AHH-1 cell viability against the negative control. 
Thus, andrographolide caused cell death in a dose-dependent manner and it can be
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speculated that such trend would be continued if the cells were challenged with 70 and 
90pM of the compound as in other previous studies.
Table 5.3. Data summary o f  cell viability (%) o f  andrographolide-treated AHH-1 cells with 6-thioguanine 
selection for HPRT  mutant detection.
0.00 100.00 100.00 100.00 100.00 100.00
1.00 76.14 97.82 95.55 94.83 91.09
5.00 76.14 90.63 85.64 74.55 81.74*
10.00 76.14 85.05 78.62 69.39 77.30*
30.00 73.86 76.64 66.14 59.49 69.03*
50.00 59.92 62.14 56.24 54.93 58.31*
MMS 84.95 87.69 88.52 83.95 86.27
Each set o f  experiment involves 5 replicates o f  96-well plates. HPRT =  Hypoxanthine phosphoribosyl 
transferase. MMS= methyl methane sulfonate.
100
Mean % Viable Cells
Andrographolide (pM)
Fig. 5.6 Shows the reduction in AHH-1 cell viability after treatment with andrographolide.
Graph was derived using plating efficiency (PE) data. Data points derived from mean o f  four experiment
replicates.
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5.5 DISCUSSION
| The HPRT mammalian forward mutation assay was employed to examine the potential
;
| mutagenicity of andrographolide, a phytochemical derived from the annual herb
!
Andrographis paniculata. To the best of the author’s knowledge, there were no previous
! publications to this date that attempted to elucidating the phytochemical’s ability to elicit
j  point mutations using mammalian cell line.
|
| The AHH-1 cell line was chosen for this assay due to a proven track-record in its utilisation
in genotoxicity testing. This lymphoblastoid cell line was chosen over rodent cell lines 
since human cells are known to be 1000 times more sensitive to some cytotoxic antibiotics 
at least six times more sensitive to hydrogen peroxide and twice as sensitive to radiation 
(Cox et al., 1977a; Cox et al., 1977b; Hoffman et al., 1984; Gupta & Prasad, 1992). The 
HPRT forward mutation assay had been used successfully in the past in evaluating 
genotoxic potencies of mutagens (Crespi et al., 1985; Furth et al., 1981; Doak et al., 2007).
The extract of the aerial parts of Andrographis paniculata with high andrographolide 
content was reported to be not mutagenic in vitro using the Ames test (Liu et al., 1990). As 
mentioned previously in the section 1.10 of Chapter 1, the use of aqueous extract of A. 
paniculata may hamper the bioavailability of the compound to cellular targets (Gupta et al., 
1990; 1993; O’Neil et al., 2001) and the anti-bacterial property of andrographolide (Singha 
et al., 2003) may affect the Salmonella typhimurium bacteria used for the Ames test.
The data generated from this study contradicted the findings made by Liu et al. (1990)
j since andrographolide was shown to be capable of inducing mutation of the HPRT locus in
AHH-1 cells in vitro. Andrographolide caused statistically significant (p<0.05) increases of 
HPRT mutations in a dose-related fashion between 5 to 30pM followed by the reduction in 
HPRT mutants frequency at the top dose of 50pM, where the value is still significantly 
(p<0.05) different against untreated cells. This mutagenic potential exerted by 
andrographolide on AHH-1 cells in vitro supported the DEREK report that this 
phytochemical can cause chromosome damage in mammals in vitro. The highest incidence 
of HPRT mutants was observed at 30p.M of andrographolide and as demonstrated earlier, 
the highest frequency of micronuclei was also registered at this particular concentration in 
AHH-1 cells.
I
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Although andrographolide was found to be mutagenic to AHH-1 cells in vitro, it also
|
\ caused a consistent decrement in cell viability. Apart from the lowest dose tested which
| was ljxM, all other doses exhibited significant (p<0.05) reduction in cell viability against
\ the negative controls. At the top dose tested, the phytochemical caused almost 50%
reduction of viable cells, which was close to the 60% cytotoxicity mark.
!
|
| Earlier, andrographolide was demonstrated to cause cytotoxicity in a dose- and time-
[
| dependent manner in V-79, AHH-1 and MCL-5 using different methods of assessment.
I There were concerns that the measurements of cell viability immediately after exposure to
toxic agents may underestimate or generate inaccurate cellular toxicity data (Greenwood et 
al., 2004; Fellows & O’Donovan, 2007). In this study, andrographolide-treated AHH-1 
cells were subsequently allowed to grow for the next 14 days in the absence of the 
phytochemical and selective agent during the mutant expression period, registered a steady 
and statistically significant (p<0.05) reduction in cell viability, measured as cloning 
efficiency. This finding provided additional support to the results obtained earlier that 
andrographolide caused a dose- and time-dependent cytotoxicity. Furthermore, it is now 
clear that this phytochemical might have a delayed effect on cytotoxicity even after its 
removal from the growth medium as demonstrated previously.
Even though this is the first finding to exhibit the potential mutagenicity of this 
phytochemical, the mutagenic mode of action is not really known due to the paucity of data 
in the literature. It cannot be ascertain whether andrographolide is acting directly or
I indirectly in causing mutations. Furthermore, as the treatment dose increased, so did cell
|
viability. Hence, mutations may not be passed efficiently since many of the cells will die.
The author believes that further studies, including independent verification are warranted to 
elucidate the biological significance of this mutagenic potential and whether this in vitro 
effect can be translated in vivo. Data derived from in silico predictions using DEREK and 
this assay employing AHH-1 cell line did not take into account the influence of a more 
profound metabolic process in vivo. MCL-5 cell line that has superior metabolic ability 
than AHH-1 was found to be able to withstand andrographolide at 10pM and high 
micronuclei incidence was observed at 50pM compared to 30pM in AHH-1. Attempts to 
use MCL-5 cell line in this assay were not successful due to inconsistencies in plating 
efficiency values.
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MCL-5 cell line only has limited Phase I biotransformation capacity and predictions made 
using METEOR with concordance to previous published studies, revealed various 
I biotransformation routes. Currently, the pharmacokinetic and pharmacodynamic data on 
andrographolide is still lacking and the serum concentration has not been determined. As a 
conclusion, andrographolide was shown to educe mutations in AHH-1 cells in vitro and 
further study is needed to determine the biological significance of this finding. However, 
the absence of initial experiments to determine the optimum expression period meant that 
AHH-1 cells harbouring larger intragenic mutations might have been lost before scoring 
can be performed, since andrographolide was shown to elicit chromosome damage. The 14- 
days incubation period was adopted because it was the routine procedure performed 
previously in the laboratory (Barber et al. 2006, Doak et al., 2007).
Even though the cell viability in this study was performed using equation (2), where 
viability was measured as part of the plating efficiency after 14-days, other methods can 
also be employed and the Relative Total Growth (RTG) calculation is one example. The 
RTG calculation depends on cell number. As stated previously, during the 14-day 
phenotypic expression period the cells were sub-cultured routinely on alternate days but the 
author inadvertently did not record the figures, since sub-culturing was performed 
primarily to maintain a low cell number and cell viability will be determined after another 
14-days (equation 2). However, based on visual observation made by the author, the cell 
number showed a dose-response relationship between sub-culturing procedures and the 
author believes that should the Relative Total Growth were calculated for cytotoxicity, the 
outcome would have be the same as that observed in Figure 5.6, where the phytochemical 
exerted a increasing cytotoxicity with increasing concentrations. Thus, the author 
recommends the inclusion of Relative Total Growth (RTG) calculation as part of 
| cytotoxicity assessment in this assay for a more accurate measurement since cell death 
during the long expression period was excluded in the cell viability calculation. This may 
lead to underestimation of cytotoxicity.
This study showed that andrographolide is able to elicit point mutations in mammalian 
AHH-1 cells in vitro at a concentration as low as 5pM with the highest frequency of 
mutants recorded at 30pM. The biological significance of this finding remains to be seen.
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CHAPTER 6 
GENERAL DISCUSSION
i
6.1. The Objectives of the Studies
The studies discussed in this thesis were performed to investigate the potential genotoxicity 
and toxicity of andrographolide, an active phytochemical found in various parts of the 
annual herb Andrographis paniculata.
Herbal products containing phytochemicals have long been an important part and parcel of 
traditional medicines, that were handed down from one generation of practitioners to 
another over hundreds of years. The plants to be used and its applications were carefully 
described in various older traditional healthcare systems such in China and Ayurveda in 
India, which are philosophically-based and regarded to be holistic in principle, which aim 
to treat the patient as a whole rather than singling the disease suffered by the patient. They 
have much in common with traditional medical herbalism as it was and still is practised in 
Europe and North America.
In Part 1, Chapter 1 of this thesis, various factors involved in the revival of interest in 
phytomedicines, current UK and EU regulations in place regarding phytomedicines, the 
efficacy and safety of herbal medicines were discussed in length. Furthermore, the 
importance of phytochemicals in drug discovery and renewed interests exhibited by the 
| pharmaceutical industry in concordant with the emergence of new technologies, allowing 
new approaches in research and development of new chemical entities isolated from plants. 
However, this increased interests in harnessing the hidden knowledge described in ancient 
medical manuscripts or those trapped within the memory of its practitioners, are not always 
welcome by the developing countries who claimed that they are being subjected to bio­
piracy. These countries have various reasons to believe so due to their rich biodiversity, 
local socio-economic status and the high percentage of the local population that still trust 
and rely on traditional herbal medications. Brazil and Malaysia for example, armed 
themselves with strict legislation regarding the sample collection and exports of flora from
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the rainforests. India on the other hand had embarked on an expensively ambitious project,
j
christened the Traditional Knowledge Digital Library with the objective of compiling a 30- 
million-page electronic encyclopaedia of ancient Indian medical systems of ayurveda, 
unani and siddha which date back thousands of years. This initiative is perfectly 
understandable in ensuring such knowledge remained in public hands rather than corporate 
patents, as the Indian government has been embroiled in many high-profile patent litigation 
cases challenging individuals and companies alike in the US and European Patent Offices.
\
\
\
| Part 1 of the first chapter also detailing the importance of safety assessment of 
phytomedicines and phytochemicals for the benefit of both the general public and the 
industry. Introduction to the compound of interest, andrographolide and previous studies on 
the potential toxicity and genotoxicity of this phytochemical was also discussed.
As elaborated previously, the increased consumption of traditional herbal products by the 
general public in conjunction with the perception that such products are entirely safe due to 
its ‘natural’ status and the paucity of reliable scientific data on their safety as well as their 
efficacy, should be immediately addressed. The author also believes that such opinions and 
attitudes by the public towards herbal products consumption would continue as the trend of 
leading a natural and ‘green’ lifestyle is currently in vogue. Data are lacking on various 
aspects of herbal medicines including subtle detrimental effects such as mutations, their 
impact on biotransformation as well as possible drug-herb interactions.
Computer-assisted structure activity relationship programmes based on expert knowledge, 
namely DEREK and METEOR were employed to provide semi-qualitative predictions on 
the toxicity and possible metabolites of andrographolide. The in vitro cytokinesis-block 
micronucleus assay (CBMA) was used to investigate the potential of andrographolide to 
induce micronuclei, a reliable genotoxic biomarker in metabolically competent cell lines, 
i The assay was also combined with kinetochore labelling using CREST antibodies to
I elucidate the mechanisms responsible in micronuclei induction (see Chapter 3).
Cytotoxicity of andrographolide was also examined using microscopical identification of 
necrotic and apoptotic cells as well as trypan-blue exclusion assay. After andrographolide 
was found to act primarily in an aneugenic manner as opposed to being a clastogen, 
assessment of the compound’s capacity to disrupt mitotic machinery and causing 
chromosome aberrations were assessed (see Chapter 4). In relation to disruption to mitotic
Copy 1 214
Y. Sharifuddin
Chapter 6
apparatus, mitotic outcome and cellular recovery after andrographolide exposure were also 
looked into. The data obtained on these studies assisted in providing better comprehension 
| of andrographolide’s possible mode of action. It is generally accepted that aneugenic 
compounds possess a threshold of genotoxicity (COM, 2002), thus the underlying mode of 
action would also show a threshold of activity. HPRT forward mutation assay was chosen 
because it was suitably robust for qualitative and quantitative determination of genotoxic 
potential (see Chapter 5).
|
[
i
| In Silico Screening of Toxicity and Prediction of Andrographolide Biotransformation
The existence of high number of phytochemicals with wide structural diversity and the 
paucity of data on their various properties are some of the factors that is slowing down the 
research & development including safety assessment procedures. Computer-assisted 
structure activity relationship (CSAR) assessment allows semi-qualitative assessment and 
priority setting for testing strategies on high number of compounds before embarking on 
laboratory-based experiments. Two expert-knowledge-based programmes namely DEREK 
and METEOR were used to predict in silico the toxicity and biotransformation of 
andrographolide respectively. The results obtained using DEREK showed that 
andrographolide is capable of causing nephropathy in rodents as well as skin sensitisation 
and chromosome damage in mammals in vitro, where the latter is attributed to the presence 
a-alkylidene y-butyrolactone moiety detected as a, p-unsaturated ester or thioester by 
DEREK. Indeed, this particular part of the chemical structure among others was supported 
by experimental data to be responsible for the phytochemical’s cytotoxic activity in vitro 
(Nanduri et al, 2004). It is worth pointing out that DEREK regarded the cytotoxic and 
| genotoxic potential of andrographolide to be plausible in vitro because the programme is 
examining the chemical structure of andrographolide whereas in vivo, the compound would 
| be subjected to biotransformation where the metabolites can either be more reactive or 
vice-versa. Thus METEOR was utilised to providing possible Phase I and II 
biotransformation routes of andrographolide. The various possible metabolites anticipated 
by METEOR exhibited similar outcome compared to those obtained experimentally. 
Previous studies involving rodents and small sample of human volunteers showed a variety 
of metabolites and all of these were anticipated by METEOR. However, the programme 
was not capable of determining whether these possible metabolites are more or less reactive
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than the parent compound. As discussed previously, CSAR programmes are useful in 
certain aspects but they can only complement but not overrule experimental findings.
DEREK, METEOR or any other expert-knowledge-based programme can also be useful in 
priority setting for testing strategies, for example the European Union adopted a legislative
|
| proposal for a new chemical management system known as REACH that for one aspect, 
requires thousands of chemicals in cosmetics to be tested against skin irritation and yet the 
EU also warrants that testing of chemicals for cosmetic products in animals to end by 2009.
6.2 Elucidating the Genotoxic Potential of Andrographolide In Vitro
The results obtained using the CSAR programmes provided a sketch on andrographolide’s 
toxicity portrait. The in vitro cytokinesis-block mironucleus assay (CBMA) in combination 
with anti-kinetochore labelling using CREST antibodies was used to paint a better picture 
of the portrait and it was revealed that andrographolide induced statistically significant 
micronuclei frequency at the lower concentrations tested, primarily in an aneugenic manner 
in V-79, AHH-1 and MCL-5 cell lines. There was significant difference in the frequency of 
micronuclei induction between the three cell lines tested and this may be attributed to the 
difference in metabolic capacity. Although V-79 cells are not metabolically competent, 
attributing the higher micronuclei frequency observed mainly due to biotransformation 
deficit might not be flawless. Ideally, data comparison between andrographolide-treated V- 
79 cells supplemented with S9-liver extract and those that are not might provide a better 
picture on the effect metabolic enzymes upon andrographolide genotoxicity potential.
1
| However, the presence of external metabolic capacity such as S9 poses disadvantages of its 
own since the low levels of certain P450 cytochromes and high levels of others, does not 
j necessarily represent normal animal or human biotransformation process (Tweats et al 
2007). Nonetheless, these data provided valuable insights into andrographolide 
biotransformation in human cell lines that also augment the in silico predictions derived 
from DEREK and METEOR. The V-79 cell line is deficient in p53 activity whereas AHH- 
1 and MCL-5 cells are capable of undergoing normal DNA repair process and judging by 
available data on the frequency of micronuclei induction, the cells’ p53 status were 
considered to be not of significant influence in cellular response towards andrographolide. 
Rajagopal et al. (2003) reported that the p53 status of cancer cells exposed to
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andrographolide did not account for the anti-proliferative properties exerted by the 
compound.
Andrographolide was also found to cause cell death in a dose-dependent fashion mainly via 
| necrosis rather than apoptosis. Different methods were employed to assess the cytotoxicity
of the phytochemical of interest and the trend observed was similar. Cellular toxicity 
exerted by andrographolide was demonstrated to be dependent on dose and incubation 
time. When MCL-5 cells were treated with andrographolide for 8 hours, the frequency of 
apoptotic cells was most prominent at 30 and 50pM but was still not as high as cells that 
suffered necrosis. Prolonging the treatment period from 8 to 24 hours caused even more 
cells to undergo necrotic cell death whereas neither increment nor reduction was recorded 
for apoptotic cells and the value still lingered less than 2% of the cell population scored.
Cell death induced by andrographolide was recently suggested to be independent of cellular 
caspase activities (Li et al., 2007). As discussed previously, andrographolide’s influence on 
apoptosis is still not clear. There were reports of anti-apoptotic properties (Burgos et al.,
2004; Chen et al., 2004) as well as pro-apoptotic effects in cells (Cheung et al., 2005; Kim 
& Milner, 2005) treated with andrographolide. Furthermore, the molecular mechanisms of 
these effects remained largely unexplored and it is still to be determined whether 
andrographolide impose its anti/pro-apoptotic effects via direct or indirect action on 
cellular target(s).
The concentrations of andrographolide at 30 and 50pM administered to cells that elicited 
relatively high apoptotic response also educed comparatively high micronuclei incidence, 
suggesting a possible link between these doses, micronucleation and apoptotic responses. 
Decordier et al., (2005) proposed that increased caspase-3 activity has a direct role in 
| micronuclei formation. Indeed, caspase-3 activity, which is a distinguishing factor in
| apoptosis execution, was observed to be up-regulated in the presence of andrographolide
i
(Li et al., 2007). It may be possible that this phytochemical only exert micronucleation at 
these concentrations after the cellular defense mechanisms has been overwhelmed or 
sufficient cellular target(s) has been damaged leading limited apoptotic reaction since cells 
die mainly via necrosis. Damage to cytoskeleton and other mitotic machinery may also 
initiate apoptosis (Decordier et al., 2002).
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The phytochemical was demonstrated to inhibit cell growth and elicit cell death primarily 
via necrosis as the dose increased. Apoptosis was found to be a minor form of cell demise. 
Andrographolide exerts it cellular toxicity in time- and dose-dependent manner, where 
necrotic response was witnessed to be increased between 8 and 24 hours, in contrast to 
apoptosis which remained fairly stagnant during the same period. It seemed 
andrographolide has higher propensity to incite necrosis than the programmed cell death. 
Necrosis results from damage to a number of cellular constituents, including the plasma 
membrane. Several mechanisms alone or in combination can trigger and promote necrosis.
These include plasma membrane permeability changes, which lead to a collapse of ion 
homeostasis, followed by cell and organelle swelling, and culminating in rupture of the cell 
membrane. For a given xenobiotic, the exact mechanisms leading to necrosis are not 
always known because the sequence of events is complex and many of these molecular 
events are causally interrelated with other mechanisms. Cause and effect cannot always be 
dissected from each other. Whether andrographolide inhibit apoptosis thus forcing 
damaged cells to die via necrosis, or various cellular targets were damaged by the 
compound and lead to necrosis, or a combination of both, is still not entirely clear.
Although the genotoxicity portrait of this main phytochemical from Andrographis 
paniculata is clearer than before, it is still lacking refined colours. Since andrographolide 
act primarily in an aneugenic manner when inducing micronuclei, it may not directly acting 
on the DNA itself but exert its genotoxic influence indirectly by targeting various other 
cellular targets including but not limited to the mitotic machinery. The study on Chinese 
hamster lung fibroblast V-79 cells showed that andrographolide caused the numerical 
amplification of the microtubule organising centres (MTOCs) with corresponding 
aberration in chromosome segregation, which supported the data on micronuclei induction 
observed in V-79 cells as well as those in AHH-1 and MCL-5. This concentration- 
dependent effect also caused accruement of cells experiencing mitotic arrest. As the cells 
challenged with andrographolide harbours abnormal polarity during mitosis, it was deemed 
an interesting venture to see if such anomaly would give rise to cells with more than one 
nuclei. MCL-5 and V-79 cells were exposed to andrographolide for one and two cell 
cycles, subsequently cell fate and cell death frequency were determined microscopically.
The presence of multiple MTOCs promoted aberrant mitoses. MCL-5 cells were also 
exposed to andrographolide for a longer period of 5 cell cycles in order to compare the 
mitotic outcome and cytotoxicity levels with cells challenged with the phytochemical in a
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shorter treatment period. The data showed that longer treatment period elicit mitotic 
aberration, cell death and reduction in cell number. As andrographolide was shown to 
induce damage in aneugenic manner and aneugens are known to involve threshold of 
damage, the possibility of cells to recover after andrographolide exposure was also 
examined and the data revealed that the effect generally persisted.I
i
The visual determination of MTOCs number is not hard and most studies rely on antibody- 
labelling followed by fluorescent microscopy. Although currently this is the preferred 
method, data has to be interpreted cautiously. Factors to be taken into account include 
antibody quality, the orientation of the centrosome relative to viewing and the fact that not 
every particle staining with anti-PCM antibodies necessarily represents a complete 
centrosome.
The author believes that andrographolide may exerts it influence on mammalian cells as a 
parent compound and metabolism of the aglycone may reduced its genotoxicity, as shown 
by the observed differences in micronuclei induction between the cell lines adopted in these 
studies and various past publications cited in this thesis point to the same conclusion. 
However, it is inappropriate to speculate further until genotoxic experiments involving the 
possible metabolites of the compound can be performed and it is also remain to be seen if 
extensive metabolism (Phase I and II) would have an impact on the cytotoxicity of the 
compound without diminishing its reported medical properties.
Andrographolide was shown to cause reduced sperm count, giant multinucleated cells 
formation and necrotic cell death in male rats (Akbarsha & Murugaian, 2000) and the 
author decided to elucidate the compounds possible mechanism of action(s) as part of the 
genotoxicity assessment. Furthermore, the phytochemical was previously demonstrated to 
be able to halt the growth of various cancer cells (Siripong et al., 1992; Rajagopal et al.,
! 2003; Kumar et al., 2004) and it was hoped that by understanding the mode of action(s)
and the effect on cell division kinetics would pave the way to the discovery of a possible 
pharmacological lead if not a potential anti-mitotic compound on its own or in combination 
with existing treatment.
The measurements of replication and mitotic indexes after exposure to andrographolide for 
one cell cycle may underestimate the compound’s cytotoxicity since these endpoints only
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take into account the percentage of cell population that proliferated and attempting to 
progress through mitosis. The proportion of dead and dying cells were excluded. These 
short-term cytotoxicity parameters and the trypan-blue exclusion assay were reported to 
underestimate cytotoxicity (Fellowes & Donovan, 2007). Andrographolide was 
demonstrated to cause necrotic cell death in a dose- and exposure time-dependent manneri
| rather than a prominent apoptotic response. At the top dose, andrographolide caused more 
than 50% cytotoxicity in the cell lines as indicated by RI, MI and trypan-blue 
measurements and significant reduction in cell number. Continuous exposure of MCL-5
! cells to andrographolide for five cell cycles also showed that the compound maintain its
I
cytotoxicity. Even though the in vitro micronucleus assay was not exclusively design for 
cell death measurement, the estimation of necrotic/apoptotic cell population after 
andrographolide exposure provided a valuable mechanistic information.
The incidence of condensed chromatin, considered to be an indication of cell death was 
determined in V-79 cells exposed to andrographolide. The data revealed a dose-dependent 
pattern of dead cell population even after the treated cells were allowed to recover for one 
cell cycle in the absence of andrographolide and the percentage of dead cells was similar to 
those treated continuously (see Table 4.6). The incidence of aberrant centrosome number 
measured directly after exposure and the incremental increases in mitotic index even after 
the removal of andrographolide indicated that it profoundly affected the cell cycle 
mechanism, which in the long term may affect cell division and cell number.
Furthermore, cell viability determined using the plating efficiency as discussed in Chapter 
5, demonstrated a dose-dependent reduction in growing AHH-1 cell colonies after 14-days 
of initial inoculation with the same cell concentration. Thus, based on the available data, 
andrographolide affected cell cycle kinetics via disruption to normal chromosome 
segregation and increased the mitotic index while a proportion of cell population exposed 
to the compound died primarily via necrosis in a dose-dependent manner. Disruption to 
normal cell division and chromosome damage as well as the cytotoxicity of the compound 
effectively reduced cell number. Furthermore, depending on the dose of exposure, the 
treated mammalian cells’ ability to segregate normally might have been impeded evident 
from the persistence of cell cycle delay even in the absence of the phytochemical. The 
author believes that andrographolide may have a higher cytotoxicity than those measured 
using the previously stated parameters and even though the Relative Total Growth
Copy 1 220
Y. Sharifuddin
Chapter 6
calculation was not determined, it can be proposed that based on the observation and 
plating efficiency figures that this phytochemical will inhibit normal cell proliferation.
The results obtained would be more meaningful if the concentration of andrographolide 
presence in human serum is known or to what extent human exposure in vivo would be. At 
the moment, reliable data on this aspect is lacking. As stated earlier, many published works 
on this phytochemical tend to concentrate on the possible medical and therapeutic benefits 
of andrographolide, often overlooking the possible risks it might pose and the current lack 
of evidence in toxicity particularly genotoxicity may place the health of the public in 
jeopardy unless more information is obtained. History may not exactly repeat itself but it 
does tend to rhyme. Previous examples of herbal products that were not tested for its 
genotoxic potential such as Aristolochia fangchi, Piper methysticum and Teuchrium 
chamaedrys, to name a few, has been costly to public health and confidence.
6.3 Further Studies
Based on the findings made in this thesis, various further studies can be carried out but not 
limited to those described below.
• Since the methods employed to elucidate cell fate after aberrant mitosis due to 
centrosome amplification after andrographolide exposure is not very specific, time- 
lapsed video-microscopy on cell should be used to obtain a clearer picture.
• Another round of in silico assessment using both DEREK and METEOR can be 
performed on the predicted metabolites of andrographolide, which will provide 
valuable additional insights.
• In relation to the previous point and the results obtained, experiments to 
characterise the possible metabolites of andrographolide from AHH-1, MCL-5 and 
V-79 cell cultures can be performed for example by using mass spectrometry.
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• Test the metabolites of this phytochemical to determine whether they can pose as a
genotoxic threats and studies should also be performed on normal diploid human
cells and cells with competent p53 activity.
• Conducting microarray studies on gene expression for cells exposed to
andrographolide to determine its impact on genes involved in cell death mainly
apoptosis, centrosome duplication and the mitotic checkpoint genes. Such studies 
would shed more lights on how andrographolide is affecting centrosome 
multiplication and cell death.
• Experiments to further examine and quantitate the effects of andrographolide on 
mammalian cells using apoptosis specific assays such as the TUNEL and caspases- 
oriented technique can be performed. Several cell types should be employed to 
provide a better picture since andrographolide is known to exert cell-specific 
response.
• Performing the in vitro cytokinesis-block micronucleus assay on larger samples 
with the aim of finding the threshold level of exposure since andrographolide 
behaves in an aneugenic manner.
• Sequencing the HPRT “mutants to obtain more information of the type of damage.
6.4 Conclusion
Major conclusions that can be drawn from these studies are:
• In silico assessment utilising expert knowledge-based program harnessing 
quantitative structure activity relationship such as DEREK and METEOR was 
useful in providing general initial information about andrographolide, where 
paucity of data exist. DEREK predicted that andrographolide is capable of causing 
skin sensitisation and chromosome damage in mammals in vitro. Whereas, 
METEOR predicted plausible Phase I and Phase II biotransformation routes of 
andrographolide that were in agreement with past published works.
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• Andrographolide induced micronuclei formation in vitro in all three cell lines 
tested, primarily at the lower doses of the compound. Difference in cellular 
metabolic capabilities may explain the difference in the level of micronuclei 
incidence.
• Andrographolide induced kinetochore positive micronuclei, hence may act in 
aneugenic manner.
• The doses between 30 and 50pM induced high micronuclei frequency compared to 
other concentration tested and these doses also caused relatively high apoptotic 
response in scored cells.
• Cytotoxicity measurement performed using replicative index calculation, 
microscopical identification and trypan-blue exclusion assay showed a similar trend 
in that andrographolide cytotoxicity is both time- and dose-dependent. Cell death 
was observed to be primarily via necrosis as opposed to programmed cell death. 
Micronuclei frequency was observed to generally increase in tandem with 
cytotoxicity, except at the top two concentrations of 70 and 90pM. This 
phytochemical also reduced cell growth as the concentration increased. However, 
the compound’s cytotoxicity might have been underestimated.
• Andrographolide instigated centrosome amplifications as the treatment dose 
increased and the presence of multiple MTOCs affected chromosomal segregation 
fidelity with corresponding increases in the mitotic index.
• V-79 cells challenged with andrographolide for 24 hours and subsequently allowed 
to grow for a further 24 and 48 hours post-treatment still retained abnormal MTOCs 
number.
• Centrosome numerical aberrations in V-79 cells challenged with andrographolide 
lead to anomalous mitoses where cells failed to undergo cytokinesis due to 
abnormal centrosome number, producing bi-, tri-, tetra- and multinucleated cells.
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Even in the absence of the phytochemical after the initial insult, there was still 
significant presence of abnormal mitoses.
• Andrographolide elicited HPRT ~ mutants formation between 5 to 50pM and the 
induction is dose-related with 30pM induced the highest mutagenic response. Cell 
viability measured as plating efficiency showed that andrographolide affected cell 
growth and supported cytotoxicity assessment conducted earlier.
All the studies completed in this thesis were conducted with the aim of adding value to the 
existing knowledge on andrographolide by determining its potential genotoxicity, 
cytotoxicity and shed more lights into its possible mode of action. There are various 
windows of opportunity in terms of necessary further work that can be pursued in the 
future, some of which have been outlined by the author earlier as there are still more 
questions need to be answered. Recently, self-organising map (SOM) analysis performed 
on andrographolide suggested that this phytochemical may possess novel mechanism(s) of 
action (Jada et al., 2007). Therefore the author would like to end his thesis as the novelist 
and lepidopterist, Vladimir Nabokov once put it, “The greater one’s science, the deeper the 
sense of mystery”.
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